


FORM PTO-1390 (REV. 5/93)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket Number 2257-137
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. Application No. (if known, see 37 C.F.R. 1.5) Unassigned 09/155023	
International Application No. PCT/SE98/01393	International Filing Date 15 July 1998	Priority Date Claimed 22 July 1997	
Title of Invention NOVEL COMPOUNDS			
Applicant(s) For DO/EO/US GUILÉ et al			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information			
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to DELAY national examination procedures (35 U.S.C. 371(f) until the expiration of the applicable time limit set in 35 U.S.C. 371(b) Articles 22 and 39(1). 4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date. 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 11. The above checked items are being transmitted: a. <input checked="" type="checkbox"/> before the 18 th month publication. b. <input type="checkbox"/> after publication and the Article 20 communication but before 20 months from the priority date. c. <input type="checkbox"/> after 20 months. d. <input type="checkbox"/> by 30 months and a proper demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date. e. <input type="checkbox"/> after 30 months. Note: Petition to revive (37 CFR 1.137(a) or (b)) is necessary if 35 U.S.C. 371 requirements submitted (1) after 20 months and no proper demand for International Preliminary Examination was made by 19 months from the earliest claimed priority date, or (2) after 30 months and a proper demand for International Preliminary Examination was made by 19 months from the earliest claimed priority date. 12. At the time of transmittal, Amendments to the claims under Article 34 a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 13. <input type="checkbox"/> Certain requirements under 35 U.S.C. 371 were previously submitted by the applicant on _____, namely: 14. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 15. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 16. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND OR SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter.			

19. <input checked="" type="checkbox"/> Other items or information: Form PTO-1449 and References; PCT Request; ISR							
20. <input checked="" type="checkbox"/> The following fees are submitted:						CALCULATION \$	PTOUSE ONLY
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)) -- Search Report has been prepared by the EPO or JPO\$930.00 -- International preliminary examination fee paid to USPTO (37 CFR 1.492).....\$720.00 -- No international preliminary examination fee paid to USPTO (37 CFR 1.492) but international search fee paid to USPTO (37 CFR 1.445(a)(2))\$790.00 -- Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$1,070.00 -- International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provision of PCT Article 33(1) to (4).....\$98.00							
ENTER APPROPRIATE BASIC FEE AMOUNT =						\$	1,070.00
Surcharge of \$130.00 for furnishing the National fee or oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 mos. from the earliest claimed priority date (37 CFR 1.492(e)).						\$	0.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE				
Total Claims	14	-20 =	0	X	\$22.00	\$	0.00
Independent Claims	3	-3 =	0	X	\$82.00		0.00
Multiple Dependent Claims(s) (if applicable)				+\$270.00		\$	0.00
TOTAL OF ABOVE CALCULATIONS =						\$	1070.00
Reduction by ½ for filing by small entity, if applicable. Affidavit must be filed also. (Note 37 CFR 1.9, 1.27, 1.28).							0.00
SUBTOTAL =						\$	1070.00
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 mos., from the earliest claimed priority date (37 CFR 1.492(f)).							0.00
TOTAL NATIONAL FEE =						\$	1070.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +						\$	40.00
Fee for Petition to Revive Unintentionally Abandoned Application (\$1,320 - Small Entity Fee = \$660)						\$	0.00
TOTAL FEES ENCLOSED =						\$	1110.00
						Amount to be refunded	\$
						Charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$1,110.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>14-1140</u> . A <u>duplicate</u> copy of this form is enclosed.							
SEND ALL CORRESPONDENCE TO:						Signature 	
NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8th Floor Arlington, Virginia 22201 Telephone: (703) 816-4000						Leonard C. Mitchard Name	
29,009						September 21, 1998	
Registration Number						Date	

09/155023

300 Rec'd PCT/PTO 21 SEP 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

GUILE et al

Atty. Ref.: 2257-137

Serial No. **Unassigned**

Group:

Filed: **September 21, 1998**

Examiner:

For: **NOVEL COMPOUNDS**

* * * * *

September 21, 1998

Honorable Commissioner of Patents
and Trademarks
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the above application as follows:

IN THE CLAIMS

Claim 3, line 1, delete "or 2".

Claim 4, line 1, delete "any one of claims 1 to 3" and replace by
--claim 1--.

Claim 5, line 1, delete "any one of claims 1 to 4" and replace by
--claim 1--.

Claim 6, line 1, delete "any one of claims 1 to 5" and replace by
--claim 1--.

GUILE et al
Serial No. Unassigned

Claim 7, line 1, delete "any one of claims 1 to 6" and replace by
--claim 1--.

Claim 9, lines 1-2, delete "any one of claims 1 to 8" and replace by
--claim 1--.

Claim 10, line 1, delete "any one of claims 1 to 8" and replace by
--claim 1--.

Claim 11, line 1, delete "any one of claims 1 to 8" and replace by
--claim 1--.

Claim 12, line 1, delete "any one of claims 1 to 8" and replace by
--claim 1--.

Claim 13, line 3, delete "any one of claims 1 to 8" and replace by
--claim 1--.

GUILE et al
Serial No. Unassigned


REMARKS

The above amendments were made to place this application in a more traditional formal.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard C. Mitchard
Reg. No. 29,009

LCM:lks
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

NOVEL COMPOUNDS

The present invention provides new triazolo[4,5-*d*]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.

5


Platelet adhesion and aggregation are initiating events in arterial thrombosis. Although the process of platelet adhesion to the sub-endothelial surface may have an important role to play in the repair of damaged vessel walls, the platelet aggregation that this initiates can precipitate acute thrombotic occlusion of vital vascular beds, leading to events with high morbidity such as myocardial infarction and unstable angina. The success of interventions used to prevent or alleviate these conditions, such as thrombolysis and angioplasty is also compromised by platelet mediated occlusion or re-occlusion.

A number of converging pathways lead to platelet aggregation. Whatever the initial stimulus, the final common event is a cross linking of platelets by binding of fibrinogen to a membrane binding site, glycoprotein IIb/IIIa (GPIIb/IIIa). The high anti-platelet efficacy of antibodies or antagonists for GPIIb/IIIa is explained by their interference with this final common event. However, this efficacy may also explain the bleeding problems that have been observed with this class of agent. Thrombin can produce platelet aggregation largely independently of other pathways but substantial quantities of thrombin are unlikely to be present without prior activation of platelets by other mechanisms. Thrombin inhibitors such as hirudin are highly effective anti-thrombotic agents, but again may produce excessive bleeding because they function as both anti-platelet and anti-coagulant agents (The TIMI 9a Investigators (1994), *Circulation* **90**, pp. 1624-1630; The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators (1994) *Circulation* **90**, pp. 1631-1637; Neuhaus K.L. et. al. (1994) *Circulation* **90**, pp.1638-1642).

It has been found that ADP acts as a key mediator of thrombosis. A pivotal role for ADP is supported by the fact that other agents, such as adrenaline and 5-hydroxytryptamine (5HT, serotonin) will only produce aggregation in the presence of ADP. The limited anti-thrombotic efficacy of aspirin may reflect the fact that it blocks only one source of ADP which is that released in a thromboxane-dependent manner following platelet adhesion (see e.g. Antiplatelet Trialists' Collaboration (1994), *Br. Med. J.* **308**, pp. 81-106; Antiplatelet Trialists' Collaboration (1994), *Br. Med. J.* **308**, pp.159-168). Aspirin has no effect on aggregation produced by other sources of ADP, such as damaged cells or ADP released under conditions of turbulent blood flow. ADP-induced platelet aggregation is mediated

by the P_{2T} -receptor subtype uniquely located on the platelet membrane. Recently it has been shown that antagonists at this receptor offer significant improvements over other anti-thrombotic agents. Accordingly there is a need to find P_{2T} -antagonists as anti-thrombotic agents.

It has now been found that a series of triazolo[4,5-*d*]pyrimidine derivatives are P_{2T} -receptor antagonists. In a first aspect the invention therefore provides a compound of formula (I):



wherein:

R^1 is a C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} -cycloalkyl or a phenyl group, each group being optionally substituted by one or more substituents selected from halogen, OR^8 , NR^9R^{10} , SR^{11} or C_{1-6} alkyl (itself optionally substituted by one or more halogen atoms);

R^2 is C_{1-8} alkyl optionally substituted by one or more substituents selected from halogen, OR^8 , NR^9R^{10} , SR^{11} , C_{3-8} -cycloalkyl, aryl (optionally substituted by one or more alkyl groups and/or halogen atoms), or C_{1-6} -alkyl; or R^2 is a C_{3-8} -cycloalkyl group optionally substituted by one or more substituents selected from halogen, OR^8 , NR^9R^{10} , SR^{11} ,

C_{1-6} -alkyl or phenyl, the latter two groups being optionally substituted by one or more substituents selected from halogen, NO_2 , $C(O)R^8$, OR^8 , SR^{11} , $NR^{12}R^{13}$, a fused 5- or 6-membered saturated ring containing one or two oxygen atoms, phenyl or C_{1-6} -alkyl the latter two groups being optionally substituted by OR^8 , NR^9R^{10} or one or more halogen atoms;

one of R^3 and R^4 is hydroxy and the other is hydrogen, hydroxy or NR^9R^{10} ;

R is a group $(CR^5R^6)_mOR^7$ where m is 0 or 1, R^5 and R^6 are independently hydrogen, C_{1-6} alkyl or phenyl the latter two groups being optionally substituted by halogen, and R^7 is hydrogen, C_{1-6} alkyl or $(CR^5R^6)_nR^{14}$ where R^5 and R^6 are as defined above, n is 1 to 3 and R^{14} is $COOH$, OR^{15} , $NR^{16}R^{17}$ or $CONR^{16}R^{17}$;

or R is a C_{1-4} alkyl or C_{2-4} alkenyl group, each of which is substituted by one or more groups selected from $=S$, $=O$, $=NR^{20}$ or OR^{21} and optionally substituted by one or more

groups selected from halogen, C₁₋₄ alkyl, phenyl, SR²¹, NO₂ or NR²²R²³ (where R²¹, R²² and R²³ are independently hydrogen, C₁₋₄ alkyl or phenyl; R²⁰ is OR²⁴ or NR²⁵R²⁶, where R²⁴ is hydrogen, C₁₋₄ alkyl or phenyl, and R²⁵ and R²⁶ are independently hydrogen, C₁₋₄ alkyl, aryl, C₁₋₆ acyl, arylsulphonyl or arylcarbonyl);

5 R⁸ is hydrogen, C₁₋₆ alkyl optionally substituted by halogen or R⁸ is phenyl optionally substituted by one or more substituents selected from halogen, NO₂, C(O)R⁶, OR⁶, SR⁹, NR¹⁰R¹¹;


R⁹, R¹⁰ and R¹¹ are independently hydrogen or C₁₋₆ alkyl;

10 R¹² and R¹³ are independently hydrogen, C₁₋₆ alkyl, acyl, alkyl sulfonyl optionally substituted by halogen, or phenyl sulfonyl optionally substituted by C₁₋₄ alkyl; and R¹⁵, R¹⁶ and R¹⁷ are independently hydrogen or C₁₋₆ alkyl;

or a pharmaceutically acceptable salt or solvate thereof.

15 Alkyl groups, whether alone or as part of another group, can be straight chained or branched. Compounds of formula (I) are capable of existing in stereoisomeric forms including enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates. The invention also extends to any tautomeric forms and mixtures thereof.

20 Preferably the compound of formula (I) has the following stereochemistry:



25 Suitably R¹ is a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkenyl, C₃₋₈-cycloalkyl or a phenyl group, each group being optionally substituted by one or more substituents selected from halogen, OR⁸, NR⁹R¹⁰, SR¹¹ or C₁₋₆ alkyl (itself optionally substituted by one or more halogen atoms). Preferably R¹ is C₁₋₄ alkyl or phenyl each of which can be substituted by trifluoromethyl. More preferably R¹ is propyl, butyl, trifluoromethylphenyl or 3,3,3-trifluoropropyl.

- Suitably R^2 is C_{1-8} alkyl optionally substituted by one or more substituents selected from halogen, OR^8 , NR^9R^{10} , SR^{11} , C_{3-8} -cycloalkyl, aryl (optionally substituted by one or more alkyl groups and/or halogen atoms), or C_{1-6} -alkyl; or R^2 is a C_{3-8} -cycloalkyl group optionally substituted by one or more substituents selected from halogen, OR^8 , NR^9R^{10} , SR^{11} , C_{1-6} -alkyl or phenyl, the latter two groups being optionally substituted by one or more substituents selected from halogen, NO_2 , $C(O)R^8$, OR^8 , SR^{11} , $NR^{12}R^{13}$, a fused 5- or 6-membered saturated ring containing one or two oxygen atoms, phenyl or C_{1-6} -alkyl the latter two groups being optionally substituted by OR^8 , NR^9R^{10} or one or more halogen atoms. Aryl groups include phenyl and naphthyl groups. Acyl groups include $C(O)C_{1-6}$ alkyl such as acetyl and 1-oxopropyl. Preferably R^2 is C_{1-6} alkyl or a C_{3-8} -cycloalkyl group optionally substituted by phenyl. More preferably R^2 is butyl or cyclopropyl optionally substituted by phenyl, the phenyl group itself being optionally substituted by one or more halogen, C_{3-8} alkyl, alkoxy, phenoxy or phenyl groups.
- Suitably one of R^3 and R^4 is hydroxy and the other is hydrogen, hydroxy or NR^9R^{10} . Preferably R^3 and R^4 are both hydroxy.


- Suitably R is a group $(CR^5R^6)_mOR^7$ where m is 0 or 1, R^5 and R^6 are independently hydrogen, C_{1-6} alkyl or phenyl the latter two groups being optionally substituted by halogen, and R^7 is hydrogen, C_{1-6} alkyl or $(CR^5R^6)_nR^{14}$ where R^5 and R^6 are as defined above, n is 1 to 3 and R^{14} is $COOH$, OR^{15} , $NR^{16}R^{17}$ or $CONR^{16}R^{17}$; or R is a C_{1-4} alkyl or C_{2-4} alkenyl group, each of which is substituted by one or more groups selected from $=S$, $=O$, $=NR^{20}$ or OR^{21} and optionally substituted by one or more groups selected from halogen, C_{1-4} alkyl, phenyl, SR^{21} , NO_2 or $NR^{22}R^{23}$ (where R^{21} , R^{22} and R^{23} are independently hydrogen, C_{1-4} alkyl or phenyl; R^{20} is OR^{24} or $NR^{25}R^{26}$, where R^{24} is hydrogen, C_{1-4} alkyl or phenyl, and R^{25} and R^{26} are independently hydrogen, C_{1-4} alkyl, aryl, C_{1-6} acyl, arylsulphonyl or arylcarbonyl).

- Preferred R groups include OH , CH_2OH , CH_2CH_2OH , OCH_2CH_2OH , $CH_2OCH_2C(CH_3)_2OH$ and $OCH_2C(CH_3)_2OH$.


Particularly preferred compounds of the invention include those exemplified herein both as free bases and as pharmaceutically acceptable salts and solvates.

According to the invention there is further provided a process for the preparation of a compound of formula (I) which comprises:

(a) reacting a compound of formula (II):




where R, R¹, R³ and R⁴ are as defined in formula (I) or are protected derivatives thereof or R³ and R⁴ together form a bond, and L is a leaving group with a compound of formula (III):




where R² is as defined in formula (I) or is a protected derivative thereof, or

(b) reacting a compound of formula (IV):



in which R¹ and R² are as defined in formula (I) or are protected derivatives thereof and P¹ and P² are protecting groups or hydrogen, with a suitable reagent to introduce a substituent R, or, for compounds where m is 0:

(c) hydroxylation of a compound of formula (V):



where R¹, R² and R⁷ are as defined in formula (I) or are protected derivatives thereof, and optionally thereafter (a), (b) or (c) and in any order:

- converting one or more functional groups into a further functional groups
- removing any protecting groups
- forming a pharmaceutically acceptable salt or solvate.

Compounds of formula (II) can be reacted with amines of formula (III) in the presence of a base such as a tertiary organic amine in an inert solvent such as dichloromethane at ambient or elevated temperature. Other suitable bases include inorganic bases such as potassium carbonate.

When one or both of R³ and R⁴ are hydroxy they can be protected as groups OP¹ and OP² where P¹ and P² are protecting groups. Examples of suitable protecting groups in compounds of formula (II) and (IV) are C₁₋₆ alkyl (preferably methyl), benzyl, (C₁₋₆alkyl)₃Si (preferably t-butyldimethylsilyl), and a C(O)C₁₋₆alkyl group such as acetyl. When both of R³ and R⁴ are hydroxy preferably the two groups P¹ and P² together with the atoms to which they are attached form an alkylidene ring such as a methylenide or isopropylidene ring. Alternatively P¹ and P² can form an alkoxymethylidene ring such as ethoxymethylidene.

Protecting groups can be added and removed using known reaction conditions. The use of protecting groups is fully described in 'Protective Groups in Organic Chemistry', edited by J W F McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 2nd edition, T W Greene & P G M Wutz, Wiley-Interscience (1991).

Ester protecting groups can be removed by basic hydrolysis, for example by using a metal hydroxide, preferably an alkali metal hydroxide, such as sodium hydroxide or lithium hydroxide, or quaternary ammonium hydroxide in a solvent, such as aqueous ethanol or aqueous tetrahydrofuran, at a temperature of from 10° to 100°C, preferably the temperature


is around room temperature; or by acidic hydrolysis using a mineral acid such as HCl or a strong organic acid such as trichloroacetic acid in a solvent such as aqueous 1,4-dioxane.

Trialkylsilyl protecting groups can be removed by the use of, for example, a fluoride ion source, for example tetra-n-butylammonium fluoride or hydrogen fluoride.

When one or both of P^1 and P^2 are C_{1-6} alkyl, deprotection can be achieved using boron tribromide.


Benzyl groups can be removed by hydrogenolysis using a transition metal catalyst, for example palladium on charcoal, under an atmosphere of hydrogen, at a pressure of from 1 to 5 bar, in a solvent, such as acetic acid.

A compound of formula (II) can be prepared by diazotising a compound of formula (VI):



wherein R and R^1 are as defined in formula (I) and L is as defined above and R^3 and R^4 are as defined in formula (I) or are protected derivatives thereof or R^3 and R^4 together form a bond, with a metal nitrite, for example an alkali metal nitrite, especially sodium nitrite in dilute aqueous acid, for example 2M HCl, or with a C_{1-6} -alkyl nitrite in an inert solvent, at a temperature of from -20 to 100°C ; preferred conditions are isoamyl nitrite in acetonitrile at 80°C .


A Compound of formula (VI) wherein R is CH_2OH , and R^3 and R^4 are hydroxyl or protected derivatives thereof, L is as defined above, can be prepared by reducing a compound of formula (VII):




wherein R^1 , L, P^1 and P^2 are as defined above. The reduction of the nitro group can be carried out for example by using hydrogenation with a transition metal catalyst at a temperature around room temperature, for example palladium on charcoal under an atmosphere of hydrogen, preferably at a pressure from 1 to 5 atmospheres, in a solvent, for example ethanol, or by using iron in an acidic solvent such as acetic acid at a temperature of about 100°C.

- Reduction of the lactam can be carried out using complex metal hydrides such as lithium aluminium hydride in a solvent such as ether or preferably by using sodium borohydride in a suitable solvent such as methanol.


A compound of formula (VII) can be prepared by reacting a compound of formula (VIII):




wherein L and R^1 are as defined above and L^1 is a leaving group, for example a halogen atom, wherein L and L^1 are preferably the same, with a compound of formula (IX):



wherein P^1 and P^2 are as defined above, in the presence of a base such as C_{1-6} -alkyl-M or MH wherein M is a metal ion, for example n-butyl lithium, in an inert solvent, such as tetrahydrofuran (THF), at a temperature of from -10 to 100°C. Preferably sodium hydride is used in THF at room temperature. Preferably the compound of formula (IX) has the following stereochemistry such that the above reactions give a compound of formula (Ia):



One or more functional groups can be converted into further functional groups using standard chemistry. For example a compound where R^7 is hydrogen can be converted to a compound where R^7 is CH_2COOH by treating with a compound of formula (X):




where R^{18} is C_{1-6} alkyl in the presence of rhodium acetate, followed by hydrolysis of the resulting ester. A compound where R^7 is hydrogen can be converted to a compound where R^7 is $(CH_2)_nR^{14}$ by treatment with base followed by $L(CH_2)_nR^{14}$ where L is a leaving group and R^{14} is as defined above or a protected version thereof. The group SR^1 can be interconverted by oxidation of the sulfur, for example using oxoneTM or MCBPA, followed by treatment with a compound R^1-SM where R^1 is a different R^1 group and M is a metal such as sodium.

Compounds of formula (IV) can be reacted with a suitable reagent to introduce the R group using conventional chemistry. For example compounds of formula (IV) can be reacted with Zn/H_2SO_4 to give a compound of formula (I) where R is $COCH_2OH$; with HI to give a compound of formula (I) where R is $COCH_3$; or with $BF_3/R'OH$ (e.g. methanol) to give a


compound of formula (I) where R is $\text{COCH}_2\text{OR}'$, or with light followed by a reducing agent (eg DIBAL-H) to give a compound of formula (I) where R is $\text{CH}_2\text{CH}_2\text{OH}$.

Compounds of formula (IV) can be prepared from compounds of formula (XI):




in which R^1 , R^2 , P^1 and P^2 are as defined above by treatment with an activating agent, such as an acyl chloride, followed by diazomethane. Compounds of formula (XI) can be prepared from compounds of formula (VII) as defined above by reduction of the nitro group followed by hydrolysis. Hydrolysis can be performed using a mineral acid such as HCl or a strong organic acid such as trifluoroacetic acid. Preferably the reduction and hydrolysis are carried out simultaneously using iron in an alcoholic solvent, for example ethanol, containing an alkaline earth halide such as calcium chloride at a temperature of about 80°C .

Compounds of formula (VI) can also be prepared by treating a compound of formula (XII)




where R^3 and R^4 are as defined in formula (I) or are protected derivatives thereof or R^3 and R^4 together form a bond with a compound of formula (VIII) as defined above, followed by reduction of the nitro group. The reaction is carried out in an inert solvent such as dichloromethane or 1,4-dioxane in the presence of a non-nucleophilic base such as *N,N*-diisopropylamine at a temperature of about -20°C to about 150°C , preferably at ambient temperature.

Preferably the compound of formula (XII) has the following stereochemistry such that the above reactions give a compound of formula (Ia) as defined above




(XIIa)

Compounds of formula (VI) where R³ and R⁴ form a bond and L is SR¹ can be prepared by reacting a compound of formula (XIII):



(XIII)


in which R¹ groups are as defined in formula (I) with a compound of formula (XIV):



(XIV)

in which R⁵ is as defined in formula (I). The reaction can be carried out in the presence of a suitable transition metal complex, preferably tetrakis(triphenylphosphine) palladium (0).

Compounds of formula (XIII) can be prepared from compounds of formula (XV):



(XV)

by reacting with a compound R^1X where R^1 is as defined in formula (I) and X is a leaving group such as halo, followed by cyclisation.

The amines R^2NH_2 can be prepared using procedures described in H Nishiyama *etal*, Bull. Chem. Soc., Jpn., 1995, **68**, 1247, P. Newman, Optical Resolution Procedures for Chemical Compounds, Vol. 1, Amines and Related Compounds; Optical Resolution and Information Centre: Manhattan College, Riverdale, NY, 1978, p120, J. Vallgarda *etal*, J. Chem. Soc. Perkin 1, 1994, 461. Certain amines R^2NH_2 are novel compounds and form a further aspect of the invention.

All novel intermediates form a further aspect of the invention.

Salts of the compounds of formula (I) may be formed by reacting the free acid, or a salt thereof, or the free base, or a salt or a derivative thereof, with one or more equivalents of the appropriate base (for example ammonium hydroxide optionally substituted by C_{1-6} -alkyl or an alkali metal or alkaline earth metal hydroxide) or acid (for example a hydrohalic (especially HCl), sulphuric, oxalic or phosphoric acid). The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, e.g. water, ethanol, THF or diethyl ether, which may be removed *in vacuo*, or by freeze drying. The reaction may also be a metathetical process or it may be carried out on an ion exchange resin. The non-toxic physiologically acceptable salts are preferred, although other salts may be useful, e.g. in isolating or purifying the product.

The compounds of the invention act as P_{2T} receptor antagonists. Accordingly, the compounds are useful in therapy, especially adjunctive therapy, particularly they are indicated for use as: inhibitors of platelet activation, aggregation and degranulation, promoters of platelet disaggregation, anti-thrombotic agents or in the treatment or prophylaxis of unstable angina, coronary angioplasty (PTCA), myocardial infarction, perithrombolysis, primary arterial thrombotic complications of atherosclerosis such as thrombotic or embolic stroke, transient ischaemic attacks, peripheral vascular disease, myocardial infarction with or without thrombolysis, arterial complications due to interventions in atherosclerotic disease such as angioplasty, endarterectomy, stent placement, coronary and other vascular graft surgery, thrombotic complications of surgical or mechanical damage such as tissue salvage following accidental or surgical trauma, reconstructive surgery including skin and muscle flaps, conditions with a diffuse thrombotic/platelet consumption component such as disseminated intravascular

coagulation, thrombotic thrombocytopenic purpura, haemolytic uraemic syndrome, thrombotic complications of septicaemia, adult respiratory distress syndrome, anti-phospholipid syndrome, heparin-induced thrombocytopenia and pre-eclampsia/eclampsia, or venous thrombosis such as deep vein thrombosis, venoocclusive disease, haematological conditions such as myeloproliferative disease, including thrombocythaemia, sickle cell disease; or in the prevention of mechanically-induced platelet activation *in vivo*, such as cardio-pulmonary bypass and extracorporeal membrane oxygenation (prevention of microthromboembolism), mechanically-induced platelet activation *in vitro*, such as use in the preservation of blood products, e.g. platelet concentrates, or shunt occlusion such as in renal dialysis and plasmapheresis, thrombosis secondary to vascular damage/inflammation such as vasculitis, arteritis, glomerulonephritis, inflammatory bowel disease and organ graft rejection, conditions such as migraine, Raynaud's phenomenon, conditions in which platelets can contribute to the underlying inflammatory disease process in the vascular wall such as atheromatous plaque formation/progression, stenosis/restenosis and in other inflammatory conditions such as asthma, in which platelets and platelet-derived factors are implicated in the immunological disease process.

According to the invention there is further provided the use of a compound according to the invention in the manufacture of a medicament for the treatment of the above disorders. In particular the compounds of the invention are useful for treating myocardial infarction, thrombotic stroke, transient ischaemic attacks, peripheral vascular disease and angina, especially unstable angina. The invention also provides a method of treatment of the above disorders which comprises administering to a patient suffering from such a disorder a therapeutically effective amount of a compound according to the invention.

The compounds may be administered topically, e.g. to the lung and/or the airways, in the form of solutions, suspensions, HFA aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, pills, capsules, syrups, powders or granules, or by parenteral administration in the form of sterile parenteral solutions or suspensions, by subcutaneous administration, or by rectal administration in the form of suppositories or transdermally.

The compounds of the invention may be administered on their own or as a pharmaceutical composition comprising the compound of the invention in combination with a pharmaceutically acceptable diluent, adjuvant or carrier. Particularly preferred are compositions not containing material capable of causing an adverse, e.g. an allergic,

reaction.

Dry powder formulations and pressurised HFA aerosols of the compounds of the invention may be administered by oral or nasal inhalation. For inhalation the compound is desirably
5 finely divided. The compounds of the invention may also be administered by means of a dry powder inhaler. The inhaler may be a single or a multi dose inhaler, and may be a breath actuated dry powder inhaler.

One possibility is to mix the finely divided compound with a carrier substance, e.g. a
10 mono-, di- or polysaccharide, a sugar alcohol or another polyol. Suitable carriers include sugars and starch. Alternatively the finely divided compound may be coated by another

substance. The powder mixture may also be dispensed into hard gelatine capsules, each containing the desired dose of the active compound.

Another possibility is to process the finely divided powder into spheres which break up
5 during the inhalation procedure. This spheronized powder may be filled into the drug reservoir of a multidose inhaler, e.g. that known as the Turbuhaler[®] in which a dosing unit meters the desired dose which is then inhaled by the patient. With this system the active compound with or without a carrier substance is delivered to the patient.

10 The pharmaceutical composition comprising the compound of the invention may conveniently be tablets, pills, capsules, syrups, powders or granules for oral administration; sterile parenteral or subcutaneous solutions, suspensions for parenteral administration or suppositories for rectal administration.

15 For oral administration the active compound may be admixed with an adjuvant or a carrier, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatine or polyvinylpyrrolidone, and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol, waxes, paraffin, and the like, and then compressed into tablets. If coated tablets are required, the
20 cores, prepared as described above, may be coated with a concentrated sugar solution which may contain e.g. gum arabic, gelatine, talcum, titanium dioxide, and the like. Alternatively, the tablet may be coated with a suitable polymer dissolved either in a readily volatile organic solvent or an aqueous solvent.

25 For the preparation of soft gelatine capsules, the compound may be admixed with e.g. a vegetable oil or polyethylene glycol. Hard gelatine capsules may contain granules of the compound using either the above mentioned excipients for tablets, e.g. lactose, saccharose, sorbitol, mannitol, starches, cellulose derivatives or gelatine. Also liquid or semisolid formulations of the drug may be filled into hard gelatine capsules.

30 Liquid preparations for oral application may be in the form of syrups or suspensions, for example solutions containing the compound, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethylcellulose as a
35 thickening agent or other excipients known to those skilled in art.

The invention is illustrated by the following examples. In the examples the NMR spectra were measured on a Varian Unity Inova 300 or 400 spectrometer and the MS spectra were measured as follows: EI spectra were obtained on a VG 70-250S or Finnigan Mat Incos-XL spectrometer, FAB spectra were obtained on a VG70-250SEQ spectrometer, ESI and
5 APCI spectra were obtained on Finnigan Mat SSQ7000 or a Micromass Platform spectrometer. Preparative HPLC separations were generally performed using a Novapak[®], Bondapak[®] or Hypersil[®] column packed with BDSC-18 reverse phase silica. Flash chromatography (indicated in the Examples as (SiO₂)) was carried out using Fisher Matrix silica, 35-70 μ m. For examples which showed the presence of rotamers in the proton NMR
10 spectra only the chemical shifts of the major rotamer are quoted.

For compounds prepared by parallel synthesis the products were taken into ethanol (500 μ l) and analysed using an analytical HPLC machine (HP1100), against a standard calibration curve, in order to estimate the concentration of the product. The ethanol was evaporated
15 and the residue taken into an appropriate volume of DMSO, based on the HPLC analysis, to yield a solution of 5mM concentration for biological testing.

Example 1

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

a)[3*aR*-[3 α ,4 α ,6 α (1*R,2*S**),6 α]-Tetrahydro-2,2-dimethyl-6-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-4*H*-cyclopenta-1,3-dioxole-4-methanol**

N,N-Diisopropylethylamine (21ml) was added to a solution of [3*aR*-(3 α ,4 α ,6 α ,6 α)]-6-[7-chloro-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol (prepared as described in WO 9703084) (55g) and (1*R-trans*)-2-phenyl-cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1) (prepared as described by L.A. Mitscher *et al.*, J. Med. Chem. 1986, **29**, 2044) (11.3g) in dichloromethane (500ml). The reaction mixture was stirred at room temperature for 3 hours, then washed with water, dried and evaporated. The residue was purified (SiO₂, ethyl acetate:dichloromethane 3:7 as eluant) to afford the subtitle compound (19g). MS (APCI) 497 (M+H⁺, 100%)

b)[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

A solution of the product from step (a) (18.5g) in methanol (1L) and 2N HCl (150ml) was stirred at room temperature for 2 hours and concentrated *in vacuo*. Water (500ml) was added and the product was collected by filtration and dried (16.7g).

MS (APCI) 457 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.33 (1H, d), 7.30-7.16 (5H, m), 5.01 (2H, m), 4.72 (2H, m), 4.43 (1H, m), 3.87 (1H, d), 3.48 (2H, m), 3.20 (1H, m), 2.95 and 2.85 (2H, 2x m), 2.26 (1H, m), 2.12 (2H, m), 1.85 (1H, m), 1.49 (3H, m), 1.33 (1H, m), 0.82 (3H, t).

Example 2

[1*R*-(1 α ,2 α ,3 β ,5 β)]-3-[7-[(Cyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

- 5 **a) [3*aR*-(3 α ,4 α ,6 α ,6 α)]-6-[7-[(Cyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

A solution of [3*aR*-(3 α ,4 α ,6 α ,6 α)]-6-[7-chloro-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol (0.5g) and cyclopropanamine (0.3ml) in 1,4-dioxane (20ml) was heated to reflux. The heat source was removed and the reaction mixture was stirred for 1 hour. The mixture was concentrated and the residue purified (SiO₂, ethyl acetate: isohexane 1:1 as eluant) to afford the subtitle compound (0.4g).

MS (APCI) 421 (M+H⁺, 100%)

15

- b) [1*R*-(1 α ,2 α ,3 β ,5 β)]-3-[7-[(Cyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

A solution of the product from step (a) (0.12g) in trifluoroacetic acid (4ml)/water (1ml) was stirred at room temperature for 2 hours, poured into dilute aqueous sodium bicarbonate and extracted with dichloromethane. The extract was concentrated and purified (SiO₂, ethyl acetate as eluant) to afford the title compound (0.10g).

MS (APCI) 381 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.00 (1H, s), 5.00 (2H, m), 4.70 (2H, m), 4.45-4.40 (1H, m), 3.90 (1H, br s), 3.50-3.40 (2H, m), 3.10-3.00 (3H, m), 2.25-2.20 (1H, m), 2.19-2.16 (1H, m), 1.90-1.80 (1H, m), 1.80-1.60 (2H, m), 1.00 (3H, t), 0.90-0.60 (4H, m).

25

Example 3

[1*R*-(1 α ,2 α ,3 β ,5 β)]-3-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

30

The title compound was prepared from [3*aR*-(3 α ,4 α ,6 α ,6 α)]-6-[7-(butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol (prepared as described in WO 9703084) according to the method of example 2 step (b).

35 MS (FAB) 397 (M+H⁺, 100%)

NMR δ H (d_6 -DMSO) 6.25 (1H, m), 5.15 (1H, s), 5.00 (1H, m), 4.45 (1H, m), 4.25 (1H, s), 3.90-3.60 (4H, m), 3.10 (2H, m), 2.94 (1H, s), 2.75 (1H, m), 2.45 (1H, m), 2.20 (1H, m), 2.05 (1H, m), 1.78 (2H, m), 1.65 (2H, m), 1.46 (2H, m), 1.07 (3H, t), 1.00 (3H, t).

5 Example 4

[1*R*-(1 α ,2 α ,3 β ,5 β)]-3-[7-(Butylamino)-5-[[4-(trifluoromethyl)phenyl]thio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

a) **[3*aR*-(3 α ,4 α ,6 α ,6 α)]-6-[7-(Butylamino)-5-(propylsulfonyl)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**
 10 3-Chloroperoxybenzoic acid (1.0g) was added to a solution of [3*aR*-(3 α ,4 α ,6 α ,6 α)]-6-[7-(butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol (0.88g) in dichloromethane (100ml) and the resulting solution was stirred at room temperature for 18 hours. The solution was
 15 washed with aqueous sodium metabisulfite solution (3 x 10ml) then dried and concentrated. Purification (SiO_2 , ethyl acetate as eluant) afforded the subtitle compound (0.3g).

MS (APCI) 469 ($\text{M}+\text{H}^+$, 100%)

20 **b) [3*aR*-(3 α ,4 α ,6 α ,6 α)]-6-[7-(Butylamino)-5-[[4-(trifluoromethyl)phenyl]thio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

4-(Trifluoromethyl)thiophenol (0.18g) was added to a suspension of sodium hydride (60%, 40mg) in THF (10ml). After 30 minutes a solution of the product of step (a) (0.23g) in THF
 25 (10ml) was added dropwise and the reaction stirred for 45 minutes. The reaction mixture was added slowly to a solution of sodium chloride (10ml) containing acetic acid (1ml) then the solution extracted with ethyl acetate (50ml). The organic phase was dried and concentrated and the residue purified (SiO_2 , diethyl ether to diethyl ether:ethanol 9:1 as eluant) to give the subtitle compound.

30 MS (APCI) 539 ($\text{M}+\text{H}^+$, 100%)

c) [1*R*-(1 α ,2 α ,3 β ,5 β)]-3-[7-(Butylamino)-5-[[4-(trifluoromethyl)phenyl]thio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

Prepared according to the method of example 2, step (b), using the the product of step (b).

35 MS (APCI) 469 ($\text{M}+\text{H}^+$, 100%)

NMR δ H (d_6 -DMSO) 9.08 (1H, m), 7.88-7.78 (4H, dd), 5.00-4.91 (2H, m), 4.71-4.64 (2H, m), 4.36-4.30 (1H, m), 3.80-3.75 (1H, m), 3.42-3.17 (1H, m), 3.29-3.15 (2H, m), 2.52-2.08 (3H, m), 1.80-1.70 (1H, m), 1.37-1.32 (2H, m), 1.17-1.07 (2H, m), 0.77 (3H, t).

5 Example 5

2-[[[1*R*-(1 α ,2 β ,3 β ,4 α)]-4-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,3-dihydroxy-cyclopentyl]methoxy]acetic acid

a) [3*aR*-(3 α ,4 α ,6 α ,6 α)]-2-[6-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methoxy]acetic acid, ethyl ester

A solution of [3*aR*-(3 α ,4 α ,6 α ,6 α)]-6-[7-chloro-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol (0.7g) and rhodium acetate (0.39g) in dichloromethane (20ml) was treated with a solution of ethyl diazoacetate (0.21ml) in dichloromethane (10ml) over 3 hours. The reaction mixture was stirred at room temperature for 60 hours, concentrated and purified (SiO₂, isohexane:ethyl acetate 3:1 as eluant). The resulting intermediate was taken into 1,4-dioxane (10ml), *n*-butylamine (0.2ml) added and the solution stirred for 18 hours then concentrated. Purification (SiO₂, dichloromethane to dichloromethane:ethyl acetate 8:2 as eluant) gave the subtitle compound (0.2g).

MS (FAB) 523 (M+H⁺, 100%)

b) 2-[[[1*R*-(1 α ,2 β ,3 β ,4 α)]-4-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,3-dihydroxy-cyclopentyl]methoxy]acetic acid, ethyl ester

Prepared according to the method of example 2, step b) using the product of step a).

MS (FAB) 483 (M+H⁺, 100%)

d) 2-[[[1*R*-(1 α ,2 β ,3 β ,4 α)]-4-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,3-dihydroxy-cyclopentyl]methoxy]acetic acid

A mixture of the product from step (c) (96mg) and lithium hydroxide monohydrate (8.5mg) in tetrahydrofuran (10ml) was stirred for 18 hours then concentrated. Purification (SiO₂, dichloromethane to ethyl acetate to ethyl acetate:methanol 9:1 gradient elution) afforded the title compound (0.04g).

MS (FAB) 455 (M+H⁺, 100%)

NMR δ H (d_6 -DMSO) 12.60 (1H, m), 8.97 (1H, m), 4.99 (2H, m), 4.82 (1H, m), 4.42 (2H, m), 4.04 (2H, m), 3.92 (2H, m), 3.60-3.51 (1H, m), 3.50-3.40 (3H, m), 3.10-3.00 (2H, t),

2.30-2.20 (2H, m), 1.88 (1H, m), 1.67 (2H, m), 1.55 (4H, m), 1.33 (2H, m), 1.07-0.83 (6H, m).

Example 6

5 **1-[[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-2,3-Dihydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]-2-hydroxy-ethanone**

a) [3*aR*-(3 α ,4 α ,6 α ,6 α)]-6-[[5-Amino-6-chloro-2-(propylthio)-4-pyrimidinyl]amino]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-carboxylic acid

10

Iron powder (10.0g) was added to a stirred solution of [3*aS*-(3 α ,4 β ,7 β ,7 α)]-5-[6-chloro-5-nitro-2-(propylthio)-pyrimidin-4-yl]-tetrahydro-4,7-methano-2,2-dimethyl-1,3-dioxolo[4,5-*c*]pyridin-6(3*aH*)-one (prepared as described in WO 9703084) (10.0g), and calcium chloride in ethanol (140ml). The reaction mixture was heated at reflux for 10 minutes then filtered through celite, washing several times with hot ethanol. The filtrate

15

was concentrated to afford the subtitle compound (9.3g).
MS (FAB) 405, 403 ($M+H^+$), 405 (100%).

b) [3*aR*-(3 α ,4 α ,6 α ,6 α)]-6-[7-Chloro-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-carboxylic acid

20

Isoamyl nitrite (6.02ml) was added to a solution of the product of step a) (9.28g) in acetonitrile (80ml) and the solution heated at 70°C for 1 hour. The cooled reaction mixture was concentrated and purified (SiO₂, ethyl acetate:isohexane 2:1 as eluant) to afford the subtitle compound (7.9g).

25

MS (FAB) 416, 414 ($M+H^+$), 414 (100%).

c) [3*aR*-(3 α ,4 α ,6 α ,6 α)]-Tetrahydro-2,2-dimethyl-6-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-4*H*-cyclopenta-1,3-dioxole-4-carboxylic acid

30

Prepared according to the method of Example 1, step a) using the product of step b).
MS (APCI) 511 ($M+H^+$, 100%).

d) 1-[[1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-2,3-Dihydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]-2-hydroxy-ethanone**

35

Isobutylchloroformate (0.38ml) was added to an ice-cooled solution of the product of step c) (0.50g) and *N*-methylmorpholine (0.11ml) in tetrahydrofuran (20 ml). The solution was then stirred at room temperature for 90 minutes before adding to a solution of diazomethane (1.0g) in ether (100ml). The solution was stirred for 30 minutes then concentrated and the diazoketone purified (SiO₂, isohexane :diethylether 1:1 as eluant). The diazoketone (0.25g) was taken into 1,4-dioxane (10 ml) / 2N sulphuric acid (10 ml) then heated at 40°C for 2 hours. The reaction mixture was extracted into ethyl acetate and the extracts washed with water then dried and concentrated. Purification (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate:acetonitrile, gradient elution 70:30 to 0:100 over 15 minutes) afforded the title compound (0.09g).

MS (APCI) 485 (M+H⁺, 100%)

NMR δH (d₆-DMSO) 9.36 (1H, d), 7.31-7.15 (5H, m), 5.24 (2H, t), 5.13 (1H, t), 5.01 (1H, m), 4.33 (1H, m), 4.23 (2H, m), 4.13 (1H, m), 3.18 (2H, m), 2.96-2.94 (1H, m), 2.96-2.84 (1H, m), 2.30 (2H, m), 2.13(1H, m), 1.49 (3H, m), 1.34 (1H, m), 0.81 (3H, t).

Example 7

1-[[1*S*-[1α,2β,3β,4α]]-4-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,3-dihydroxy-cyclopentyl]-2-hydroxy-ethanone

a) [3a*R*-(3α,4α,6α,6α)]-6-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-carboxylic acid

The title compound was prepared according to the method of Example 1, step a) using the product of example 6, step b) and butylamine.

MS (APCI) 411 (M+H⁺, 100%).

b) 1-[[1*S*-[1α,2β,3β,4α]]-4-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,3-dihydroxy-cyclopentyl]-2-hydroxy-ethanone

Prepared according to the method of Example 6, step d) using the product of step a).

MS (APCI) 425 (M+H⁺, 100%)

NMR δH (d₆-DMSO) 9.00 (1H, t), 5.26 (1H, t), 5.24 (1H, t), 5.14 (1H, t), 5.03 (1H, m), 4.38 (1H, m), 4.21 (1H, m), 4.13 (1H, m), 3.51 (2H, m), 3.15 (1H, m), 3.09 (1H, m), 2.30 (2H, m), 1.73 (1H, m), 1.61 (2H, m), 1.38 (2H, m), 1.09 (3H, t), 0.91 (3H, t).

Example 8

1-[[1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-2,3-Dihydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]-ethanone**

Isobutylchloroformate (2.54 ml) was added to an ice-cooled solution of the product of
 5 Example 6, step c) (2.00g) and *N*-methylmorpholine (0.52 ml) in tetrahydrofuran (50 ml).
 The solution was stirred at room temperature for 90 minutes before adding to a solution of
 diazomethane (4.0g) in ether (200ml). The reaction mixture was then stirred for 30
 minutes and concentrated. The crude diazoketone (2.05 g) was dissolved in chloroform
 (50 ml), 47% aqueous HI (25 ml) was added and the solution stirred at room temperature
 10 for 10 minutes before adding saturated sodium thiosulphate solution (100 ml). The
 reaction mixture was extracted with dichloromethane and the extracts washed with water,
 dried and concentrated. The residue was taken into methanol (300 ml), filtered and the
 filtrate concentrated to ¼ volume before adding trifluoroacetic acid : water (1:1) (50 ml).
 After 2 hours the mixture was concentrated and the residue purified (SiO₂, ethyl
 15 acetate:dichloromethane 1:3 as eluant, then HPLC, Novapak® C18 column, 0.1% aqueous
 ammonium acetate:acetonitrile, gradient elution 60:40 to 0:100 over 15 minutes) to afford
 the title compound (0.11g).

MS (APCI) 469 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.35 (1H, d), 7.31-7.15 (5H, m), 5.21 (2H, m), 4.99 (1H, m), 4.27
 20 (1H, m), 4.17 (1H, m), 3.21 (1H, m), 3.10 (1H, m), 2.95-2.83 (2H, m), 2.35 (2H, m), 2.22
 (3H, s), 2.13 (1H, m), 1.50 (3H, m), 1.33 (1H, m), 0.81 (3H, t).

Example 9

**1-[[1*S*-[1 α ,2 β ,3 β ,4 α]-4-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-
 25 *d*]pyrimidin-3-yl]-2,3-dihydroxy-cyclopentyl]-ethanone**

The title compound was prepared according to the method of Example 8 using the product
 of Example 7, step a).

MS (APCI) 409 (M+H⁺, 100%)

30 NMR δ H (d₆-DMSO) 8.98 (1H, t), 5.22 (2H, m), 5.00 (1H, q), 4.27 (1H, m), 4.19 (1H, m),
 3.48 (2H, m), 3.13 (3H, m), 2.32 (2H, m), 2.23 (3H, s), 1.71 (2H, m), 1.63 (2H, m), 0.98
 (3H, m), 0.91 (3H, t).

Example 10

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(1-Hydroxy-1-methylethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

5

Methylmagnesium bromide (3M solution in diethyl ether, 4 ml) was added to a solution of the product of Example 8 (0.15 g) in tetrahydrofuran and the solution stirred at room temperature for 30 minutes before adding ice/water (3 ml), followed by 1N hydrochloric acid (1 ml). The reaction mixture was extracted into ethyl acetate and the extracts washed with water, dried and concentrated. Purification (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate:acetonitrile, gradient elution 70:30 to 0:100 over 15 minutes) gave the title compound (0.13g).

10

MS (APCI) 485 (M+H⁺, 100%)

15

NMR δ H (d₆-DMSO) 9.34 (1H, d), 7.31-7.15 (5H, m), 4.90 (2H, m), 4.57 (1H, m), 4.35 (3H, m), 3.93 (1H, m), 3.22 (1H, m), 2.97-2.51 (2H, m), 2.07 (3H, m), 1.95 (1H, s), 1.51 (3H, m), 1.33 (1H, m), 1.31 (3H, s), 1.18 (3H, s), 0.80 (3H, t).

Example 11

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

20

a) [1*R*-[1 α ,2 β ,3 β ,4 α (1*R,2*S**)]]-2,3-Dihydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentaneacetic acid, ethyl ester**

25

Isobutylchloroformate (2.54 ml) was added to an ice-cooled solution of the product of Example 6, step c) (2.00g) and *N*-methylmorpholine (0.52 ml) in tetrahydrofuran (50 ml). The solution was stirred at room temperature for 90 minutes then added to a solution of diazomethane (4.0g) in ether (200ml). The solution was stirred for 30 minutes then concentrated. The crude diazoketone (1.50 g) was taken into methanol (100 ml), cooled in ice/water and irradiated with a 400W mercury lamp for 10 minutes. The solution was concentrated and purified (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate:acetonitrile, gradient elution 40:60 to 0:100 over 15 minutes) to afford the subtitle compound (0.39g).

30

35

MS (APCI) 539 (M+H⁺, 100%).

b) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

DIBAL-H[®] (1.5 M solution in toluene, 2 ml) was added to an ice-cooled solution of the product of step a) (0.35 g) in toluene (20 ml) and the solution stirred at this temperature for 30 minutes before adding ethyl acetate (2 ml). The solution was concentrated and the residue was taken into trifluoroacetic acid (15 ml) /water (15 ml) and stirred for 30 minutes. The reaction mixture was concentrated and the residue taken into methanol (10 ml) and 10% aqueous potassium carbonate solution (5 ml) added. After 30 minutes the reaction mixture was extracted with ethyl acetate and washed with water, dried and concentrated. Purification (HPLC, Novapak[®] C18 column, 0.1% aqueous ammonium acetate:acetonitrile, gradient elution 60:40 to 0:100 over 15 minutes) afforded the title compound (0.21g).

MS (APCI) 471 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.33 (1H, d), 7.31-7.15 (5H, m), 5.00 (1H, d), 4.96 (1H, m), 4.77 (1H, d), 4.51 (1H, t), 4.39 (1H, m), 3.76 (1H, m), 3.45 (2H, m), 3.18 (1H, m), 2.87 (2H, m), 2.37 (1H, m), 2.13 (1H, m), 2.03 (1H, m), 1.75 (2H, m), 1.51 (4H, m), 1.34 (1H, m), 0.83 (3H, t).

Example 12

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

a) (1*S*-*cis*)-4-[[6-Chloro-5-nitro-2-(propylthio)-pyrimidin-4-yl]amino]-2-cyclopentene-1-ol

To a solution of 4,6-dichloro-5-nitro-2-propylthiopyrimidine (prepared as described in WO 9703084) (4.00g) and triethylamine (2.00ml) in dry tetrahydrofuran (THF) (100ml) was added a solution of [1*S*-*cis*]-4-amino-2-cyclopenten-1-ol (prepared as described by S. F. Martin et al., Tetrahedron Lett., 1992, **33**, 3583) (1.48g) in THF /1,4-dioxane 2:1 (150ml) dropwise over 1 hour. The reaction mixture was filtered, concentrated and purified (SiO₂, ethyl acetate:isohexane 1:4 to 1:1 as eluant) to afford the subtitle compound (3.18g).

MS (APCI) 313 (M-H₂O+H⁺, 100%)

b) (1*S*-cis)-4-[[5-Amino-6-chloro-2-(propylthio)-pyrimidin-4-yl]amino]-2-cyclopentene-1-ol

Iron powder (2.30g) was added to a stirred solution of the product of step (a) (2.61g) in acetic acid (100ml). The reaction mixture was stirred at room temperature for 2 hours, concentrated to half volume, diluted with ethyl acetate and washed with water. The organic phase was dried and concentrated to afford the subtitle compound (2.28g).

NMR δ H (d_6 -DMSO) 7.03 (1H, d), 5.93-5.90 (1H, m), 5.85-5.82 (1H, m), 5.05 (1H, d), 4.91-4.85 (2H, m), 4.66-4.60 (1H, m), 2.94 (2H, t), 2.77-2.68 (1H, m), 1.69-1.57 (2H, sextuplet), 1.48-1.42 (1H, quintuplet), 0.94 (3H, t).

c) (1*S*-cis)-4-[7-Chloro-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2-cyclopentene-1-ol

Prepared according to the method of example 6, step b) using the product of step b).

MS (APCI) 312 ($M+H^+$), 224 (100%)

d) (1*R*-trans)-*N*-[(2,4-Dimethoxyphenyl)methyl]-2-phenyl-cyclopropanamine

A solution of (1*R*-trans)-2-phenyl-cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1) (prepared as described by L.A. Mitscher et al., J. Med. Chem. 1986, **29**, 2044) (1.92g) in 1N aqueous NaOH (50ml) was stirred for 10 minutes and extracted with dichloromethane. The extract was dried, evaporated and the residue was dissolved in methanol (30ml). To this was added 2,4-dimethoxybenzaldehyde (1.12g) and the pH adjusted to 5 with acetic acid. Sodium cyanoborohydride (0.46g) was added. The mixture was stirred overnight, basified with 2N NaOH and extracted with ethyl acetate. The extract was dried, evaporated and purified (SiO_2 , methanol:dichloromethane: 0.880 ammonia 2: 98: 0.1 as eluant) to afford the subtitle compound (1.10g).

NMR δ H ($CDCl_3$) 7.23-6.97 (6H, m), 6.49-6.41 (2H, m), 3.73 (3H, s), 3.69 (3H, s), 3.66 (2H, s), 2.21-2.16 (1H, m), 1.82-1.76 (1H, m), 1.01-0.87 (2H, m).

e) [1*S*-[1 α ,4 α -(1*S,2*R**)]]-4-[7-[*N*-[(2,4-Dimethoxyphenyl)methyl]-(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2-cyclopentene-1-ol**

A solution of the product from step (c) (0.73g), the product from step (d) (0.73g) and *N,N*-diisopropylethylamine (815 μ l) in 1,4-dioxane (25ml) was stirred at room temperature for 1 hour. The reaction mixture was concentrated and the residue purified (SiO_2 , ethyl acetate: hexane 1:2 as eluant) to afford the subtitle compound (1.18g).

MS (APCI) 559 ($M+H^+$, 100%)

f) [1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-4-[7-[*N*-[(2,4-Dimethoxyphenyl)methyl]-(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

- 5 To a solution of the product of step (e) (0.50g) in acetone (10ml) and water (7ml) was added *N*-methylmorpholine-*N*-oxide (0.38g) followed by osmium tetroxide (390 μ l, 2.5% solution in *t*-butanol). The mixture was stirred at room temperature overnight then treated with sodium hydrosulphite (0.90g). The suspension was filtered through celite and the product purified (SiO₂, ethyl acetate: hexane 1:1 as eluant) to afford the subtitle compound
- 10 (0.22g).

MS (APCI) 593 (M+H⁺, 100%)

g) [1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-4-[7-[2-(Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

- 15 Prepared according to the method of example 2, step b) using the product of step f). Purification (HPLC, Novapak[®] C18 column, 0.1% aqueous ammonium acetate:acetonitrile, 60:40) afforded the title compound (0.12g).

MS (APCI) 443 (M+H⁺, 100%)

- NMR δ H (d₆-DMSO) 7.29 (2H, m), 7.16 (3H, m), 5.11-4.91 (3H, m), 4.97 (1H, q), 4.67 (1H, m), 3.93 (1H, br s), 3.78 (1H, m), 3.22 (1H, quintet), 2.95-2.81 (2H, m), 2.58 (1H, m), 2.13 (1H, m), 1.91 (1H, m), 1.51 (3H, m), 1.31 (1H, m), 0.81 (3H, t).
- 20

Example 13

- 2-[[[1*S*-[1 α ,3 β ,4 α (1*S**,2*R**)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]oxy]acetic acid, hemiammonium salt**
- 25

- a) 2-[[[1*S*-[1 α ,4 α (1*S**,2*R**)]]-4-[7-[*N*-[(2,4-Dimethoxyphenyl)methyl]-(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2-cyclopentenyl]oxy]acetic acid, 1,1-dimethylethyl ester**
- 30

- To a solution of the product from example 1 step (e) (1.20g) in toluene (10ml) was added aqueous NaOH (5N, 10ml) followed by tetrabutylammonium bromide (0.10g) and the mixture stirred for 30 minutes. Dimethyl sulfoxide (670 μ l) and *tert*-butyl bromoacetate (3.47ml) were added and the reaction mixture stirred for 1 hour. The organic phase was
- 35

washed with water and brine, dried and evaporated. The residue was purified (SiO₂, ethyl acetate: hexane 15:85 to 3:7 as eluant) to afford the subtitle compound (0.96g).

MS (APCI) 673 (M+H⁺, 100%)

- 5 b) 2-[[[1*S*-[1 α ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[*N*-[(2,4-Dimethoxyphenyl)methyl]-(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-3-hydroxy-cyclopentyl]oxy]acetic acid, 1,1-dimethylethyl ester and 2-[[[1*S*-[1 α ,2 β ,4 α (1*S**,2*R**)]]-4-[7-[*N*-[(2,4-Dimethoxyphenyl)methyl]-(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2-hydroxy-cyclopentyl]oxy]acetic acid, 1,1-dimethylethyl ester

10 A solution of the product from step (a) (1.08g) in tetrahydrofuran (15ml) at 0°C was treated with borane-tetrahydrofuran complex (1M solution in tetrahydrofuran, 8.02ml) dropwise. The reaction mixture was stirred at 0°C for 16 hours. Methanol was added and the mixture was stirred at room temperature and then concentrated. The residue was dissolved in
15 diglyme (10ml) then treated with trimethylamine-*N*-oxide (0.48g). The reaction mixture was heated at 130°C for 2 hours then diluted with ethyl acetate and washed with brine, 1*N* HCl and aqueous sodium bicarbonate, dried and concentrated. Purification (SiO₂, ethyl acetate: hexane 3:7 as eluant) gave the two products:

- 20 (i) 2-[[[1*S*-[1 α ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[*N*-[(2,4-Dimethoxyphenyl)methyl]-(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-3-hydroxy-cyclopentyl]oxy]acetic acid, 1,1-dimethylethyl ester (0.33g).
NMR δ H (d₆-DMSO) 7.27-7.11 (5H, m), 6.98 (1H, d), 6.54 (1H, d), 6.39 (1H, m), 5.23 (2H, br m), 5.03 (1H, d), 4.80 (3H, m), 4.20 (1H, m), 3.95 (2H, s), 3.71 (3H, s), 3.66 (3H, s), 3.00-2.90 (3H, m), 2.65 (1H, m), 2.38 (1H, br m), 2.30-2.10 (2H, m), 1.95 (1H, m), 1.60 (2H, sextuplet), 1.45 (1H, m), 1.43 (9H, s), 0.90 (3H, t).

- 30 (ii) 2-[[[1*S*-[1 α ,2 β ,4 α (1*S**,2*R**)]]-4-[7-[*N*-[(2,4-Dimethoxyphenyl)methyl]-(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2-hydroxy-cyclopentyl]oxy]acetic acid, 1,1-dimethylethyl ester (0.21g).
NMR δ H (d₆-DMSO) 7.27-7.11 (5H, m), 6.98 (1H, d), 6.54 (1H, d), 6.40-6.36 (1H, m), 5.27 (2H, m), 4.89 (1H, d), 4.25 (1H, m), 4.04 (2H, s), 3.88 (1H, m), 3.71 (3H, s), 3.65 (3H, s), 3.00-2.90 (3H, m), 2.67 (1H, m), 2.37 (1H, m), 2.30-2.10 (2H, m), 1.61 (2H, sextuplet), 1.44 (1H, m), 1.43 (9H, s), 0.91 (3H, t).

c) 2-[[[1*S*-[1 α ,3 β ,4 α (1*S,2*R**)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]oxy]acetic acid, hemiammonium salt**

The title compound was prepared according to the method of example 2, step (b) using the product of step (b)(i).

MS (APCI) 485 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 7.31-7.15 (5H, m), 4.78-4.68 (2H, m), 4.17 (1H, m), 3.90 (2H, s), 3.20 (1H, m), 2.97-2.81 (2H, m), 2.65-2.52 (1H, m), 2.25-2.11 (3H, m), 1.92-1.85 (1H, m), 1.55-1.45 (3H, m), 1.34 (1H, m), 0.81 (3H, t).

Example 14

2-[[[1*S*-[1 α ,2 β ,4 α (1*S,2*R**)]]-2-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]oxy]acetic acid, hemiammonium salt**

The title compound was prepared according to the method of example 2 step (b) using the product of step (b)(ii).

MS (APCI) 485 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 7.31-7.16 (5H, m), 5.21 (1H, quintet), 4.28 (1H, m), 4.03-3.92 (2H, m), 3.82 (1H, m), 3.19 (1H, m), 2.96-2.83 (2H, m), 2.64 (1H, m), 2.41 (1H, m), 2.16-2.08 (3H, m), 1.54-1.47 (3H, m), 1.33 (1H, m), 0.82 (3H, t).

Example 15

2-[[[1*S*-(1 α ,2 β ,3 β ,4 α)]-4-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,3-dihydroxy-cyclopentyl]oxy]acetic acid

a) 5,7-Bis(propylthio)-1*H*-1,2,3-triazolo[4,5-*d*]pyrimidine

A mixture of 4,5-diamino-2,6-dimercaptopyrimidine (25g), potassium hydroxide (36.9g) and propyl iodide (62.9ml) in water (710ml) was stirred for 72 hours. The product was collected by filtration, washed with water and dried. The material was taken into water (710ml)/glacial acetic acid (710ml), cooled to 5°C and a solution of sodium nitrite (9.38g) in water (109ml) added, maintaining the temperature below 5°C. The mixture was allowed to reach room temperature and the product was collected by filtration, washed with water and dried (28.9g).

MS (EI) 269 (M⁺)

b) Mixture of (1*S*-cis)-4-[5,7-bis(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2-cyclopentene-1-ol and (1*S*-cis)-4-[5,7-bis(propylthio)-2*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-2-yl]-2-cyclopentene-1-ol

To a solution of the product from step (a) (3.7g), (1*S*-cis)-4-acetoxy-2-cyclopenten-1-ol (2.0g) and triethylamine (6ml) in THF (100ml) at 60°C was added

tetrakis(triphenylphosphine)palladium (0) (2.0g), as a suspension in THF (50ml). The reaction mixture was stirred at 60°C for 4.5 hours and purified (SiO₂, ethyl acetate: hexane 1:3 as eluant) to give the product as a 2:1 isomeric mixture.

MS (APCI) 352 (M+H⁺, 100%)

c) [3*aR*-(3*a*α,4*a*α,6*a*α,6*a*α)]-6-[5,7-Bis(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-ol

A mixture of the product from step (b) (2.0g), 4-methylmorpholine-*N*-oxide (1.27g) and osmium tetroxide (2.5% solution in *tert*-butanol, 2.9ml) in acetone (110ml) and water (25ml) was stirred at room temperature for 16 hours. Sodium hydrosulfite (2.0g) was added and the mixture was stirred for 1 hour then filtered through celite, washing with ethyl acetate. The combined filtrates were concentrated and the residue dissolved in acetone (75ml). Tosic acid (1.08g) and 1,1-dimethoxypropane (6ml) were added and the mixture was stirred for 1 hour. The solution was concentrated and the residue was partitioned between dichloromethane and water. The organic phase was dried and concentrated and the residue purified (SiO₂, ethyl acetate: hexane 1:4 as eluant) to give the subtitle compound (1.08g).

MS (APCI) 426 (M+H⁺, 100%)

d) 2-[[[3*aR*-(3*a*α,4*a*α,6*a*α,6*a*α)]-6-[5,7-Bis(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-yl]oxy]acetic acid, 1,1-dimethylethyl ester

To a solution of the product from step (c) (0.36g) in THF (10ml) at 0°C was added sodium hydride (60% in oil, 37mg). The mixture was stirred at 0°C for 15 minutes and *tert*-butyl bromoacetate (0.14ml) was added. The mixture was stirred at room temperature for 24 hours and purified (SiO₂, ethyl acetate: hexane 1:10 as eluant) to give the subtitle compound (0.16g).

MS (APCI) 482 (M+H⁺, 100%)

e) 2-[[[3a*R*-(3a α ,4 α ,6 α ,6a α)]-6-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-yl]oxy]acetic acid, 1,1-dimethylethyl ester

A mixture of the product from step (d) (0.15g) and *n*-butylamine (5ml) in 1,4-dioxane (10ml) was stirred at room temperature for 1 hour, concentrated and purified (SiO₂, ethyl acetate: hexane 1:5 as eluant) to give the subtitle compound (0.14g).

MS (APCI) 537 (M+H⁺, 100%)

f) 2-[[[1*S*-(1 α ,2 β ,3 β ,4 α)]-4-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,3-dihydroxy-cyclopentyl]oxy]acetic acid

The product was prepared according to the method of example 2, step (b) using the product of step (e).

MS (ESI) 441 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.01 (1H, t), 4.94 (1H, q), 4.53 (1H, m), 4.04 (2H, m), 4.00 (1H, m), 3.85 (1H, m), 3.50 (2H, q), 3.08 (2H, m), 2.64 (1H, m), 2.08 (1H, m), 1.65 (4H, m), 1.34 (2H, m), 0.99 (3H, t), 0.91 (3H, t).

Example 16

2-[[[1*S*-(1 α ,2 β ,3 β ,4 α)]-4-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,3-dihydroxycyclopentyl]oxy]acetamide

To a solution of the product of example 15 (0.21g) in *N,N*-dimethylformamide (25ml) was added a solution of ammonia in acetonitrile (5ml) and bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (0.35g). The mixture was stirred for 10 minutes and *N,N*-diisopropylethylamine (300 μ l) was added. The reaction mixture was stirred at room temperature for 2 hours, concentrated and purified (Sep-pak[®] C18 silica, water to acetonitrile gradient elution followed by HPLC, Nova-pak[®] C18 column, 0.1% aqueous trifluoroacetic acid:acetonitrile 50:50) to give the title compound (0.09g).

MS (APCI) 440 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 8.99 (1H, t), 7.33 (1H, br s), 7.18 (1H, br s), 5.20-5.10 (2H, br s), 4.95 (1H, q), 4.57-4.53 (1H, m), 4.04-4.02 (1H, m), 3.88 (2H, s), 3.81-3.79 (1H, m), 3.49 (2H, q), 3.11-3.06 (2H, m), 2.70-2.60 and 2.15-2.01 (1H, m), 1.70 (2H, sextet), 1.63 (2H, quintet), 1.34 (2H, sextet), 0.99 (3H, t), 0.91 (3H, t).

Example 17

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-4-[[5-(Methylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

- 5 **a) [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylsulphonyl)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

Prepared according to the method of example 4, step (a) using the product of example 12.
MS (APCI) 475 (M+H⁺, 100%)

10

b) [1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-4-[[5-(Methylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

Sodium thiomethoxide (0.11g) was added to a solution of the product of step a) (0.34g) in THF (20ml) and the reaction stirred for 1 hour. The reaction mixture was concentrated and the residue purified (SiO₂, ethyl acetate as eluant) to give the title compound (0.20g).

15

MS (APCI) 415 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.36 (1H, d), 7.31-7.16 (5H, m), 5.11-5.10 (1H, m), 5.04-5.01 (1H, m), 4.97 (1H, d), 4.94-4.93 (1H, m), 4.68-4.63 (1H, m), 3.94-3.92 (1H, m), 3.79 (1H, s), 3.21-3.18 (1H, m), 2.62-2.57 (1H, m), 2.32 (3H, s), 2.15-2.11 (1H, m), 2.14-2.10 (2H, m), 1.94-1.87 (1H, m), 1.51-1.47 (1H, m), 1.36-1.32 (1H, m)

20

Example 18

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-4-[5-[(Methylethyl)thio]-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

25

Prepared according to the method of example 4, step (b) using the product of example 17, step (a).

MS (APCI) 443 (M+H⁺, 100%)

30 NMR δ H (d₆-DMSO) 9.38 (1H, d), 7.31-7.16 (5H, m), 5.11 (1H, d), 5.04-4.96 (1H, m), 4.93-4.91 (1H, m), 4.67-4.63 (1H, m), 3.94-3.92 (1H, m), 3.79 (1H, s), 3.61 (1H, sept) 3.20-3.16 (1H, m), 2.62-2.57 (1H, m), 2.11-2.07 (1H, m), 1.93-1.89 (1H, m), 1.60-1.54 (1H, m), 1.38-1.30 (1H, m), 1.13 (3H, d), 1.07 (3H, d)

Example 19

[1*S*-(1 α ,2 β ,3 β ,4 α (1*S, 2*R**))]-4-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

5 **a) (1*R*-*cis*)-Bis(1,1-dimethylethyl)-4-hydroxy-2-cyclopentenylimidodicarbonate**

To a suspension of ether washed sodium hydride (60% dispersion in oil; 0.31 g) in THF (30 ml) was added imidodicarbonic acid bis-(1,1-dimethylethyl)ester (1.84 g). The mixture was stirred at 40°C for 1 hour. To the mixture, at ambient temperature, was then added (1*S*-*cis*)-4-acetoxy-2-cyclopenten-1-ol (0.5 g) and tetrakis(triphenylphosphine)palladium (0) (0.185 g). The reaction mixture was stirred for 24 hours then purified (SiO₂, ethyl acetate: hexane 1:9 as eluant) to give the subtitle compound as a colourless solid (0.9 g). NMR δ H (d₆-DMSO) 1.43 (18H, s), 1.61 (1H, ddd, *J*=12.3, 7.7, 6.4 Hz), 2.54 (1H, dt, *J*=12.6, 7.4 Hz), 4.51-4.57 (1H, m), 4.86 (1H, tq, *J*=8.0, 1.8 Hz), 4.91 (1H, d, *J*=5.4 Hz), 5.71-5.77 (2H, m).

15 **b) [1*R*-(1 α ,2 β ,3 β ,4 α)]-2,3,4-Trihydroxy-cyclopentenylimidodicarbonic acid, bis(1,1-dimethylethyl) ester**

The subtitle compound was prepared according to the method of example 12, step (f) using the product of step (a).

20 NMR δ H (d₆-DMSO) 1.44 (18H, s), 1.46-1.60 (1H, m), 1.97-2.05 (1H, m), 3.55-3.58 (1H, m), 3.66-3.73 (1H, m), 4.11-4.21 (2H, m), 4.54 (1H, d, *J*=4.8 Hz), 4.56 (1H, d, *J*=5.9 Hz), 4.82 (1H, d, *J*=4.6 Hz)

25 **c) [1*S*-(1 α ,2 β ,3 β ,4 α)]-4-[[6-Chloro-5-nitro-2-(propylthio)-pyrimidin-4-yl]amino]-2-cyclopentane-1,2,3-triol**

A mixture of the product of step (b) (0.68 g), methanol (10 ml) and hydrochloric acid (2M; 5 ml) was stirred for 24 hours then concentrated under reduced pressure. To the residue was added THF (10 ml) and *N,N*-diisopropylethylamine (1.78 ml) followed by 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine (prepared as described in WO 9703084) (0.82 g). The mixture was heated at reflux for 20 hours then cooled and concentrated under reduced pressure. The residue was purified (SiO₂, ethyl acetate: hexane 7:3 as eluant) to give the subtitle compound as a yellow solid (0.47 g).

MS (APCI) 365/367 (M+H⁺, 100%)

d) [1*S*-(1 α ,2 β ,3 β ,4 α)]-4-[[5-Amino-6-chloro-2-(propylthio)-pyrimidin-4-yl]amino]-2-cyclopentane-1,2,3-triol

The subtitle compound was prepared according to the method of example 12, step (b) using the product of step (c).

5 MS (APCI) 335/337 (M+H⁺, 100%)

e) [1*S*-(1 α ,2 β ,3 β ,4 α)]-4-[7-Chloro-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

10 The subtitle compound was prepared according to the method of example 12, step (c) using the product of step (d).

MS (APCI) 346/348 (M+H⁺), 318 (100%)

f) [3*aS*-[1(*E*),3 α ,6 α ,7 $\alpha\beta$]]-1-[3-(4-Fluorophenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide

15 A mixture of 3-(4-fluorophenyl)-2-propenoic acid (3.0 g) and thionyl chloride (5.0 ml) was stirred at 70°C for 1 hour, the reaction mixture was then concentrated under reduced pressure. The residue was azeotroped twice with dichloromethane then dissolved in toluene (10 ml). To a suspension of sodium hydride (60% dispersion in oil; 0.99 g) in toluene (40 ml) was added a solution of [3*aS*-(3 α ,6 α ,7 $\alpha\beta$)]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide (3.89 g) in toluene (40 ml) and the mixture
20 stirred for 30 minutes. To the reaction mixture was then added the solution described above and the resulting suspension was stirred for 16 hours. Water (200 ml) was added, the organics collected and the aqueous extracted into dichloromethane (3x100 ml). The organics were combined, dried and concentrated. Recrystallisation (ethanol) gave the
25 subtitle compound as colourless needles (5.92 g).

MS (APCI) 364 (M+H⁺, 100%)

g) [3*aS*-[1(1*S,2*S**),3*aa*,6*a*,7*ab*]]-1-[[2-(4-Fluorophenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

30 A solution of diazomethane (2.9 g) in ether (150 ml) (prepared as described in Vogel's textbook of practical organic chemistry, fifth edition, Longman scientific and technical, p432) was added to a solution of the product of step f) (5.90 g) and palladium(II) acetate (18 mg) in dichloromethane (350 ml) at 0°C and the reaction mixture stirred at 0°C for 5 hours. Acetic acid (5 ml) was added and the reaction mixture was then washed with
35 saturated sodium bicarbonate solution (200 ml) and the organics filtered through a plug of

silica. After concentrating in *vacuo*, the residue was recrystallised (ethanol) to give the subtitle compound as colourless needles (3.81g).

MS (APCI) 378 (M+H⁺, 100%)

5 **h) (1*R*-trans)-2-(4-Fluorophenyl)-cyclopropanecarboxylic acid**

A suspension of the product from step g) (3.74 g) and lithium hydroxide monohydrate (4.11g) in tetrahydrofuran (100 ml) and water (3 ml) was stirred at 50°C for 24 hours. The reaction mixture was concentrated in *vacuo*, and the residue dissolved in water (100 ml), acidified with 2N HCl and extracted into dichloromethane (3x75 ml).

10 The organics were dried and concentrated. Purification (SiO₂, isohexane:diethylether 2:1 as eluant) gave the subtitle compound as a colourless solid (1.78g).

MS (APCI) 179 (M-H⁺, 100%)

i) (1*R*-trans)-2-(4-Fluorophenyl)cyclopropanamine

15 To a solution of the product from step h) (2.6 g) and triethylamine (2.7 ml) in acetone /water (10:1, 33 ml) at 0 °C was added ethyl chloroformate (2.0 ml) over 5 min. The solution was maintained at 0 °C for 0.5 h before addition of sodium azide (1.52 g) in water (6 ml). After a further hour, water (350 ml) was added and the reaction mixture extracted with toluene (3x100 ml). The organic extracts were combined and dried, then heated at

20 reflux for 2 hours behind a blast screen. After cooling the solution, 6N HCl (50 ml) was added and the mixture heated at reflux for 3 hours. Water (150 ml) was added and the aqueous phase basified with 2N NaOH (aq), then extracted into dichloromethane (3x100 ml). The organic phase was dried and concentrated to give the subtitle compound as a colourless oil (1.31g).

25 NMR δH (CDCl₃) 0.88-0.95 (1H, m), 0.99-1.06 (1H, m), 1.81-1.87 (1H, m), 2.47-2.52 (1H,m), 6.90-7.00 (4H, m)

j) [1*S*-(1α,2β,3β,4α(1*S,2*R**))]-4-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]cyclopentane-1,2,3-triol**

30 The title compound was prepared according to the method of example 12, step (e) using the products of step (e) and step (i).

MS (APCI) 461 (M+H⁺, 100%)

NMR δH (d₆-DMSO) 0.99 (3H, t, J=7.2 Hz), 1.29-2.15 (6H, m), 2.55-2.63 (1H, m), 2.81-3.15 (2H, m), 3.14-3.33 (1H, m), 3.78 (1H, br s), 3.93 (1H, br s), 4.66 (1H, br s), 4.92-5.12

35 (4H, m), 7.11-7.26 (4H, m), 9.33 (1H, d, J=4.2 Hz)

Example 20

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S, 2*R**)]]-4-[7-[[2-(4-Methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]cyclopentane-1,2,3-triol**

a) [1*R*-(*trans*)]-2-(4-Methoxyphenyl)cyclopropane carboxylic acid

To a solution of dichloro(*p*-cymene)ruthenium (II) dimer (250 mg) and 2,6-bis[(4*S*)isopropyl-2-oxazolin-2-yl]pyridine (240 mg) in dichloromethane (150 ml) at room temperature was added 4-vinylanisole (25 g). To this solution was added ethyl diazoacetate (5.0 g) over 6 hr. The solution was maintained at room temperature for 18 hours then
 10 diluted with *i*-hexane (200 ml) and passed through a plug of silica (50g) with a further 250 ml of 1:1 *i*-hexane/dichloromethane. The filtrate was concentrated and the residue dissolved in methanol (100 ml) and LiOH (4g) in water (10ml) added, the mixture was then refluxed for 4h. The resulting solution was concentrated to give a colourless solid which was washed with 1:1 ether/*i*-hexane (100 ml). The solid was then triturated with 2N HCl
 15 and the precipitate collected to give the subtitle compound (5.06 g).
 MS (APCI) 191 (M-H⁺, 100%)

b) [1*R*-(*trans*)]-2-(4-Methoxyphenyl)cyclopropanamine, [*R*-(*R,*R**)]-2,3-dihydroxybutanedioate (1:1)**

20 The amine was prepared according to the method of example 19, step i) using the product of step a). The amine was dissolved in ethanol (5 ml) and a solution of L-tartartic acid (0.75 g) in ethanol (5 ml) was added. After 20 minutes the solid was collected and recrystallised (isopropanol/water 3:1) affording the subtitle compound as colourless needles. M.p. 192-3°C.

25 NMR δ H (d₆-DMSO) 7.05 (2H, d), 6.85 (2H, d), 3.91 (2H, s), 3.71 (3H, s), 2.70-2.60 (1H, m), 2.15-2.07 (1H, m) 1.22-1.08 (1H, m), 1.03 (1H, dd)

c) [1*S*-[1 α ,2 β ,3 β ,4 α (1*S, 2*R**)]]-4-[7-[[2-(4-Methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

30 The title compound was prepared according to the method of example 12, step (e) using the products of step (b) and the product of example 19, step (e).

MS (APCI) 473 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 0.83 (3H, t, J=7.2 Hz), 1.20-2.25 (6H, m), 2.50-2.60 (1H, m), 2.81-3.04 (2H, m), 3.06-3.17 (1H, m), 3.33 (3H, s), 3.73 (1H, br s), 3.91-3.98 (1H, m), 4.60-4.70
 35 (1H, m), 4.90-5.13 (4H, m), 6.86 (2H, d, J=8.7 Hz), 7.14 (2H, d, J=8.7 Hz), 9.30 (1H, d, J=4.2 Hz)

Example 21

[1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]]-4-[7-[[2-(4-Methylphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

a) (1R-trans)-2-(4-Methylphenyl)cyclopropane carboxylic acid

Prepared according to the method of Example 20, step a) using 4-methyl-1-ethenylbenzene.

MS (APCI) 175 (M-H⁺, 100%)

b) (1R-trans)-2-(4-Methylphenyl)cyclopropanamine, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1)

Prepared according to the method of Example 20, step b) using the product of step a).

NMR δ H (d₆-DMSO) 7.08 (2H, d), 7.00 (2H, d), 3.98 (2H, s), 2.75-65 (1H, m), 2.50 (3H, s), 2.30-2.20 (1H, m) 1.30-1.22 (1H, m), 1.09 (1H, dd)

c) [1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]]-4-[7-[[2-(4-Methylphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

The title compound was prepared according to the method of example 1, step (a), using the products of step (b) and example 19, step (e).

MS (APCI) 457 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 0.99 (3H, t, J=7.2 Hz), 1.30-1.40 (1H, m), 1.45-1.54 (1H, m), 1.50 and 1.70 (2H, sex, J=7.2Hz), 1.87-1.94 (1H, m), 2.07-2.12 (1H, m), 2.27 (3H, s), 2.54-2.61 (1H, m), 2.83-2.99 (2H, m), 3.15-3.17 (1H, m), 3.78 (1H, br s), 3.93 (1H, br s), 4.66-4.67 (1H, m), 4.91-5.11 (4H, m), 7.09 (4H, br s), 9.35 (1H, br s)

Example 22

[1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]]-4-[7-[[2-(4-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

a) [1R-[1 α (S*),2 β]]-N-[2-(4-Chlorophenyl)cyclopropyl]-2-methoxy-2-phenyl-acetamide and [1S-[1 α (R*),2 β]]-N-[2-(4-Chlorophenyl)cyclopropyl]-2-methoxy-2-phenyl-acetamide

Oxalyl chloride (4.00ml) was added to a solution of (S)- α -methoxyphenylacetic acid (2.00g) in dichloromethane (100ml)/DMF (10ml). The reaction mixture was stirred at room temperature for 4 hours then concentrated and the residue azeotroped with

dichloromethane (3x10ml). The resulting oil was taken into dichloromethane (4ml) and treated with a solution of 2-(4-chlorophenyl)cyclopropylamine (Prepared as described by C Kaiser *et al* J. Med. Pharm. Bul., 1962, 5, 1243) (1.86g) in pyridine (8ml). The reaction mixture was stirred at room temperature for 30 minutes then partitioned between
 5 dichloromethane (500ml) and water (500ml). The organic phase was dried and concentrated and the residue purified (SiO₂, isohexane:ethyl acetate:acetic acid 66:33:1) to afford [1*S*-[1 α (*R**),2 β]]-*N*-[2-(4-Chlorophenyl)cyclopropyl]-2-methoxy-2-phenyl-acetamide (1.23g)

MS (APCI, negative ionization) 314 (*M*-H⁺, 100%)

10 Further elution of the column gave [1*R*-[1 α (*S**),2 β]]-*N*-[2-(4-Chlorophenyl)cyclopropyl]-2-methoxy-2-phenyl-acetamide (1.40g).

MS (APCI, negative ionization) 314 (*M*-H⁺, 100%).

b) (1*R*-*trans*)-2-(4-Chlorophenyl)-cyclopropanamine

15 A solution of [1*R*-[1 α (*S**),2 β]]-*N*-[2-(4-Chlorophenyl)cyclopropyl]-2-methoxy-2-phenyl-acetamide (1.10g) (prepared as described in step (a)) in 1,4-dioxane (20ml) containing 5M HCl (aq) (40ml) was heated at reflux for 18 hours. The reaction was concentrated and the residue partitioned between water and diethyl ether. The aqueous phase was treated with 2M aqueous sodium hydroxide solution (100ml) then extracted with diethyl ether
 20 (2x100ml). The organic phase was concentrated to afford the subtitle compound (0.55g). Optical rotation -138.3° (c=0.2, methanol).

c) [1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-4-[7-[[2-(4-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

25 The title compound was prepared according to the method of example 12, step (e), using the products of step (b) and example 19, step (e).

MS (APCI) 477/479 (*M*+H⁺, 100%)

NMR δ H (d₆-DMSO) 0.99 (3H, t, J=7.2 Hz), 1.30-1.40 (1H, m), 1.48 and 1.68 (2H, sex, J=7.2Hz), 1.52-1.60 (1H, m), 1.87-1.94 (1H, m), 2.10-2.15 (1H, m), 2.50-2.60 (1H, m),
 30 2.76-3.15 (2H, m), 3.13-3.21 (1H, m), 3.73 (1H, br s), 3.93 (1H, br s), 4.60-4.68 (1H, m), 4.89-5.11 (4H, m), 7.22 (2H, d, J=8.4 Hz), 7.33 (2H, d, J=8.4 Hz), 9.35 (1H, br s)

Example 23

2-[[[1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]]-2,3-Dihydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentyl]oxy]-acetamide

- 5 **a) [3aR-[3 α ,4 α ,6 α (1R*,2S*),6a α]]-6-[7-[N-[(2,4-Dimethoxyphenyl)methyl-(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol**

To a solution of product of example 12, step (f) (4.50g) in acetone (100ml), 2,2-dimethoxypropane (12.60ml) and *p*-toluenesulphonic acid (2.34g) were added and the
10 reaction mixture stirred for 1 hour. Purification (SiO₂, ethyl acetate:isohexane 2:7 as eluant) afforded the subtitle compound (4.34g).

MS (APCI) 633 (M+H⁺, 100%)

- 15 **b) 2-[[[3aR-[3 α ,4 α ,6 α ,6a α (1R*,2S*)]]-6-[7-[N-(2,4-Dimethoxyphenyl)methyl-(2-phenylcyclopropyl)-amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-acetic acid, 1,1-dimethylethyl ester**

To a solution of product of step (a) (0.40g) in toluene (3.00ml) were added 5M NaOH (3.00ml) and tetrabutylammonium bromide (31mg). The reaction mixture was stirred for
20 30 minutes, then dimethylsulphoxide (0.18ml) and 1,1-dimethylethyl-2-bromoacetate were added and stirring continued for 4 hours. The toluene layer was separated and concentrated. Purification (SiO₂, ethyl acetate:isohexane 1:3 as eluant) afforded the subtitle compound (0.41g).

MS (APCI) 747 (M+H⁺, 100%)

- 25 **c) 2-[[[1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]]-2,3-Dihydroxy-4-[6-[7-(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopent-1-yl]oxy]acetic acid**

The subtitle compound was prepared according to the method of example 2, step (b).

- 30 **MS (APCI) 501 (M+H⁺, 100%)**

- d) 2-[[[1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]]-2,3-Dihydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentyl]oxy]-acetamide**

Prepared according to the method of example 16 using the product of step (c).

- 35 Purification (HPLC, Novapak[®] C18 column, 0.1% aqueous ammonium acetate:acetonitrile, 63:37) afforded the title compound (0.04g).

MS (APCI) 501 ($M+H^+$, 100%)

NMR δ H (d_6 -DMSO) 9.35 (1H, d), 7.33-7.16 (7H, m), 5.20 (2H, br m), 5.00-4.90 (1H, q), 4.55 (1H, m), 4.05 (1H, br s), 3.85 (2H, s), 3.80 (1H, m), 3.20 (1H, br m), 3.15 (1H, m), 3.00-2.90 (1H, m), 1.91 (1H, m), 1.51 (3H, m), 1.31 (1H, m), 0.81 (3H, t).

5

Example 24

[1*S*-(1 α ,2 β ,3 β ,4 α (1*S,2*R**))]-4-[7-[[2-(3-Methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

10 a) [3*aR*-(3*aa*,4*a*,6*a*,6*aa*)]-6-Amino-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-ol, hydrochloride

The product from example 19, step (b) (17.37g) in 6M HCl (100ml) and methanol (500ml) was stirred for 18 hours. The mixture was evaporated and then azeotroped with toluene (4 x 200ml) to give a colourless powder (8.67g). This solid was suspended in acetone (250ml) containing 2,2-dimethoxypropane (25ml) and conc. HCl (0.2ml) then heated under reflux
15 for 2 hours. The mixture was cooled, evaporated and azeotroped with toluene (3 x 200ml). The residue was dissolved in 20% aqueous acetic acid and stirred for 2 hours. The mixture was evaporated and azeotroped with toluene (4 x 200ml) to afford the subtitle compound (10.1g).

20 MS (APCI) 174 ($M+H^+$, 100%)

b) [3*aR*-(3*aa*,4*a*,6*a*,6*aa*)]-6-[[6-Chloro-5-nitro-2-(propylthio)-pyrimidin-4-yl]amino]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-ol

A solution of the product from step (a) (10.0g) and *N,N*-diisopropylethylamine (35ml) in THF (600ml) was stirred for 1 hour. The mixture was filtered and the solution was added
25 over 1 hour to a solution of 4,6-dichloro-5-nitro-2-(propylthio)-pyrimidine (prepared as described in WO 9703084) (25.57g) in THF (1000ml) and stirred for a further 2 hour. The solvent volume was reduced *in vacuo* and ethyl acetate was added (1000ml). The mixture was washed with water and the organic layers were dried ($MgSO_4$), evaporated and
30 purified (SiO_2 , isohexane-ethyl acetate as eluant) to afford the sub-title compound (14.22g).

MS (APCI) 405 ($M+H^+$, 100%)

c) [3a*R*-(3aa,4a,6a,6aa)]-6-[[5-Amino-6-chloro-2-propylthiopyrimidin-4-yl]amino]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-ol

The subtitle compound was prepared according to the method of example 12, step (b) using the product of step (b).

5 MS (APCI) 375 ($M+H^+$, 100%)

d) [3a*R*-(3aa,4a,6a,6aa)]-6-[7-Chloro-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]-pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-ol

10 The subtitle compound was prepared according to the method of example 12, step (c) using the product of step (c).

MS (APCI) 386 ($M+H^+$, 100%)

e) (1*R*-trans)-2-(3-Methoxyphenyl)cyclopropanamine hydrochloride

15 The subtitle compound was prepared according to the method of example 19, step (i) using (1*R*-trans)-2-(3-methoxyphenyl)-cyclopropanecarboxylic acid (Prepared as described by Vallgaard *et al.* J. Chem. Soc., Perkin Trans. 1, 1994, 461-70). The product was taken up in 2N HCl and freeze dried to afford the hydrochloride salt.

MS (APCI) 164 ($M+H^+$).

20 **f) [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**, 2*R**)]]-4-[7-[[2-(3-Methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

To a suspension of the product from step (d) (0.40g) and step (e) (0.28g) in dichloromethane (20ml) was added *N,N*-diisopropylethylamine (0.89ml), the resulting solution was then stirred at room temperature for 7 hours. The reaction mixture was concentrated and the residue taken up in methanol (45ml)/2N HCl (5ml), this solution was then stirred at room temperature for 16 hours. The reaction mixture was concentrated and the residue partitioned between water (50ml) and dichloromethane (50ml), the organics were dried (MgSO₄), filtered, and concentrated. The product was purified (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate:acetonitrile, 50:50) to afford the title compound (0.44g).

30 MS (APCI) 473 ($M+H$, 100%)

NMR δ H (d_6 -DMSO) 9.39 (1H, d, $J=4.0$ Hz), 7.23-6.81(4H, m), 5.17-4.97 (4H, m), 4.74-4.69 (1H, m), 4.00 (1H, br s), 3.84 (1H, br s), 3.79 (3H, br s), 3.29-3.26 (1H, m), 3.06-2.87 (2H, m), 2.69-2.61 (1H, m), 2.19-2.14 (1H, m), 2.00-1.94 (1H, m), 1.76-1.51 (3H, m), 1.42-1.29 (1H, m), 0.87 and 1.05 (3H, t, $J=7.6$ Hz).

Example 25

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S, 2*R**)]]-4-[7-[[2-(3-Methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

5 **a) (1*R*-trans)- 2-(3-Methylphenyl)cyclopropane carboxylic acid**

Prepared according to the method of Example 20, step a) using 1-ethenyl-3-methylbenzene.

MS (APCI) 175 (M-H⁺, 100%)

10 **b) (1*R*-trans)-2-(3-Methylphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)**

Prepared according to the method of Example 20, step b) using the product of step a).

NMR δ H (d₆-DMSO) 7.17 (1H, t), 6.98 (1H, d), 6.93-6.89 (2H, m), 3.93 (2H, s), 2.70-2.66 (1H, m), 2.27 (3H, s), 2.13-2.08 (1H, m), 1.24-1.19 (1H, m), 1.19-1.09 (1H, m)

15 **c) [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**, 2*R**)]]-4-[7-[[2-(3-Methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

The title compound was prepared according to the method of example 24, step (f) using the products of step (b) and example 24, step (d).

20 MS (APCI) 457 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.33 (1H, s), 7.19-7.14 (1H, m), 7.04-6.96 (3H, m), 5.12-5.10 (1H, m), 5.03-4.97 (1H, m), 4.94-4.92 (1H, m), 4.92-4.90 (1H, m), 4.69-4.64 (1H, m), 3.94-3.92 (1H, m), 3.78 (1H, s), 3.20-3.17 (1H, m), 2.97-2.85 (2H, m), 2.62-2.58 (1H, m), 2.29 (3H, s), 2.05-2.10 (1H, m), 1.97-1.83 (1H, m), 1.54-1.47 (2H, m), 0.84-0.79 (3H, t).

25 **Example 26**

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S, 2*R**)]]-4-[7-[[2-(3-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

30 **a) [3*aS*-[1(*E*),3*a* α ,6*a* α ,7*a* β]]-1-[3-(3-Chlorophenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

The subtitle compound was prepared according to the method of example 19, step (f) using 3-(3-chlorophenyl)-2-propenoic acid.

MS (APCI) 382/380 (M+H⁺), 153 (100%)

b) [3aS-[1(1*S,2*S**),3α,6α,7αβ]]-1-[[2-(3-Chlorophenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3*H*-3a,6-methano-2,1-benzisothiazole-2,2-dioxide**

The subtitle compound was prepared according to the method of example 19, step (g) using the product of step (a).

5 MS (APCI) 396/394 (M+H⁺), 411 (100%)

c) (1*R*-trans)-2-(3-Chlorophenyl)-cyclopropane carboxylic acid

The subtitle compound was prepared according to the method of example 19, step (h) using the product of step (b).

10 MS (APCI) 195/197 (M-H⁺), 195 (100%)

d) [1*R*-trans]-2-(3-Chlorophenyl)cyclopropylamine, [*R*-(*R,*R**)]-2,3-dihydroxybutanedioate (1:1)**

15 The subtitle compound was prepared according to the method of example 20, step (b) using the product of step (c).

NMR δH (d₆-DMSO) 1.13-1.23 (2H, m), 2.10-2.20 (1H, m), 2.70-2.74 (1H, m), 3.95 (2H, s), 7.08-7.32 (4H, m)

e) [1*S*-[1α,2β,3β,4α(1*S,2*R**)]]-4-[7-[[2-(3-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

20 The title compound was prepared according to the method of example 24, step (f) using the products of step (d) and example 24, step (d).

MS (APCI) 477/479 (M+H⁺), 477 (100%)

25 NMR δH (d₆-DMSO) 7.33-7.15 (4H, m), 5.00-4.93 (1H, m), 4.68-4.65 (1H, m), 3.94 (1H, br s), 3.79 (1H, br s), 3.20 (1H, br s), 2.97-2.79 (2H, m), 2.64-2.56 (1H, m), 2.26-2.13 (1H, m), 1.92-1.88 (1H, m), 1.70-1.40 (4H, m), 0.98 (3H, t, *J*=7.2 Hz),

Example 27

[1*S*-[1α,2β,3β,4α(1*S,2*R**)]]-4-[7-[[2-(3-Nitrophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

a) (1*R*-trans)-2-(3-Nitrophenyl)-cyclopropane carboxylic acid

Prepared according to the method of example 20, step (a) using 3-nitrostyrene.

MS (APCI) 206 (M-H⁺, 100%)

b) (1*R*-trans)-2-(3-Nitrophenyl)cyclopropanamine [*R*-(*R*^{*},*R*^{*})]-2,3-dihydroxybutanedioate (1:1)

Prepared according to the method of Example 20, step (b) using the product of step (a).

NMR δH (d₆-DMSO) 8.06-7.98 (2H, m), 7.62-7.53 (2H, m), 4.00 (2H, s), 2.84-2.77 (1H, m), 2.41-2.34 (1H, m), 1.41-32 (1H, m), 1.32-1.23 (1H, m).

c) [3*aR*-[3*aa*,4*a*,6*a*(1*R*^{*}, 2*S*^{*}),6*aa*]]-6-[7-[2-[(3-Nitrophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopentan-1,3-dioxol-4-ol

Prepared according to the method of Example 1, step (a) using the product of step (b) and Example 24, step (b).

d) [1*S*-[1α,2β,3β,4α(1*S*^{*}, 2*R*^{*})]]-4-[7-[[2-(3-Nitrophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

Prepared according to the method of Example 1, step (b) using the product of step (c).
m.p. 112-4°C.

MS (APCI) 488 (M+H⁺, 100%)

NMR δH (d₆-DMSO) 9.43 (1H, d), 8.08-8.01 (2H, m), 7.70-7.56 (1H, m), 5.13-4.87 (4H, m), 4.69-4.60 (1H, m), 3.97-3.76 (2H, m), 3.31-3.04 (1H, m), 2.93-2.77 (2H, m) 2.54-2.51 (1H, m), 2.38-2.28 (1H, m) 1.97-1.88 (2H, m), 1.63-1.38 (3H, m), 0.76 (3H, t).

Example 28

[1*S*-[(1α,2β,3β,4α(1*S*^{*}, 2*R*^{*})]]-4-[7-[[2-(4-Phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

a) (1*R*-trans)-2-(4-Phenoxyphenyl)cyclopropane carboxylic acid

Prepared according to the method of Example 20, step (a) using 1-ethenyl-4-phenoxybenzene.

b) (1*R*-trans)-2-(4-Phenoxyphenyl)cyclopropanamine, [*R*-(*R*^{*},*R*^{*})]-2,3-dihydroxybutanedioate (1:1)

Prepared according to the method of Example 20, step b) using the product of step a).

c) [1*S*-(1α,2β,3β,4α(1*S*^{*}, 2*R*^{*})]-4-[7-[[2-(4-Phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

Prepared according to the method of Example 24, step (f) using the product from step (b) and the product from Example 24, step (d).

MS (APCI) 534 ($M+H^+$, 100%)

NMR δ H (d_6 -DMSO) 9.35 (1H, d), 7.41-7.35 (2H, m), 7.25-7.22 (2H, m), 7.14-7.09 (1H, m), 6.99-6.94 (4H, m), 5.12-5.11 (1H, m), 5.04-5.01 (1H, m), 4.94-4.91 (2H, m), 4.67-4.64 (1H, m), 3.94-3.92 (1H, m), 3.80 (1H, s), 3.20-3.17 (1H, m), 2.99-2.87 (2H, s), 2.62-2.57 (1H, m), 2.19-2.10 (1H, m), 1.99-1.90 (1H, m), 1.56-1.49 (2H, m), 1.32-1.30 (1H, m), 0.85 (3H, t).

10 **Example 29**

[1S-[1 α ,2 β ,3 β ,4 α (1S*, 2R*)]]-4-[7-[[2-(3-Phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

a) 1-Ethenyl-3-Phenoxy-benzene

15 A suspension of triphenylmethylphosphonium bromide (25.23g) and potassium *tert*-butoxide (1M solution in tetrahydrofuran) (75.67ml) was stirred at 0°C for 0.5h. A solution of 3-phenoxy-benzaldehyde (10.0g) in THF (10 ml) was added to the mixture and the reaction mixture stirred at 0°C for 4h. Ammonium chloride solution was added and the mixture extracted with diethyl ether. The organic extracts were combined, washed with water, dried and concentrated. Purification (SiO₂, isohexane:ethyl acetate 4:1 as eluant) gave the subtitle compound (7.12g).

20 NMR δ H (CDCl₃) 7.78-7.65 (1H, m), 7.58-7.41 (1H, m), 7.36-7.26 (3H, m), 7.16-7.06 (2H, m), 7.04-7.00 (2H, m), 6.92-6.88 (1H, m), 6.72-6.62 (1H, m), 5.75 (1H, d), 5.27 (1H, m).

b) (1R-trans)-2-(3-Phenoxyphenyl)cyclopropane carboxylic acid

Prepared according to the method of Example 20, step a) using the product from step (a).

MS (APCI) 253 ($M-H^+$, 100%)

30

c) (1R-trans)-2-(3-Phenoxyphenyl)cyclopropanamine, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1)

Prepared according to the method of Example 20, step b) using the product of step b).

35 NMR δ H (d_6 -DMSO) 7.42-7.36 (2H, m), 7.31-7.25 (1H, m), 7.16-7.11 (1H, m), 7.00-6.96 (2H, m), 6.90-6.88 (1H, m), 6.81-6.77 (2H, m), 3.94 (2H, s), 2.71-2.66 (1H, m), 2.14-2.11 (1H, m), 1.26-1.20 (1H, m), 1.15-1.11 (1H, m).

d) [1*S*-[1 α ,2 β ,3 β ,4 α (1*S, 2*R**)]]-4-[7-[[2-(3-Phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

Prepared according to the method of Example 24, step (f) using the product from step (c) and the product from Example 24, step (d).

5 MS (APCI) 534 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.35 (1H, d), 7.41-7.36 (2H, m), 7.32-7.27(1H, t), 7.15-7.10 (1H, m), 7.01-6.95 (3H, m), 6.90 (1H, m), 6.82-6.79 (1H, m), 5.12-5.10 (1H, m), 5.03-5.01 (1H, m), 4.93-4.91 (2H, m), 4.68-4.64 (1H, m), 3.94-3.92 (1H, m), 3.78 (1H, s), 3.20 (1H, m), 2.97-2.85 (2H, m), 2.61-2.57 (1H, m), 2.18-2.13 (1H, m), 1.96-1.92 (1H, m) 1.55-1.47 (2H, m),
10 1.35-1.32 (1H, m), 0.83 (3H, t).

Example 30

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S, 2*R**)]]-4-[7-[[2-(3-Aminophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

15

A suspension of 5% palladium on charcoal (40mg) and the product from example 27, step (d) (114mg) in ethanol (10ml) was stirred under two atmospheres pressure of hydrogen for 20 hours. The mixture was filtered and purified (SiO₂, isohexane:acetone, 1:1 as eluent) to give the title compound (71mg).

20 m.p. 105-7°C

MS (APCI) 458 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 9.27 (1H, d), 6.91 (1H, t), 6.39-6.29 (3H, m), 5.16-5.07 (1H, m), 5.06-4.88 (5H, m), 4.70-4.59 (1H, m), 3.95-3.90 (1H, m), 3.84-3.75 (1H, m), 3.21-2.83 (3H, m), 2.64-2.53 (1H, m), 2.02-1.87 (2H, m), 1.72-1.11 (4H, m), 0.86 (3H, t).

25

Example 31

[1*S*-(1 α ,2 α ,3 β ,5 β)]-3-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(3-hydroxypropoxy)-cyclopentane-1,2-diol.

30 **a) *N*-Butyl-(2,4-dimethoxyphenyl)methanamine**

The subtitle compound was prepared according to the method of example 12, step (d) using butylamine.

NMR δ H (CDCl₃) 0.90 (3H, t, J=7.2 Hz), 1.33 (2H, sextet, J=7.2 Hz), 1.48 (2H, m), 2.57 (2H, m), 3.71 (2H, m), 3.80 (3H, s), 3.81 (3H, s), 6.41-6.46 (2H, m), 7.12 (1H, d, J=8.1
35 Hz).

b) (1*S*-cis)-4-[7-[*N*-Butyl-[(2,4-dimethoxyphenyl)methyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2-cyclopentene-1-ol

The subtitle compound was prepared according to the method of example 12, step (e) using the products of step (a) and example 12, step c).

5 MS (APCI) 499 ($M+H^+$, 100%)

c) [3*aR*-(3*a* α ,4*a* α ,6*a* α ,6*a* α)]-6-[7-[*N*-Butyl-[(2,4-dimethoxyphenyl)methyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-ol

10 The subtitle compound was prepared according to the method of example 15, step (c) using the product of step (b).

MS (APCI) 573 ($M+H^+$, 100%)

d) [3*aS*-(3*a* α ,4*a* α ,6*a* α ,6*a* α)]-*N*-Butyl-*N*-[2,4-(dimethoxyphenyl)methyl]-3-[[[(tetrahydro-2*H*-pyran-2-yl)oxy]propyl]oxy]-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-yl]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-amine.

15 The subtitle compound was prepared according to the method of example 13, step (a) using the product of step (c) and 2-(3-bromopropoxy)-2*H*-tetrahydropyran, except that the reaction was allowed to proceed for 18 hours at reflux temperature.

20 MS (APCI) 715 ($M+H^+$, 100%)

e) [1*S*-(1*a* α ,2*a* α ,3*b* β ,5*b* β)]-3-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(3-hydroxypropoxy)-cyclopentane-1,2-diol.

25 The title compound was prepared according to the method of example 2, step (b) using the product of step (d).

MS (APCI) 441 ($M+H^+$, 100%)

NMR δ H (d_6 -DMSO) 0.91 (3H, t, $J=7.5$ Hz), 0.99 (3H, t, $J=7.5$ Hz), 1.34 (2H, sextet, $J=7.2$ Hz), 1.58-1.74 (6H, m), 2.02 (1H, m), 2.62 (1H, m), 3.08 (2H, m), 3.44-3.56 (6H, m), 3.70 (1H, m), 3.91 (1H, m), 4.40 (1H, t, $J=5.1$ Hz), 4.54-4.59 (1H, m), 4.95 (1H, q, $J=9.0$ Hz), 5.03 (1H, d, $J=3.9$ Hz), 5.10 (1H, d, $J=6.3$ Hz), 8.97 and 8.60 (1H, t, $J=5.4$ Hz).

30

Example 32

[1S-[1 α ,2 α ,3 β ,5 β (1S*,2R*)]]-3-(2-Hydroxyethoxy)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2-diol.

a) *N*-[2,4-(Dimethoxyphenyl)methyl]-*N*-(2-phenylcyclopropyl)-3-[[3aS-[3 α ,4 α (1S*,2R*),6 α ,6 α]]-[[[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]oxy]-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-7-amine.

The subtitle compound was prepared according to the method of example 31, step (d) using the product of example 23, step (a) and 2-(2-bromoethoxy)-2H-tetrahydropyran (prepared according to the method of K. F. Bernady *et al.* J. Org. Chem. , 1979, 44, 1438.)

MS (APCI) 761 (M+H⁺, 100%)

b) **[1S-[1 α ,2 α ,3 β ,5 β (1S*,2R*)]]-3-(2-Hydroxyethoxy)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2-diol.**

The title compound was prepared according to the method of example 2, step (b) using the product of step (a).

MS (APCI) 487 (M+H⁺, 100%)

NMR δ H (DMSO-d₆) 9.36 (1H, d, 4.0Hz), 7.31-7.27 (2H, m), 7.20-7.16 (3H, m), 5.13 (1H, d, *J*=6.4Hz), 5.06 (1H, d, *J*=4.0Hz), 4.97 (1H, q, *J*=9.2Hz), 4.63-4.55 (2H, m), 3.94 (1H, br), 3.75 (1H, m), 3.52-3.47 (4H, m), 3.21 (1H, m), 2.96-2.93 (1H, m), 2.85-2.82 (1H, m), 2.58-2.70 (1H, m), 2.13 (1H, m), 2.03 (1H, m), 1.54-1.46 (3H, m), 1.36-1.31 (1H, m), 0.80 (3H, t, *J*=7.6Hz).

Example 33

[1S-[1 α ,2 α ,3 β ,5 β (1S*,2R*)]]-3-(Hydroxymethyl)-5-[7-[[2-(4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2-diol

a) [3aR-[3 α ,4 α ,6 α (1R*,2S*),6 α]-Tetrahydro-6-[7-[[2-(4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-methanol

Prepared according to the method of Example 1, step a) using the product of Example 20, step (b).

MS (APCI) 527 ($M+H^+$, 100%).

- 5 **b) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

Prepared according to the method of Example 1, step b) using the product of step a).

MS (APCI) 487 ($M+H^+$, 100%)

- 10 NMR δ H (d_6 -DMSO) 9.28 (1H, d), 7.14 (4H, d), 6.85 (2H, d), 5.00-4.95 (2H, m), 4.75-4.68 (2H, m), 4.47-4.40 (1H, m), 3.88 (1H, q), 3.73 (3H, s), 3.50-3.40 (2H, m), 3.13-2.80 (3H, m), 2.27-2.02 (3H, m), 1.90-1.77 (1H, m), 1.60-1.40 (3H, m), 1.28-1.20 (1H, m), 0.85 (3H, t).

15 **Example 34**

[1*R*-[1*a*,2*a*,3*b*(1*R,2*S**),5*b*]]-3-[7-[[2-(4-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

- 20 **a) [3*aR*-[3 α ,4 α ,6 α (1*R**,2*S**),6 α]-6-[7-[[2-(4-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step a) using the product of Example 22, step b) and 1,4-dioxane as solvent.

- 25 MS (APCI) 531 ($M+H^+$, 100%)

NMR δ H ($CDCl_3$) 7.31-7.13 (4H, m), 5.28-5.15 (2H, m), 4.72-4.69 (1H, m), 3.82-3.65 (2H, t), 3.06-3.01 (2H, m), 2.62-2.45 (2H, m), 2.45-2.28 (1H, m), 2.21-2.07 (1H, m), 2.01-2.00 (1H, m), 1.68-1.60 (1H, m), 1.58 (3H, s), 1.40-1.35 (2H, m), 1.33 (3H, s), 0.94 (3H, t)

- 30 **b) [1*R*-[1*a*,2*a*,3*b*(1*R**,2*S**),5*b*]]-3-[7-[[2-(4-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

Prepared according to the method of Example 1, step b), using the product of step b).

MS (APCI) 491 ($M+H^+$, 100%)

- 35 NMR δ H (d_6 -DMSO) 9.33 (1H, d), 7.35-7.21 (4H, dd), 5.00-4.95 (2H, m), 4.73-4.70 (2H, m), 4.43-4.40 (1H, m), 3.88-3.87 (1H, m), 3.45 (2H, m), 3.15-3.05 (1H, m), 3.00-2.80 (2H,

m), 2.27-2.00 (1H, m), 2.17- 2.00 (2H, m), 1.90-1.80 (1H, m), 1.60-1.40 (4H, m), 1.40-1.30 (1H, m), 0.82 (3H, t).

Example 35

5 **[1*R*-[1 α ,2 α ,3 β (1*S**,2*R**),5 β]]-3-[7-[[2-(3-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

10 **a) [3*aR*-[3 α ,4 α ,6 α (1*R**,2*S**),6 α]-6-[7-[[2-(3-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step a) using the product of Example 26, step d) and 1,4-dioxane as solvent.

MS (APCI) 531 (M+H⁺, 100%).

15 **b) [1*R*-[1 α ,2 α ,3 β (1*S**,2*R**),5 β]]-3-[7-[[2-(3-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

Prepared according to the method of Example 1, step b) using the product of step a).

20 MS (APCI) 491 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.34 (1H, d), 7.28-7.10 (4H, m), 5.05-4.93 (2H, m), 4.78-4.71 (2H, m), 4.48-4.40 (1H, m), 3.86-3.80 (1H, m), 4.50-4.40 (2H, m), 3.24-3.18 (1H, m), 3.00-2.80 (2H, m), 2.34-2.21 (1H, m), 2.20-2.00 (2H, m), 1.90-1.80 (1H, m), 1.60-1.38 (4H, m), 0.82 (3H, t).

25 Example 36

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**))] -3-(Methoxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

30 **a) [3*aR*-[3 α ,4 α ,6 α (1*R**,2*S**),6 α]-6-[7-[(2,4-Dimethoxyphenyl)methyl-(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step a) using the product of Example 12, step d).

35 MS (APCI) 647 (M+H⁺, 100%).

b) [3aS-[3aa,4a(1*S, 2*R**),6a,6aa]]-N-[(2,4-Dimethoxyphenyl)methyl]-3-[6-(methoxymethyl)-2,2-dimethyl-tetrahydro-4*H*-cyclopenta-1,3-dioxolan-4-yl]-N-(2-phenylcyclopropyl)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine-7-amine**

Sodium hydride (31mg, 60% in oil) was added to a solution of the product from step (a) (0.26g) and methyl iodide (0.15ml) in *N,N*-dimethylformamide (1.5ml) and the resultant mixture was stirred for 2 hours. Water was added and the mixture was extracted with ethyl acetate and the extracts washed with water, dried, concentrated and purified (SiO₂, ethyl isohexane:acetone, 4:1 as eluant) to afford the subtitle compound (0.12g).

MS (APCI) 661 (M+H⁺, 100%).

c) [1*S*-[1α,2α,3β,5β(1*S,2*R**)]]-3-(Methoxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

Prepared according to the method of Example 2, step b) using the product of step b).

m.p. 149-150°C.

MS (APCI) 471 (M+H⁺, 100%).

NMR δH (d₆-DMSO) 9.33 (1H, d), 7.20 (5H, m), 5.02 (1H, m), 4.81 (1H, m), 4.41 (1H, m), 3.85 (1H, m), 3.40 (2H, m), 3.28 (3H, m), 3.20 (1H, m), 2.90 (2H, m), 2.25 (2H, m), 2.13 (1H, m), 1.86 (2H, m), 1.52 (2H, m), 1.49-1.32 (2H, m), 0.83 (3H, t, *J*= 7Hz).

Example 37

[1*S*-[1α,2α,3β,5β(1*S,2*R**)]]-3-(Hydroxymethyl)-5-[5-(methylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

a) [1*S*-[1α,2α,3β,5β(1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylsulfonyl)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

Prepared according to the method of Example 4, step (a) using the product of Example 1, step (b).

MS (APCI) 489 (M+H⁺, 100%)

b) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[5-(methylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

Prepared according to the method of Example 17, step (b) using the product of step (a).

5 MS (APCI) 429 ($M+H^+$, 100%)

NMR δ H (d_6 -DMSO) 9.33 (1H, d), 7.31-7.15 (5H, m), 5.03-4.97 (2H, m), 4.74-4.71 (2H, m), 4.47-4.40 (1H, m), 3.91-3.878 (1H, m), 3.51-3.46 (2H, m), 3.19-3.18 (1H, m), 2.33 (3H, s), 2.29-2.24 (1H, m), 2.14-2.10 (2H, m), 1.92-1.80 (1H, m), 1.51-1.47 (1H, m), 1.35-1.32 (1H, m).

Example 38

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-[(1-methylethyl)thio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

15 The title compound was prepared according to the method of Example 4, step b) using the product of Example 37, step a) and 1-methylethanethiol.

MS (APCI) 457 ($M+H^+$, 100%)

NMR δ H (d_6 -DMSO) 9.35 (1H, s), 7.26-7.19 (5H, m), 5.00-4.97 (2H, m), 4.72 (2H, s), 4.41 (1H, s), 3.87 (1H, s), 3.60-3.64 (1H, m), 3.47 (2H, s), 3.17 (1H, s), 2.23-2.27 (1H, m), 2.09 (2H, s), 1.83-1.85 (1H, m), 1.53-1.55 (1H, m), 1.23-1.36 (1H, m), 1.15 (3H, d), 1.09 (3H, d)

Example 39

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(prop-2-enylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

a) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(prop-2-enylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

30 The title compound was prepared according to the method of Example 4, step (b) using the product of Example 37, step (a) and 2-propene-1-thiol.

MS (APCI) 455 ($M+H^+$, 100%)

NMR δ H (d_6 -DMSO) 9.00 (1H, s), 7.30-7.16 (5H, m), 5.95-5.80 (1H, m), 5.22 (1H, d), 5.04-4.98 (2H, m), 4.67 (1H, d), 4.47-4.38 (3H, m), 3.91 (1H, q), 3.75-3.65 (2H, m), 3.55-3.48 (2H, m), 2.30-2.12 (3H, m), 1.93-1.86 (1H, m), 1.50-1.45 (1H, m), 1.34-1.28 (1H, m).

Example 40

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[5-(4-methylphenylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

5

Prepared according to the method of Example 4, step (b) using the product of Example 37, step (a) and *p*-thiocresol.

MS (APCI) 505 ($M+H^+$, 100%)

NMR δ H (d_6 -DMSO) 9.28 (1H, d), 7.48-7.44 (2H, m), 7.32-7.11 (7H, m), 4.94-4.88 (2H, m), 4.64-4.60 (2H, m), 4.32-4.27 (1H, m), 3.30-3.20 (2H, m), 3.13-3.10 (1H, m), 2.34 (3H, s), 2.22-2.15 (2H, m), 2.02-1.98 (1H, m), 1.70-1.60 (1H, m), 1.42-1.38 (1H, m), 1.20-1.15 (1H, m).

10

Example 41

15

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

20

a) [3*aR*-[3 α ,4 α ,6 α (1*R,2*S**),6 α]-Tetrahydro-2,2-dimethyl-6-[7-[[2-(4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step a) using the product of Example 21, step b) and 1,4-dioxane as solvent.

MS (APCI) 511 ($M+H^+$, 100%).

25

b) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

Prepared according to the method of Example 1, step b) using the product of step a).

30

MS (APCI) 471 ($M+H^+$, 100%)

NMR δ H (d_6 -DMSO) 9.30 (1H, d), 7.09 (4H, s), 5.03-4.92 (2H, m), 4.71 (2H, s), 4.42-4.36 (1H, m), 3.84 (1H, s), 3.56-3.41 (2H, m), 3.20-3.10 (1H, m), 3.00-2.80 (2H, m), 2.27 (3H, s), 2.25-2.20 (1H, m), 2.15-2.05 (2H, m), 1.89-1.81 (1H, m), 1.60-1.40 (3H, m), 1.28 (1H, dd), 0.84 (3H, t).

35

Example 42

[1S-[1 α ,2 α ,3 β ,(*R*^{*}),5 β (1*S*^{*},2*R*^{*})]]-3-(1-Hydroxyethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

5

Sodium borohydride (0.50g) was added to a solution of the product of example 8 (2.10g) in methanol (100ml). The mixture was stirred for 1 hour then poured into water (300ml). The mixture was extracted with diethyl ether, washed with water, dried and concentrated. Purification (HPLC, Chiralpak AD, isohexane:ethanol, 8:2 as eluant) afforded the title compound (0.16g). Secondary alcohol stereochemistry determined by the method of B Trost *et al* J. Org. Chem., 1986, **51**, 2370.

10

MS (APCI) 471 (M+H⁺, 100%)

15

NMR δ H (d₆-DMSO) 9.31 (1H, d), 7.31-7.15 (5H, m), 4.91 (2H, m), 4.62 (1H, d), 4.57 (1H, d), 4.37 (1H, m), 3.84 (1H, m), 3.74 (1H, m), 3.18 (1H, m), 2.96-2.81 (2H, m), 2.11 (3H, m), 1.96 (1H, m), 1.54 (3H, m), 1.35 (1H, m), 1.01 (3H, d), 0.79 (3H, t).

Example 43

[1S-[1 α ,2 α ,3 β ,(*S*^{*}),5 β (1*S*^{*},2*R*^{*})]]-3-(1-Hydroxyethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

20

Prepared according to the method of Example 42, further elution (HPLC, Chiralpak AD, isohexane:ethanol, 8:2) afforded the title compound (0.18g). Secondary alcohol stereochemistry determined by the method of B Trost *et al* J. Org. Chem., 1986, **51**, 2370.

25

MS (APCI) 471 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.33 (1H, d), 7.30-7.16 (5H, m), 4.95 (2H, m), 4.68 (1H, m), 4.62 (1H, d), 4.37 (1H, m), 4.02 (1H, m), 3.62 (1H, m), 3.21 (1H, m), 2.96-2.82 (2H, m), 2.13 (2H, m), 1.89 (2H, m), 1.48 (3H, m), 1.33 (1H, m), 1.15 (3H, d), 0.82 (3H, t).

Example 44

[1*R*-[1 α ,2 α ,3 β (1*R,2*S**),5 β]]-3-[5-(Ethylthio)-7-[[2-phenylcyclopropyl]amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

- 5 **a) [3*aR*-[3 α ,4 α ,6 α (1*R**,2*S**),6 α]-6-[5-(Ethylthio)-7-[[2-phenylcyclopropyl]amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 4, step (b) using the product of Example 37, step (a) and ethanethiol.

- 10 MS (APCI) 483 (M+H⁺, 100%)

b) [1*R*-[1 α ,2 α ,3 β (1*R,2*S**),5 β]]-3-[5-(Ethylthio)-7-[[2-phenylcyclopropyl]amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

Prepared according to the method of Example 1, step (b) using the product of step (a).

- 15 MS (APCI) 443 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.34 (1H, d), 7.31-7.15 (5H, m), 5.01-4.97 (2H, m), 4.73-4.70 (2H, m), 4.45-4.41 (1H, m), 3.88 (1H, q), 3.51-3.45 (2H, m), 3.21-3.17 (1H, m), 2.90-2.86 (2H, m), 2.28-2.23 (1H, m), 2.11-2.08 (2H, m), 1.90-1.82 (1H, m), 1.54-1.51 (1H, m), 1.35-1.30 (1H, m), 1.09 (3H, t).

20

Example 45

[1*R*-[1 α ,2 α ,3 β (1*R,2*S**),5 β]]-3-[7-[[2-[(1,1'-Biphenyl)-4-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

25

a) (1*R-trans*)-2-[(1,1'-Biphenyl)-4-yl]cyclopropane carboxylic acid

Prepared according to the method of Example 20, step (a) using 1-ethenyl-4-phenylbenzene.

- 30 NMR δ H (CDCl₃) 7.50-7.30 (7H, m), 7.19 (2H, d), 2.70-2.60 (1H, m), 1.99-1.93 (1H, m), 1.75-1.68 (1H, m), 1.47-1.41 (1H, m).

b) (1*R-trans*)-2-[(1,1'-Biphenyl)-4-yl]cyclopropanamine, [*R*-(*R,*R**)]-2,3-dihydroxybutanedioate (1:1)**

Prepared according to the method of Example 20, step (b) using the product of step (a).

- 35 MS (APCI) 210 (M+H⁺, 100%).

c) [3a*R*-[3a α ,4 α ,6 α (1*R**,2*S**),6a α]-6-[7-[[2-[(1,1'-Biphenyl)-4-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol

Prepared according to the method of Example 1, step (a) using the product of step (b) and 1,4-dioxane as solvent.

MS (APCI) 573 (M+H⁺, 100%).

d) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-[(1,1'-Biphenyl)-4-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

Prepared according to the method of Example 1, step (b) using the product of step (c).

MS (APCI) 433 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.38 (1H, d), 7.64 (2H, d), 7.59 (2H, d), 7.46 (2H, t), 7.33 (1H, t), 7.27 (2H, d), 5.10-5.00 (2H, m), 4.78 (2H, s), 4.47-4.40 (1H, m), 3.92-3.83 (1H, m), 3.50-3.40 (2H, m), 3.27-3.20 (1H, m), 3.00-2.80 (2H, m), 2.35-2.04 (3H, m), 1.89-1.80 (1H, m), 1.70-1.39 (4H, m), 0.79 (3H, t).

Example 46

[1*R*-(1 α ,2 α ,3 β ,5 β)]-3-[7-(Butylamino)-5-(cyclopentylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

Prepared according to the method of Example 4, step (b) using the product of Example 4, step (a) and cyclopentanethiol, followed by the method of Example 2, step (b)

m. p. 187-8 °C

MS (APCI) 437 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 8.96 (1H, t), 4.98-4.96 (2H, dd), 4.73-4.69 (2H, m), 4.46-4.39 (1H, m), 3.90-3.85 (1H, m), 3.47 (1H, br s), 3.52-3.43 (4H, m), 2.25-1.28 (17H, m), 0.91 (3H, t).

Example 47

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-[4-(trifluoromethyl)-phenylthio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

The title compound was prepared according to the method of Example 4, step (b) using the product of Example 37, step (a) and 4-(trifluoromethyl)thiophenol.

m. p. 100-102 °C

MS (APCI) 559 ($M+H^+$, 100%)

NMR δ H (d_6 -DMSO) 9.44 (1H, d), 7.83 (2H, d), 7.61 (2H, d), 7.29-7.08 (5H, m), 4.90 (2H, m), 4.62 (2H, m), 4.32 (1H, m), 3.75 (1H, m), 3.39-3.27 (2H, m), 3.06 (1H, m), 2.21 (2H, m), 2.01 (1H, m), 1.72 (1H, m), 1.40 (1H, m), 1.19 (1H, m).

5

Example 48

[1S-[1 α ,2 α ,3 β ,5 β (1S*,2R*)]]-3-(Hydroxymethyl)-5-[7-[[2-(4-phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2-diol

10

a) [1R-(1 α ,2 α ,3 β ,5 β)]-3-[7-Chloro-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

15

A solution of [3aR-(3 α ,4 α ,6 α ,6 α)]-6-[7-chloro-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-methanol (0.50 g) in acetonitrile (20 ml) was stirred with Dowex® 50WX8-200 (H^+ -form) ion-exchange resin (0.49 g) at 60 °C for 7 hours then at room temperature overnight. The resin was removed by filtration and the filtrate concentrated. The crude product was purified by chromatography (SiO_2 , ethyl acetate as eluant) to afford the subtitle compound as a colourless solid (0.31 g).

20

MS (APCI) 360 ($M+H^+$, 100%).

b) [1S-[1 α ,2 α ,3 β ,5 β (1S*,2R*)]]-3-(Hydroxymethyl)-5-[7-[[2-(4-phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2-diol

25

Prepared according to the method of Example 1, step (a) using the products of step (a) and Example 28, step (b), and acetonitrile as solvent.

MS (APCI) 549 ($M+H^+$, 100%).

30

NMR δ H (d_6 -DMSO) 9.33 (1H, d), 7.42-7.34 (2H, m), 7.27-7.17 (2H, m), 7.12 (1H, t), 7.01-6.92 (4H, m), 5.06-4.95 (2H, m), 4.75-4.68 (2H, m), 4.48-4.38 (1H, m), 3.91-3.85 (1H, m), 3.56-3.40 (2H, m), 3.21-3.13 (1H, m), 3.05-2.83 (2H, m), 2.32-2.19 (1H, m), 2.18-2.03 (2H, m), 1.91-1.79 (1H, m), 1.61-1.46 (3H, m), 1.36-1.26 (1H, m), 0.85 (3H, t).

Example 49

[1*R*-[1 α ,2 α ,3 β (1*S,2*R**),5 β]]-3-[7-[[2-(2-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

a) (1*R*-trans)-2-(2-Chlorophenyl)-cyclopropane carboxylic acid

Prepared according to the method of Example 20, step (a) using 2-chloro-1-ethenylbenzene.

MS (APCI) 195 (M-H, 100%)

b) (1*R*-trans)-2-(2-Chlorophenyl)cyclopropanamine, [*R*-(*R,*R**)]-2,3-dihydroxybutanedioate (1:1)**

Prepared according to the method of Example 20, step (b) using the product of step a).

MS (APCI) 166 (M+H⁺, 100%)

c)[3*aR*-[3 α ,4 α ,6 α (1*R,2*S**),6 α]-6-[7-[[2-(2-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step (a) using the product of step (b) and 1,4-dioxane as solvent.

MS (APCI) 531 (M+H⁺, 100%).

d) [1*R*-[1 α ,2 α ,3 β (1*S,2*R**),5 β]]-3-[7-[[2-(2-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

Prepared according to the method of Example 1, step (b) using the product of step (c).

MS (APCI) 471 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.38 (1H, d), 7.43 (1H, d), 7.30-7.22 (3H, m), 5.03-4.95 (2H, m), 4.75-4.70 (2H, m), 4.45-4.38 (1H, m), 3.91-3.82 (1H, m), 3.52-3.40 (2H, m), 3.00-2.80

(2H, m), 2.60-2.40 (3H, m), 2.13-2.02 (1H, m), 1.93-1.81 (1H, m), 1.70-1.35 (4H, m), 0.80 (3H, t).

Example 50

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(2-Hydroxyethoxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

a) [3*aR*-[3 α ,4 α ,6 α (1*R**,2*S**),6 α]-*N*-[(2,4-Dimethoxyphenyl)methyl]-3-[6-[[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethoxymethyl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-yl]-*N*-(2-phenylcyclopropyl)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine-7-amine

Sodium hydride (35mg, 60% dispersion in oil) and (2-bromoethoxy)-*tert*-butyldimethylsilane (0.2ml) were added to a solution of the product from example 36, step (b) (333mg) in toluene (3ml) and the reaction mixture heated at 65°C for 6h then at 100°C for 16 hours. Further sodium hydride (35mg) and silane (0.2ml) were added and the mixture heated for 6 hours. Ammonium chloride solution was added and the mixture was extracted with ethyl acetate. The organic extracts were dried, concentrated and purified (SiO₂, petrol:ether 2:1 and petrol:ethyl acetate 4:1 as eluant) to give the subtitle compound (77mg).

NMR δ H (CDCl₃) 7.27-7.12 (6H, m), 6.40-6.28 (2H, m), 5.37-5.17 (3H, m), 3.79 (1H, m), 3.78-3.73 (5H, m), 3.6-3.51 (7H, m), 3.1-2.95 (2H, m), 2.6-2.1 (2H, m), 1.68-1.61 (2H, m), 1.59-1.57 (6H, m), 1.48-1.41 (1H, m), 1.30-1.21 (5H, m), 0.94 (3H, t), 0.86 (9H, s), 0.06 (6H, s).

b) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(2-Hydroxyethoxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]cyclopentane-1,2-diol**

Prepared according to the method of example 2, step (b) using the product of step (a).

Purification (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate:acetonitrile, isocratic elution 35% MeCN over 30 minutes) afforded the title compound (33mg).

MS (APCI) 501 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.35 (1H, s), 7.38-7.05 (5H, m), 5.09-4.92 (2H, m), 4.81 (1H, d), 4.63-4.54 (1H, m), 4.47-4.38 (1H, m), 3.90-3.84 (1H, m), 3.6-3.3 (8H, m), 3.24-3.16 (1H, m), 3.01-2.79 (2H, m), 2.35-2.08 (3H, m), 1.90-1.78 (1H, m), 1.56-1.44 (2H, m), 1.37-1.27 (1H, m), 0.80 (3H, t).

Example 51

[1*R*-[1 α ,2 β ,3 β ,4 α (1*R,2*S**)]]-3-Hydroxy-2-methoxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentanemethanol**

5

(a) [1*R*-[1*a*,2*a*,3*b*(1*R,2*S**),5*b*]]-3-[7-[*N*-(2,4-Dimethoxyphenylmethyl)-(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

A solution of the product from Example 36, step (a) (1.39g) in trifluoroacetic acid (1.5ml)/methanol (15ml) was stirred for two days. Ethyl acetate was added and the mixture was concentrated. Sodium hydrogen carbonate solution was added and the mixture was extracted with ethyl acetate. The organic extracts were dried, concentrated and purified (SiO₂, petrol:acetone 1:1 as eluant) to give the subtitle compound (1.11g). MS (APCI) 607 (M+H⁺, 100%)

(b) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-5-[7-[*N*-(2,4-Dimethoxyphenylmethyl)-[(2-phenylcyclopropyl)amino]]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-cyclopentane-1,2-diol**

A solution of the product of step (a) (1.11g), imidazole (417mg) and *tert*-butylchlorodiphenylsilane (0.75ml) in dry DMF (4ml) was stirred for 18 hours. Water was added and the mixture was extracted with ethyl acetate. The organic extracts were dried, concentrated and purified (SiO₂, petrol:acetone 3:1 as eluant) to give the subtitle compound (1.16g).

NMR δ H (CDCl₃) 7.70-7.04 (16H, m), 6.44-6.30 (2H, m), 5.83-5.63 (2H, m), 5.45-5.31 (1H, m), 5.04-4.78 (1H, m), 4.50-4.40 (1H, m), 4.32-4.27 (1H, m), 3.86-3.52 (8H, m), 3.13-2.63 (4H, m), 2.53-2.17 (3H, m), 1.79-1.40 (4H, m), 1.01 (9H, s), 0.97 (3H, t).

(c) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-5-[7-[*N*-(2,4-Dimethoxyphenylmethyl)-[(2-phenylcyclopropyl)amino]]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2-methoxy-cyclopentanol**

Sodium hydride (65.3mg) was added to a solution of the diol from step (b) (1.23g) and methyl iodide (0.13ml) in DMF (4ml) and the mixture was stirred for 4h. Ammonium chloride solution was added and the mixture was extracted with ethyl acetate. The organic extracts were dried, concentrated and purified (SiO₂, petrol:acetone 4:1 and petrol:ethyl acetate 2:1 as eluants) to give the subtitle compound (676mg) as a 1:2.5 mixture with the regioisomeric [1*R*-[1 α ,2 α ,3 β ,5 β (1*R**,2*S**)]]-3-[7-[*N*-(2,4-dimethoxyphenylmethyl)-(2-

35

phenylcyclopropyl)amino]]-5-propylthio-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2-methoxycyclopentanol compound.

NMR δ H (CDCl₃) 7.5-7.0 (16H, m), 6.43-6.31 (2H, m), 5.84-4.60 (4H, m), 4.35-4.27 (1H, m), 3.82-3.12 (11H, m), 3.15-2.85 (2H, m), 2.64-2.58 (1H, m), 2.53-1.97 (2H, m), 1.77-1.22 (5H, m), 1.01 (9H, s), 0.97 (3H, t).

(d) [1*R*-[1 α ,2 β ,3 β ,4 α (1*R,2*S**)]]-3-Hydroxy-2-methoxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]cyclopentanemethanol**

A solution of the mixture of compounds from step (c) (676mg) in trifluoroacetic acid - water (9:1) (3ml) was stirred for 20 hours. The solvent was removed *in vacuo* and the residue was dissolved in THF (1ml) and treated with tetrabutylammonium fluoride in THF (2ml, 1M solution) and stirred for 4 hours. The solvent was removed *in vacuo* and the residue purified (SiO₂, petrol:acetone 2:1, dichloromethane:methanol 29:1 and petrol:ethyl acetate 1:2 as eluants) to give two fractions:-

Fraction 1, 161mg, [1*R*-[1 α ,2 β ,3 β ,4 α (1*R**,2*S**)]]-3-hydroxy-2-methoxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]cyclopentanemethanol.

Fraction 2, 330mg, [1*R*-[1 α ,2 β ,3 β ,4 α (1*R**,2*S**)]]-2-hydroxy-3-methoxy-4-[7-[(2-phenylcyclopropyl)amino]-5-propylthio-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]cyclopentanemethanol; further purified in example 52.

Further purification of fraction 1 (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate:acetonitrile, isocratic elution 45% MeCN over 40 minutes) afforded the title compound (58.9mg).

MS (APCI) 471 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.33 (1H, bs), 7.34-7.13 (5H, m), 5.10-4.69 (3H, m), 4.60-4.49 (1H, m), 3.68-2.79 (6H, m), 3.37 (3H, s), 2.32-2.07 (3H, m), 1.92-1.80 (1H, m), 1.60-1.47 (3H, m), 1.38-1.28 (1H, m), 0.80 (3H, t).

Example 52

[1*R*-[1 α ,2 β ,3 β ,4 α (1*R,2*S**)]]-2-Hydroxy-3-methoxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentanemethanol**

5

Purification of fraction 2 from Example 51 (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate:acetonitrile, isocratic elution 45% MeCN over 40 minutes) afforded the title compound (133.5mg).

MS (APCI) 471 (M+H⁺, 100%)

10 NMR δ H (d₆-DMSO) 9.35 (1H, s), 7.34-7.13 (5H, m), 5.14 (1H, q), 4.79 (1H, s), 4.23-4.05 (2H, m), 3.57-3.25 (5H, m), 3.25-3.18 (1H, m), 3.04-2.79 (2H, m), 2.37-2.06 (3H, m), 1.92-1.80 (1H, m), 1.60-1.47 (3H, m), 1.38-1.28 (1H, m), 0.83 (3H, t).

Example 53

15 **[1*S*-[1 α ,2 α ,3 β (*E*),5 β (1*S**,2*R**)]]-3-(3-Hydroxy-prop-1-enyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

a) 3-[[3*aR*-[3 α ,4 α (*E*),6 α (1*R,2*S**),6 α]]-6-[7-[(Cyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-yl]-2-propenoic acid, methyl ester**

A solution of the product of Example 1, step (a) (1.6g) in dimethylsulphoxide (15ml) was treated with pyridine (0.25g) followed by trifluoroacetic acid (0.18g). To this mixture was added 1,3-dicyclohexylcarbodiimide (1.99g). After stirring for 5 hours at the reaction mixture was treated with methyl(triphenylphosphoranylidene)acetate (1.72g) and then stirred for a further 18 hours. The mixture was poured into ethyl acetate (300ml) and treated with oxalic acid (1.59g). After stirring for 30 minutes the mixture was filtered and the ethyl acetate solution was washed with dilute aqueous sodium bicarbonate and then with dilute aqueous brine, before being dried and concentrated. Purification (SiO₂, ethyl acetate: isohexane 1:4 as eluant) afforded the subtitle compound (1.5g).

30

MS (APCI) 551 (M+H⁺, 100%)

b) 3-[[1*R*-[1 α (*E*),2 β ,3 β ,4 α (1*R**,2*S**)]]-2,3-Dihydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]-2-propenoic acid, methyl ester

Prepared according to the method of Example 2, step (b) using the product of step (a).

5 MS (APCI) 511 $(M+H^+)$, 100%

c) [1*S*-[1 α ,2 α ,3 β (*E*),5 β (1*S**,2*R**)]]-3-(3-Hydroxyprop-1-enyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

10 A solution of the product from step (b) (0.7g) in tetrahydrofuran (25ml) at -78°C was treated with DIBAL-H[®] (1.5 M solution in toluene, 8.2ml). The mixture was then stirred at 0°C for 1 hour before being quenched with methanol (1ml) and then poured into dilute aqueous sodium hydroxide (50ml). This mixture was extracted with ethyl acetate (200ml), the extract was dried and concentrated. Purification (SiO₂, ethyl acetate as eluant) afforded the title compound (0.2g).

15 MS (APCI) 483 $(M+H^+)$, 100%

NMR δ H (d₆-DMSO) 9.34 (1H, d), 7.31-7.15 (5H, m), 5.80-5.70 (1H, m), 5.66-5.58 (1H, m), 5.09 (1H, d), 4.98 (1H, q), 4.88 (1H, d), 4.67 (1H, t), 4.33 (1H, q), 3.93 (2H, t), 3.84 (1H, q), 3.22-3.18 (1H, m), 3.00-2.80 (2H, m), 2.65-2.60 (1H, m), 2.42-2.38 (1H, m), 2.15-2.10 (1H, m), 2.00-1.85 (1H, m), 1.55-1.47 (3H, m), 1.35-1.30 (1H, m), 0.85-0.80 (3H, m).

Example 54

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(3-Hydroxypropyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

25 A solution of the product of Example 53, step (c) (0.2g) and triisopropylbenzenesulphonylhydrazide (0.3g) in tetrahydrofuran (10ml) was heated at 70°C for 4 hours. The mixture was then purified (SiO₂, ethyl acetate as eluant) to afford the title compound (0.13g).

MS (APCI) 485 $(M+H^+)$, 100%

NMR δ H (d₆-DMSO) 9.32 (1H, d), 7.31-7.15 (5H, m), 5.00-4.95 (2H, m), 4.71 (1H, d), 4.42-4.36 (2H, m), 3.73 (1H, q), 3.41 (2H, q), 3.20-3.17 (1H, m), 2.97-2.83 (2H, m), 2.37-2.33 (1H, m), 2.13-2.11 (1H, m), 1.95-1.85 (1H, m), 1.77-1.31 (9H, m), 0.83 (3H, t).

Example 55

1-[[1*S*-(1 α ,2 β ,3 β ,4 α (1*S,2*R**))]-2,3-Dihydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]-2-methoxyethanone**

5 Boron trifluoride etherate (1.0 ml) was added to a solution of the diazoketone, prepared as described in Example 8 (0.60g) in methanol (50 ml), and the solution heated at 50°C for 1 hour. The reaction mixture was extracted into ethyl acetate and the extracts washed with water then dried and concentrated. Purification (SiO₂, ethyl acetate:dichloromethane 2:3 as eluant) afforded the title compound (0.16g).

10 MS (APCI) 499 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.36 (1H, d), 7.31-7.16 (5H, m), 5.25 (2H, m), 4.99 (1H, m), 4.30 (1H, m), 4.24 (2H, m), 4.13 (1H, m), 3.21 (3H, s), 3.19 (1H, m), 3.13 (1H, m), 2.96-2.83 (2H, m), 2.35 (2H, m), 2.14 (1H, m), 1.51 (3H, m), 1.34 (1H, m), 0.81 (3H, t).

15 **Example 56**

[1*S*-(1 α ,2 α ,3 β ,5 β)]-3-(Hydroxymethyl)-5-[7-[[(*trans*)-2-(3,4-methylenedioxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

20 **a)[3*aR*-(3 α ,4 α ,6 α ,6 α]-Tetrahydro-2,2-dimethyl-6-[7-[[(*trans*)-2-(3,4-methylenedioxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step (a) using (*trans*)-2-(3,4-methylenedioxyphenyl)cyclopropanamine hydrochloride.

25 MS (APCI) 541 (M+H⁺, 100%).

b) [1*S*-(1 α ,2 α ,3 β ,5 β)]-3-Hydroxymethyl-5-[7-[[(*trans*)-2-(3,4-methylenedioxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

30 Prepared according to the method of Example 1, step (b) using the product of step a).

MS (APCI) 501 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.28 (1H, d), 6.84-6.80 (2H, m), 6.71-6.69 (1H, m), 5.96 (2H, s), 5.01-4.97 (2H, m), 4.73-4.71 (2H, m), 4.44-4.40 (1H, m), 3.87 (1H, q), 3.51-3.44 (2H, m), 3.10-3.07 (1H, m), 3.00-2.90 (2H, m), 2.27-2.23 (1H, m), 2.08-2.05 (2H, m), 1.86-1.83 (1H, m), 1.59-1.53 (2H, m), 1.45-1.42 (1H, m), 1.29-1.24 (1H, m), 0.86 (3H, t).

35

Example 57

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(3-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

a) [3*aR*-[3 α ,4 α ,6 α (1*R,2*S**),6 α]-Tetrahydro-6-[7-[[2-(3-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step (a) using the product of Example 24, step (e).

MS (APCI) 527 (M+H⁺, 100%).

b) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(3-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

A solution of the product from step (b) (0.29 g) in 80% aqueous acetic acid (10 ml) was heated at 80° for 1 hour. The solution was concentrated *in vacuo* and purified by chromatography (SiO₂, methanol : dichloromethane, 5:95 as eluant) to give the crude product. Further purification (HPLC, Novapak® C18 column, 0.1% aqueous ammonium acetate:acetonitrile, isocratic elution 45% MeCN over 15 minutes) afforded the title compound as a colourless solid (0.19 g).

MS (APCI) 487 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 9.32 (1H, d), 7.19 (1H, t), 6.78-6.72 (3H, m), 5.04-4.95 (2H, m), 4.75-4.69 (2H, m), 4.47-4.38 (1H, m), 3.91-3.84 (1H, m), 3.75 (3H, s), 3.55-3.41 (2H, m), 3.24-3.17 (1H, m), 3.01-2.92 (1H, m), 2.90-2.81 (1H, m), 2.31-2.19 (1H, m), 2.14-2.04 (2H, m), 1.90-1.79 (1H, m), 1.59-1.45 (3H, m), 1.37-1.30 (1H, m), 0.83 (3H, t).

Example 58

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(4-hydroxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

a) (1*R*-trans)-2-(4-Hydroxyphenyl)cyclopropanamine, hydrobromide

A solution of the free base of the product from Example 20, step (b), (300mg) in 47% aqueous hydrobromic acid (9 ml) was heated at 100 °C for 2 hours. The reaction mixture was concentrated and the residue azeotroped with toluene (3 x 30 ml). The residue was

then taken into ethanol (30 ml) and the product precipitated by the slow addition of ether (100 ml) to afford the subtitle compound (290 mg).

NMR δ H (D₂O) 6.98 (2H, m), 6.74 (2H, m), 2.68 (1H, m), 2.25 (1H, m), 1.25 (1H, m), 1.14 (1H, m).

5

b) [3aR-[3a α ,4 α ,6 α (1*R,2*S**),6a α]-Tetrahydro-6-[7-[[2-(4-hydroxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step (a) using the product of step (a) and tetrahydrofuran as solvent.

10

MS (APCI) 513 (M+H⁺, 100%).

c) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]-3-(Hydroxymethyl)-5-[7-[[2-(4-hydroxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

15

Prepared according to the method of Example 57, step (b) using the product of step (b).

MS (APCI) 473 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 9.25 (1H, d), 7.05 (2H, dd), 6.69 (2H, dd), 6.62 (4H, m), 5.00 (1H, m), 4.41 (1H, m), 3.87 (1H, m), 3.45 (2H, m), 3.05 (1H, m), 2.95 (2H, m), 2.27 (1H, m), 2.06 (2H, m), 1.86 (1H, m), 1.54 (2H, m), 1.39 (1H, m), 1.20 (1H, m), 0.87 (3H, t).

20

Example 59

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]-3-(Hydroxymethyl)-5-[7-[[2-(3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

25

a) [3aR-[3a α ,4 α ,6 α (1*R,2*S**),6a α]-Tetrahydro-6-[7-[[2-(3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step (a) using the product of Example 25, step (b).

30

MS (APCI) 511 (M+H⁺, 100%).

b) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

Prepared according to the method of Example 57, step (b) using the product of step (a).

5 MS (APCI) 471 ($M+H^+$, 100%).

NMR δ H (d_6 -DMSO) 9.31 (1H, d), 7.17 (1H, t), 7.07-6.93 (3H, m), 5.06-4.94 (2H, m), 4.76-4.68 (2H, m), 4.48-4.38 (1H, m), 3.91-3.81 (1H, m), 3.56-3.40 (2H, m), 3.21-3.13 (1H, m), 3.03-2.81 (2H, m), 2.29 (3H, s), 2.27-2.18 (1H, m), 2.16-2.02 (2H, m), 1.92-1.78 (1H, m), 1.60-1.43 (3H, m), 1.37-1.26 (1H, m), 0.84 (3H, t).

10 Example 60

[1*S*-[1*a*,2*a*,3*b*,5*b*(1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(3-phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

15 **a) [3*aR*-[3*a* α ,4 α ,6 α (1*R**,2*S**),6*a* α]-Tetrahydro-2,2-dimethyl-6-[7-[[2-(3-phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step (a) using the product of Example 29,
20 step (c).

MS (APCI) 589 ($M+H^+$, 100%).

b) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(3-phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

Prepared according to the method of Example 57, step (b) using the product of step (a).

MS (APCI) 549 ($M+H^+$, 100%).

30 NMR δ H (d_6 -DMSO) 9.32 (1H, d), 7.41-7.38 (2H, m), 7.30 (1H, t), 7.01-6.96 (3H, m), 6.95 (1H, s), 6.80 (1H, dd), 5.01-4.96 (2H, m), 4.73-4.70 (2H, m), 4.45-4.38 (1H, m), 3.51-3.45 (2H, m), 3.20-3.18 (1H, m), 3.03-2.81 (2H, m), 2.31-2.22 (1H, m), 2.15-2.06 (2H, m), 1.89-1.91 (1H, m), 1.56-1.49 (3H, m), 1.33-1.30 (1H, m), 0.84 (3H, t).

Example 61

[1*R*-[1 α ,2 α ,3 β (1*R,2*S**),5 β]]-3-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

5

a) [3*aR*-[3 α ,4 α ,6 α (1*R,2*S**),6 α]-6-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step (a) using the product of Example 19, step (i).

10

MS (APCI) 515 (M+H⁺, 100%).

b) [1*R*-[1 α ,2 α ,3 β (1*R,2*S**),5 β]]-3-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

15

Prepared according to the method of Example 57, step (b) using the product of step (a).

MS (APCI) 475 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 9.33 (1H, d), 7.29-7.17 (2H, m), 7.17-7.07 (2H, m), 5.05-4.95 (2H, m), 4.76-4.68 (2H, m), 4.48-4.38 (1H, m), 3.92-3.84 (1H, m), 3.55-3.41 (2H, m), 3.18-3.05 (1H, m), 3.01-2.81 (2H, m), 2.31-2.19 (1H, m), 2.18-2.04 (2H, m), 1.91-1.79 (1H, m), 1.58-1.46 (3H, m), 1.36-1.28 (1H, m), 0.83 (3H, t).

20

Example 62

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]-3-(Hydroxymethyl)-5-[7-[[2-(3-nitrophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

25

a) [3*aR*-[3 α ,4 α ,6 α (1*R,2*S**),6 α]-Tetrahydro-2,2-dimethyl-6-[7-[[2-(3-nitrophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-4*H*-cyclopenta-1,3-dioxole-4-methanol**

30

Prepared according to the method of Example 1, step (a) using the product of Example 27, step (b).

MS (APCI) 542 (M+H⁺, 100%).

b) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(3-nitrophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

Prepared according to the method of Example 57, step (b) using the product of step (a).

5 MS (APCI) 502 ($M+H^+$, 100%).

NMR δ H (d_6 -DMSO) 8.10-8.00 (2H, m), 7.71-7.55 (2H, m), 5.06-4.92 (2H, m), 4.82-4.64 (2H, br), 4.47-4.37 (1H, m), 3.91-3.83 (1H, m), 3.55-3.41 (2H, m), 3.28-3.20 (1H, m), 2.97-2.72 (2H, m), 2.37-2.17 (2H, m), 2.16-2.03 (1H, m), 1.92-1.77 (1H, m), 1.74-1.60 (1H, m), 1.59-1.39 (3H, m), 0.78 (3H, t).

Example 63

[1*R*-[1 α ,2 α ,3 β ,5 β (1*R,2*S**)]]-3-[7-[[2-(3-Aminophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

15 Prepared by the method of Example 30, using the product of Example 62.

MS (APCI) 472 ($M+H^+$, 100%).

NMR δ H (d_6 -DMSO) 6.91 (1H, t), 6.42-6.29 (3H, m), 5.07-4.86 (1H, m), 4.49-4.38 (1H, m), 3.91-3.85 (1H, m), 3.56-3.40 (2H, m), 3.23-3.15 (1H, m), 3.14-2.84 (2H, m), 2.32-2.18 (1H, m), 2.17-2.05 (1H, m), 2.05-1.96 (1H, m), 1.91-1.78 (1H, m), 1.64-1.50 (2H, m), 1.46-1.36 (1H, m), 1.25-1.13 (1H, m), 0.87 (3H, t).

Example 64

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-4-[7-[[2-(3,5-Dimethoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

a) 3-(3,5-Dimethoxyphenyl)-2-propenoic acid

To a solution of 3,5-dimethoxybenzaldehyde (12.5g) in pyridine (20 ml) was added malonic acid (8.61g) and piperidine (1ml). The resulting solution was heated at 100°C for 16 hours, cooled to room temperature, poured onto ice and acidified using conc. HCl. The resulting precipitate was collected, extracted into sodium bicarbonate solution and washed with isohexane. The aqueous phase was acidified using conc. HCl to yield a white precipitate which was filtered off, washed with water and dried to afford the subtitle compound (11.07g).

35 MS (APCI) 207 ($M-H^+$, 100%)

b) [3aS-[1(*E*),3α,6α,7αβ]]-1-[3-(3,5-Dimethoxyphenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3a,6-methano-2,1-benzisothiazole-2,2-dioxide

The subtitle compound was prepared according to the method of Example 19, step (f) using the product from step (a).

5 MS (APCI) 406 (M+H⁺ 100%).

c) [3aS-[1(1*S,2*S**),3aa,6a,7ab]]-1-[[2-(3,5-Dimethoxyphenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3*H*-3a,6-methano-2,1-benzisothiazole-2,2-dioxide**

The subtitle compound was prepared according to the method of Example 19, step (g)

10 using the product of step (b).

MS (APCI) 418 (M-H⁺, 100%)

d) (1*R-trans*)-2-(3,5-Dimethoxyphenyl)-cyclopropane carboxylic acid

The subtitle compound was prepared according to the method of Example 19, step (h)

15 using the product of step (c).

MS (APCI) 221 (M-H⁺, 100%)

e) [1*R-trans*]-2-(3,5-Dimethoxyphenyl)cyclopropanamine, [*R*-(*R,*R**)]-2,3-dihydroxybutanedioate (1:1)**

20 The subtitle compound was prepared according to the method of Example 20, step (b) using the product of step (d).

NMR δH (d₆-DMSO) 6.32-6.31 (1H, m), 6.26-6.25 (2H, m), 3.92 (2H, s), 3.71 (6H, s), 2.73-2.66 (2H, m), 2.10-2.03 (1H, m), 1.23-1.08 (2H, m).

f) [1*S*-[1α,2β,3β,4α(1*S,2*R**)]]-4-[7-[[2-(3,5-Dimethoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

The title compound was prepared according to the method of Example 24, step (f), using the products of step (e) and Example 24, step (d).

MS (APCI) 503 (M+H⁺, 100%)

30 NMR δH (d₆-DMSO) 6.35-6.30 (3H, m), 5.10 (1H, bs), 5.00-4.91 (3H, m), 4.67-4.63 (1H, m), 3.93 (1H, s), 3.78-3.77 (1H, m), 3.73 (6H, s), 3.22-3.17 (1H, m), 3.01-2.84 (2H, m), 2.62-2.61 (1H, m), 2.08-2.05 (1H, m), 1.91-1.87 (1H, m), 1.53-1.46 (2H, m), 1.35-1.32 (1H, m), 0.85-0.80 (3H, s).

Example 65

[1*S*-[1*a*,2*a*,3*b*,5*b*(1*S,2*R**)]]-3-[(2-Hydroxy-2,2-dimethyl)ethoxy]-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol.**

a) 2-[[[3*aR*-[3*a*α,4α(1*R,2*S**),6α,6*a*α]]-6-[7-[*N*-[(2,4-Dimethoxyphenyl)methyl]-2-(phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-yl]oxy]-1,1-dimethyl-ethanol**

To a solution of the product from Example 23, step (b) (1.15g) in tetrahydrofuran (25ml) at 0°C was added methylmagnesium bromide (0.45ml, 3M solution in THF). The reaction was stirred for 1 hour then quenched with 10% ammonium chloride solution and the reaction mixture partitioned between ethyl acetate and water. The organic phase was separated dried and concentrated. Purification (SiO₂, ethyl acetate: hexane 1:3 to as eluent) afforded the subtitle compound (0.80g).

MS (APCI) 705 (M+H⁺, 100%)

b) [1*S*-[1*a*,2*a*,3*b*,5*b*(1*S,2*R**)]]-3-[(2-Hydroxy-2,2-dimethyl)ethoxy]-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol.**

The title compound was prepared according to the method of Example 2, step (b) using the product of step (a).

MS (APCI) 705 (M+H⁺, 100%)

NMR δH (d₆-DMSO) 9.35 (1H, t, *J*=4.5Hz), 7.31-7.27 (2H, m), 7.21-7.15 (3H, m), 5.13 (1H, d, *J*=6.3Hz), 5.05 (1H, d, *J*=3.9Hz), 4.98 (1H, q, *J*=9.0Hz) 4.63-4.56 (1H, m), 3.94 (1H, s), 3.74 (1H, s), 3.27 (1H, d, *J*=8.7Hz), 3.21 (1H, d, *J*=9.0Hz), 3.21 (1H, m), 2.97-2.81 (2H, m), 2.63 (1H, m), 2.13 (1H, m), 2.04 (1H, m), 1.52 (2H, m), 1.48 (1H, m), 1.34 (1H, m), 1.10 (3H, s), 1.09 (3H, s), 0.81 (3H, t, *J*=7.5Hz)

Example 66

[1*S*-[1α,2α,3β,5β(1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-[4-(1-methylethoxy)phenyl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

a) 1-Ethenyl-4-(1-methylethoxy)benzene

Prepared according to the method of Example 29, step (a) using 4-(1-methylethoxy)-benzaldehyde.

MS (EI) 162 (M^+ , 100%)

b) (1*R*-trans)-2-[4-(1-Methylethoxy)phenyl]-cyclopropane carboxylic acid

Prepared according to the method of Example 20, step (a) the product of step (a).

5 MS (APCI) 219 ($M-H^+$, 100%).

c) (1*R*-trans)-2-[4-(1-Methylethoxy)phenyl]-cyclopropanamine

Prepared according to the method of Example 19, step i) using the product of step (b).

10 NMR δ H (d_6 -DMSO) 7.00 (2H, d), 6.76 (2H, d), 4.51 (1H, sept), 2.30-2.25 (1H, m), 1.67-1.61 (1H, m), 1.21 (6H, d), 0.85-0.75 (2H, m).

d) [3*aR*-[3*aa*,4*a*,6*a*(1*R*^{*},2*S*^{*}),6*aa*]-Tetrahydro-2,2-dimethyl-6-[7-[[2-[4-(1-methylethoxy)phenyl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-4*H*-cyclopenta-1,3-dioxole-4-methanol

15 Prepared according to the method of Example 1, step (a) using the product of step (c).
MS (APCI) 219 ($M+H^+$, 100%).

e) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S*^{*},2*R*^{*})]-3-(Hydroxymethyl)-5-[7-[[2-[4-(1-methylethoxy)phenyl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

20 Prepared according to the method of Example 57, step (b) using the product of step (d).
NMR δ H (d_6 -DMSO) 9.28 (1H, d), 7.11 (2H, d), 6.83 (2H, m), 5.01-4.97 (2H, m), 4.74-4.70 (2H, m), 4.55 (1H, sept), 4.46-4.39 (1H, m), 3.89-3.85 (1H, m), 3.51-3.45 (2H, m), 3.14-3.07 (1H, m), 3.03-2.82 (2H, m), 2.30-2.20 (1H, m), 2.09-2.06 (2H, m), 1.89-1.79
25 (1H, m), 1.59-1.49 (1H, m), 1.47-1.41 (1H, m), 1.24 (7H, m), 0.99 (3H, t).

Example 67

[1*S*-[1*a*,2*a*,3*b*,5*b*(1*S,2*R**)]]-3-(3-Hydroxypropoxy)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

a) **[3*aS*-[3*a*α,4α(1*S**,2*R**),6α,6*a*α]]-*N*-[2,4-(Dimethoxyphenyl)methyl]-3-[2,2-dimethyl-6-[[[3-(tetrahydro-2*H*-pyran-2-yl)oxy]propyl]oxy]-4*H*-cyclopenta-1,3-dioxol-4-yl]-*N*-(2-phenylcyclopropyl)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-amine.**

The subtitle compound was prepared according to the method of Example 31, step (d) using the product of Example 23, step (a) and 2-(3-bromopropoxy)-2*H*-tetrahydropyran. MS (APCI) 775 (M+H⁺, 100%)

b) **[1*S*-[1*a*,2*a*,3*b*,5*b*(1*S**,2*R**)]]-3-(3-Hydroxypropoxy)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

The title compound was prepared according to the method of Example 2, step (b) using the product of step (a).

MS (APCI) 501 (M+H⁺, 100%)

NMR δ_H (d₆-DMSO) 9.34 (1H, d, *J*=4.0 Hz), 7.32-7.25 (2H, m), 7.22-7.15 (3H, m), 5.11 (1H, d, *J*=3.3 Hz), 5.04 (1H, d, *J*=3.8 Hz), 4.97 (1H, q, *J*=9.1 Hz), 4.62-4.52 (1H, m), 4.40 (1H, t, 5.2 Hz), 3.95-3.92 (1H, m), 3.75-3.66 (1H, m), 3.59-3.41 (4H, m), 3.25-3.14 (1H, m), 3.13-2.78 (2H, m), 2.70-2.55 (1H, m), 2.30-1.95 (2H, m), 1.73-1.61 (2H, m), 1.57-1.28 (4H, m), 0.82 (3H, t, *J*=7.5 Hz).

Example 68

[1*S*-[1α,2β,3β,4α(1*S, 2*R**)]]-4-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

a) **[3*aS*-[1(*E*),3*a*α,6α,7*a*β]]-1-[3-(3,4-Difluorophenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

The subtitle compound was prepared according to the method of Example 19, step (f) using 3-(3,4-difluorophenyl)-2-propenoic acid.

MS (APCI) 382 (M+H⁺, 100%)

b) [3aS-[1(1S*,2S*),3aa,6a,7ab]]-1-[[2-(3,4-Difluorophenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3H-3a,6-methano-2,1-benzisothiazole-2,2-dioxide

The subtitle compound was prepared according to the method of Example 19, step (g) using the product of step (a).

5 MS (APCI) 396 (M+H⁺, 100%)

c) (1R-trans)-2-(3,4-Difluorophenyl)-cyclopropane carboxylic acid

The subtitle compound was prepared according to the method of Example 19, step (h) using the product of step (b).

10 NMR δH (CDCl₃) 7.68 (1H, dd, J=10.0, J=8.5 Hz), 7.46-7.31 (2H, m), 3.12-3.03 (1H, m), 2.37 (1H, dt, J=8.5, J=4.4 Hz), 2.17 (1H, dt, J=9.2, J=4.8 Hz), 1.86 (1H, ddd, J=8.5, J=6.9, J=5.2 Hz).

d) (1R-trans)-2-(3,4-Difluorophenyl)cyclopropanamine, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1)

15 The subtitle compound was prepared according to the method of Example 20, step (b) using the product of step (c).

MS (APCI) 170 (M+H⁺, 100%)

e) [1S-[1α,2β,3β,4α(1S*, 2R*)]]-4-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

The title compound was prepared according to the method of Example 24, step (f) using the products of step (d) and Example 24, step (d).

MS (APCI) 479 (M+H⁺, 100%)

25 NMR δH (d₆-DMSO) 9.36 (1H, d, J=4.2 Hz), 7.40-7.22 (2H, m), 7.10-7.00 (1H, m), 5.13-4.90 (4H, m), 4.68-4.60 (1H, m), 3.97-3.90 (1H, m), 3.82-3.76 (1H, m), 3.20-2.80 (3H, m), 2.62-2.50 (1H, m), 2.32-2.04 (1H, m), 1.96-1.83 (1H, m), 1.75-1.36 (4H, m), 0.82 (3H, t, J=7.5 Hz).

Example 69

[1*R*-[1 α ,2 α ,3 β (1*S,2*R**),5 β]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

5

a) [3*aR*-[3 α ,4 α ,6 α (1*R,2*S**),6 α]-6-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

10

Prepared according to the method of Example 1, step (a) using the product of Example 68, step (d).

MS (APCI) 533 (M+H⁺, 100%).

15

b) [1*R*-[1 α ,2 α ,3 β (1*S,2*R**),5 β]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

20

Prepared according to the method of Example 57, step (b) using the product of step (a).
NMR δ H (d₆-DMSO) 9.36 (1H, d), 7.39-7.27 (2H, m), 7.10-7.05 (1H, m), 5.05-4.95 (2H, m), 4.74-4.71 (2H, m), 4.46-4.39 (1H, m), 3.90-3.86 (1H, m), 3.53-3.41 (2H, m), 3.18-3.12 (1H, m), 3.00-2.81 (2H, m), 2.31-2.21 (1H, m), 2.16-2.06 (2H, m), 1.90-1.79 (1H, m), 1.58-1.46 (3H, m), 1.41-1.34 (1H, m), 0.83 (3H, t).

Example 70

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S, 2*R**)]-4-[7-[[2-(3,5-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

25

a) [3*aS*-[1(*E*),3 α ,6 α ,7 $\alpha\beta$]]-1-[3-(3,5-Difluorophenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide

The subtitle compound was prepared according to the method of Example 19, step (f) using 3-(3,5-difluorophenyl)-2-propenoic acid.

30

MS (APCI) 382 (M+H⁺, 100%)

b) [3*aS*-[1(1*S,2*S**),3*aa*,6*a*,7*ab*]]-1-[[2-(3,5-Difluorophenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

35

The subtitle compound was prepared according to the method of Example 19, step (g) using the product of step (a).

MS (APCI) 396 (M+H⁺, 100%)

c) (1*R*-trans)-2-(3,5-Difluorophenyl)-cyclopropane carboxylic acid

The subtitle compound was prepared according to the method of Example 19, step (h) using the product of step (b).

5 MS (APCI) 197 (M-H⁺, 100%)

d) [1*R*-(trans)]-2-(3,5-Difluorophenyl)cyclopropanamine, [*R*-(*R*^{*}, *R*^{*})]-2,3-dihydroxybutanedioate (1:1)

10 The subtitle compound was prepared according to the method of Example 20, step (b) using the product of step (c).

NMR δH (d₆-DMSO) 7.00-6.84 (3H, m), 3.98 (2H, s), 2.75-2.69 (1H, m), 2.16-2.10 (1H, m), 1.28-1.15 (2H, m).

e) [1*S*-[1α,2β,3β,4α(1*S*^{*}, 2*R*^{*})]-4-[7-[[2-(3,5-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

15 The title compound was prepared according to the method of Example 24, step (f) using the products of step (d) and Example 24, step (d).

MS (APCI) 479 (M+H⁺, 100%)

20 NMR δH (d₆-DMSO) 9.38 (1H, d, *J*=4.2 Hz), 7.01-6.95 (3H, m), 5.11-4.91 (4H, m), 4.68-4.64 (1H, m), 3.94-3.91 (1H, m), 3.77 (1H, bs), 3.20-2.80 (3H, m), 2.65-2.55 (1H, m), 2.20-2.10 (1H, m), 1.95-1.85 (1H, m), 1.63-1.43 (4H, m), 0.81 (3H, t, *J*=7.5 Hz).

Example 71**[1*S*-[1α,2β,3β,4α(1*S*^{*}, 2*R*^{*})]-4-[7-[[1,1'-Biphenyl]-3-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol****a) [3*aS*-[1(*E*),3α,6α,7αβ]]-1-[3-[[1,1'-Biphenyl]-3-yl]-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

30 The subtitle compound was prepared according to the method of Example 19, step (f) using 3-(3,5-difluorophenyl)-2-propenoic acid.

MS (APCI) 422 (M+H⁺, 100%)

b) [3*aS*-[1(1*S*^{*}, 2*S*^{*}),3*aa*,6*a*,7*ab*]]-1-[[2-[[1,1'-Biphenyl]-3-yl]cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide

35 The subtitle compound was prepared according to the method of Example 19, step (g) using the product of step (a).

MS (APCI) 436 (M+H⁺, 100%)

c) (1*R*-trans)-2-[[1,1'-Biphenyl]-3-yl]-cyclopropane carboxylic acid

The subtitle compound was prepared according to the method of Example 19, step (h) using the product of step (b).

MS (APCI) 237 (M-H⁺, 100%)

d) [1*R*-(trans)]-2-[[1,1'-Biphenyl]-3-yl]cyclopropanamine, [*R*-(*R,*R**)]-2,3-dihydroxybutanedioate (1:1)**

The subtitle compound was prepared according to the method of Example 20, step (b) using the product of step (c).

MS (APCI) 210 (M-H⁺, 100%)

e) [1*S*-[1 α ,2 β ,3 β ,4 α (1*S, 2*R**)]]-4-[7-[[2-[[1,1'-Biphenyl]-3-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

The title compound was prepared according to the method of Example 24, step (f) using the products of step (d) and Example 24, step (d).

MS (APCI) 519 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.37 (1H, d, *J*=4.2 Hz), 7.70-7.18 (9H, m), 5.12-4.91 (4H, m), 4.67-4.64 (1H, m), 3.94-3.93 (1H, m), 3.78 (1H, bs), 3.28-2.80 (3H, m), 2.62-2.50 (1H, m), 2.25-2.15 (1H, m), 1.95-1.85 (1H, m), 1.59-1.41 (4H, m), 0.75 (3H, t, *J*=7.5 Hz).

Example 72

[1*R*-[1 α ,2 α ,3 β (1*R,2*S**),5 β]]-3-[7-[[2-[1,1'-Biphenyl]-3-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

a) [3*aR*-[3 α ,4 α ,6 α (1*R,2*S**),6 α]-6-[7-[[2-[1,1'-Biphenyl]-3-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step (a) using the product of Example 71, step (d).

MS (APCI) 573 (M+H⁺, 100%).

b) [1*R*-[1 α ,2 α ,3 β (1*R,2*S**),5 β]]-3-[7-[[2-[1,1'-Biphenyl]-3-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

Prepared according to the method of Example 57, step (b) using the product of step (a).

5 MS (APCI) 533 ($M+H^+$, 100%).

NMR δ H (d_6 -DMSO) 9.35 (1H, d), 7.68 (2H, dd), 7.49-7.44 (4H, m), 7.41-7.33 (2H, m), 7.19 (1H, d), 6.80 (1H, dd), 5.05-4.95 (2H, m), 4.74-4.71 (2H, m), 4.46-4.39 (1H, m), 3.90-3.87 (1H, m), 3.51-3.45 (2H, m), 3.27-3.20 (1H, m), 3.00-2.77 (2H, m), 2.30-2.17 (2H, m), 2.12-2.04 (1H, m), 1.90-1.79 (1H, m), 1.60-1.53 (1H, m), 1.50-1.41 (3H, m), 0.77 (3H, t).

10 Example 73

***N*-Ethyl-[[[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-2,3-dihydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]oxy]-acetamide**

15 **a) [1*S*-[1 α ,4 α (1*S**,2*R**)]]-2-[[4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2-cyclopentenyl]oxy]acetic acid**

The subtitle compound was prepared according to the method of Example 2, step (b) using the product of example 13, step (a).

20 MS (APCI) 467 ($M+H^+$, 100%)

b) *N*-Ethyl-2-[[[1*S*-[1 α ,4 α (1*S,2*R**)]]-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2-cyclopentenyl]oxy]-acetamide.**

25 The subtitle compound was prepared according to the method of Example 16, using the product of step (a) and 40% aqueous ethylamine.

MS (APCI) 494 ($M+H^+$, 100%).

30 **c) *N*-Ethyl-[[[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-2,3-dihydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]oxy]-acetamide**

The title compound was prepared according to the method of Example 12, step (f) using the product of step (b).

MS (APCI) 528 ($M+H^+$, 100%).

35 NMR δ H (d_6 -DMSO) 9.36 (1H, m), 7.75-7.68 (1H, m), 7.31-7.26 (2H, m), 7.21-7.15 (3H, m), 5.23-5.18 (2H, m), 5.00-4.92 (1H, m), 4.60-4.53 (1H, m), 4.05-4.01 (1H, m), 3.93-3.78

(3H, m), 3.24-3.08 (3H, m), 2.98-2.90 (1H, m), 2.87-2.79 (1H, m), 2.69-2.61 (1H, m), 2.30-2.06 (2H, m), 1.72-1.29 (4H, m), 1.04 (3H, t, $J=7.1$ Hz), 0.80 (3H, t, $J=7.2$ Hz).

Example 74

- 5 **[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**, 2*R**)]]-4-[7-[[2-(3-Methoxy-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

a) 3-(3-Methoxy-4-methylphenyl)-2-propenoic acid.

- 10 The subtitle compound was prepared according to the method of Example 64, step (a) using (3-methoxy-4-methyl)benzaldehyde.

MS (APCI) 191 ($M-H^+$, 100%)

- 15 **b) [3*aS*-[1(*E*),3*a* α ,6*a*,7*a* β]]- Hexahydro-1-[3-(3-methoxy-4-methylphenyl)-1-oxo-2-propenyl]-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

The subtitle compound was prepared according to the method of Example 19, step (f) using the product of step (a).

MS (APCI) 390 ($M+H^+$, 100%)

- 20 **c) [3*aS*-[1(1*S**,2*S**),3*aa*,6*a*,7*ab*]]-Hexahydro-1-[[2-(3-methoxy-4-methylphenyl)cyclopropyl]carbonyl]-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

The subtitle compound was prepared according to the method of Example 19, step (g) using the product of step (b).

MS (APCI) 404 ($M+H^+$, 100%)

25

d) (1*R-trans*)-2-(3-Methoxy-4-methylphenyl)cyclopropane carboxylic acid

The subtitle compound was prepared according to the method of Example 19, step (h) using the product of step (c).

- 30 NMR δ H ($CDCl_3$) 7.04 (1H, d, $J=7.3$ Hz), 6.60 (1H, s), 6.59 (1H, d, $J=7.3$ Hz), 3.82 (3H, s), 2.63-2.55 (1H, m), 2.18 (3H, s), 1.89 (1H, ddd, $J=9.2$, $J=5.2$, $J=4.2$ Hz), 1.64 (1H, dt, $J=9.4$, $J=4.6$ Hz), 1.40 (1H, ddd, $J=11.3$, $J=6.7$, $J=4.6$ Hz).

e) [1*R-(trans)*]-2-(3-Methoxy-4-methylphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)

- 35 The subtitle compound was prepared according to the method of Example 20, step (b) using the product of step (d).

MS (APCI) 178 (M+H⁺, 100%)

f) [1*S*-[1 α ,2 β ,3 β ,4 α (1*S, 2*R**)]]-4-[7-[[2-(3-Methoxy-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

The title compound was prepared according to the method of Example 24, step (f) using the products of step (e) and Example 24, step (d).

MS (APCI) 487 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.31 (1H, d, *J*=4.2 Hz), 7.03 (1H, d, *J*=7.7 Hz), 6.77 (1H, m), 6.64 (1H, dd, *J*=7.7, *J*=1.2 Hz), 5.12-4.89 (4H, m), 4.70-4.62 (1H, m), 3.97-3.89 (1H, m), 3.80 (3H, s), 3.81-3.76 (1H, m), 3.22-2.80 (3H, m), 2.64-2.53 (1H, m), 2.10 (3H, s), 2.27-2.06 (1H, m), 1.96-1.87 (1H, m), 1.73-1.27 (4H, m), 0.82 (3H, t, *J*=7.5 Hz).

Example 75

[1*R*-[1 α ,2 α ,3 β (1*R, 2*S**),5 β]]-3-[7-[[2-(4-*N,N*-Dimethylaminophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-hydroxymethyl-cyclopentane-1,2-diol**

a) [3*aS*-[1(*E*),3 α ,6 α ,7 α]]-1-[3-(4-*N,N*-Dimethylaminophenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide

Prepared according to the method of Example 19, step (f) using (*E*)-3-(4-*N,N*-dimethylaminophenyl)-2-propenoyl chloride (Prepared by the method of K. Venkataraman *et al.*, Tetrahedron Lett., 1979, 32, 3037).

MS (APCI) 389 (M+H⁺, 100%)

b) [3*aS*-[1(1*S, 2*S**),3 $\alpha\alpha$,6 α ,7 $\alpha\beta$]]-1-[[2-(4-*N,N*-Dimethylaminophenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

Prepared according to the method of Example 19, step (g) using the product of step (a).

MS (APCI) 403 (M+H⁺, 100%)

c) (1*R-trans*)-2-(4-*N,N*-Dimethylaminophenyl)-cyclopropane carboxylic acid

Prepared according to the method of Example 19, step (h) using the product of step (b).

MS (APCI) 206 (M+H⁺, 100%)

d) (1*R-trans*)-2-(4-*N,N*-Dimethylaminophenyl)cyclopropanamine, [*R*-(*R*^{*},*R*^{*})]-2,3-dihydroxybutanedioate (1:1)

Prepared according to the method of Example 20, step (b) using the product of step (c).

NMR δ H (d₆-DMSO) 6.95 (2H, d), 6.64 (2H, d), 3.91 (2H, s), 2.84 (6H, s), 2.61-2.56 (1H, m), 2.12-2.05 (1H, m), 1.21-1.14 (1H, m), 1.06-0.98 (1H, m).

e) [3a*R*-[3a α ,4 α ,6 α (1*R*^{*},2*S*^{*}),6a α]-6-[7-[[2-(4-*N,N*-Dimethylaminophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol

Prepared according to the method of Example 1, step (a) using the product of step (d).

MS (APCI) 540 (M+H⁺, 100%)

f) [1*R*-[1 α ,2 α ,3 β (1*R*^{*},2*S*^{*}),5 β]-3-[7-[[2-(4-*N,N*-dimethylaminophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-hydroxymethyl-cyclopentane-1,2-diol

Prepared according to the method of Example 1, step (b) using the product of step (e).

MS (APCI) 500 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.25 (1H, d), 7.04 (2H, d), 6.67 (2H, d), 5.01-4.96 (2H, m), 4.73-4.70 (2H, m), 4.46-4.41 (1H, m), 3.88 (1H, q), 3.51-3.44 (2H, m), 3.10-2.90 (3H, m), 2.85 (6H, s), 2.27-2.23 (1H, m), 2.08-2.01 (2H, m), 1.87-1.82 (1H, m), 1.60-1.53 (2H, m), 1.40-1.37 (1H, m), 1.21-1.18 (1H, m), 0.86 (3H, t).

Example 76

[1*R*-[1 α ,2 α ,3 β (1*R*^{*},2*S*^{*}),5 β]-3-[7-[[2-(3-Fluoro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

a) [3a*S*-[1(*E*),3a α ,6 α ,7a β]-1-[3-(3-Fluoro-4-methoxyphenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3a,6-methano-2,1-benzisothiazole-2,2-dioxide

Prepared according to the method of Example 19, step (f) using (*E*)-3-(3-fluoro-4-methoxyphenyl)-2-propenoic acid.

MS (APCI) 394 (M+H⁺, 100%)

b) [3aS-[1(1*S,2*S**),3aa,6a,7ab]]-1-[[2-(3-Fluoro-4-methoxyphenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3*H*-3a,6-methano-2,1-benzisothiazole-2,2-dioxide**

5 Prepared according to the method of Example 19, step (g) using the product of step (a).
MS (APCI) 408 (M+H⁺, 100%)

c) (1*R*-trans)-2-(3-Fluoro-4-methoxyphenyl)-cyclopropane carboxylic acid

Prepared according to the method of Example 19, step (h) using the product of step (b).
10 NMR δ H (CDCl₃) 6.91-6.81 (3H, m), 3.87 (3H, s), 2.58-2.51 (1H, m), 1.86-1.80 (1H, m), 1.66-1.60 (1H, m), 1.37-1.25 (1H, m).

d) [1*R*-(trans)]-2-(3-Fluoro-4-methoxyphenyl)cyclopropanamine, [*R*-(*R,*R**)]-2,3-dihydroxybutanedioate (1:1)**

15 Prepared according to the method of Example 20, step (b) using the product of step (c).
NMR δ H (d₆-DMSO) 7.08-6.91 (3H, m), 3.93 (2H, s), 3.79 (3H, s), 2.67-2.62 (1H, m), 2.14-2.08 (1H, m), 1.23-1.17 (1H, m), 1.11-1.05 (1H, m).

e) [3a*R*-[3a α ,4 α ,6 α (1*R,2*S**),6a α]-6-[7-[[2-(3-Fluoro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step (a) using the product of step (d).
MS (APCI) 545 (M+H⁺, 100%)

25 **f) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Fluoro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

Prepared according to the method of Example 1, step (b) using the product of step (e).
MS (APCI) 505 (M+H⁺, 100%)
30 NMR δ H (d₆-DMSO) 9.30 (1H, d), 7.11-6.98 (3H, m), 5.04-4.97 (2H, m), 4.73-4.70 (2H, m), 4.46-4.39 (1H, m), 3.89-3.86 (1H, m), 3.81 (3H, s), 3.51-3.45 (2H, m), 3.11-3.09 (1H, m), 3.00-2.85 (2H, m), 2.27-2.20 (1H, m), 2.09-2.06 (2H, m), 1.90-1.83 (1H, m), 1.57-1.47 (3H, m), 1.33-1.27 (1H, m), 0.84 (3H, t).

Example 77

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(4-methoxy-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

5

a) [3*aS*-[1(*E*),3 α ,6 α ,7 α β]]-1-[3-(4-Methoxy-3-methylphenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide

Prepared according to the method of Example 19, step (f) using (*E*)-3-(4-methoxy-3-methylphenyl)-2-propenoic acid.

10

MS (APCI) 390 ($M+H^+$, 100%)

b) [3*aS*-[1(1*S,2*S**),3*aa*,6*a*,7*ab*]]-1-[[2-(4-Methoxy-3-methylphenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

15

Prepared according to the method of Example 19, step (g) using the product of step (a).
MS (APCI) 404 ($M+H^+$, 100%)

c) (1*R-trans*)-2-(4-Methoxy-3-methylphenyl)-cyclopropane carboxylic acid

Prepared according to the method of Example 19, step (h) using the product of step (b).

20

NMR δ H (CDCl₃) 6.94-6.89 (2H, m), 6.74 (1H, d), 3.81 (3H, s), 2.57-2.51 (1H, m), 2.19 (3H, s), 1.85-1.79 (1H, m), 1.63-1.57 (1H, m), 1.38-1.32 (1H, m).

d) (1*R-trans*)-2-(4-Methoxy-3-methylphenyl)cyclopropanamine, [*R*-(*R,*R**)]-2,3-dihydroxybutanedioate (1:1)**

25

Prepared according to the method of Example 20, step (b) using the product of step (c).
NMR δ H (d₆-DMSO) 6.93-6.90 (2H, m), 6.83-6.80 (1H, m), 3.92 (2H, s), 3.74 (3H, s), 2.64-2.59 (1H, m), 2.13-2.07 (4H, m), 1.22-1.16 (1H, m), 1.08-1.01 (1H, m).

30

e) [3*aR*-[3 α ,4 α ,6 α (1*R,2*S**),6 α]-6-[7-[[2-[4-Methoxy-3-methylphenyl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step (a) using the product of step (d).

MS (APCI) 541 ($M+H^+$, 100%)

f) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(4-methoxy-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

Prepared according to the method of Example 1, step (b) using the product of step (e).

5 MS (APCI) 501 (M+H⁺,100%)

NMR δ H (d₆-DMSO) 9.27 (1H, d), 7.04-6.98 (2H, m), 6.83 (1H, d), 5.01-4.97 (2H, m), 4.73-4.71 (2H, m), 4.46-4.42 (1H, m), 3.88 (1H, q), 3.75 (3H, s), 3.51-3.45 (2H, m), 3.09-3.06 (1H, m), 3.02-2.99 (1H, m), 2.91-2.88 (1H, m), 2.27-2.24 (1H, m), 2.14 (3H, s), 2.13-2.03 (2H, m), 1.90-1.81 (1H, m), 1.59-1.53 (2H, m), 1.43-1.41 (1H, m), 1.25-1.22 (1H, m),
10 0.85 (3H, t).

Example 78

[1*R*-[1*a*,2*a*,3*b*(1*R,2*S**),5*b*]]-3-[7-[[2-(3,4-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**
15

a) [3*aS*-[1(*E*),3*a* α ,6 α ,7*a* β]]-1-[3-(3,4-Dichlorophenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide

Prepared according to the method of Example 19, step (f), using (*E*)-3-(3,4-dichlorophenyl)-2-propenoic acid.
20

m. p .198-200°C

MS (APCI) 414 (M+H⁺,100%)

b) [3*aS*-[1(1*S,2*S**),3*aa*,6*a*,7*ab*]]-1-[[2-(3,4-Dichlorophenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**
25

Prepared according to the method of Example 19, step (g) using the product of step (a).
m.pt. 162-163°C

MS (APCI) 429 (M+H⁺,100%)

30 **c) (1*R-trans*)-2-(3,4-Dichlorophenyl)-cyclopropane carboxylic acid**

Prepared according to the method of Example 19, step (h) using the product of step (b).

NMR δ H (CDCl₃) 7.40-7.30 (2H, m), 7.20 (1H, d), 6.96-6.93 (1H, dd), 2.57-2.51 (1H, m), 1.92-1.85 (1H, m), 1.71-1.65 (1H, m), 1.41-1.34 (1H, m).

35 **d) (1*R-trans*)-2-(3,4-Dichlorophenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)**

Prepared according to the method of Example 20, step (b) using the product of step (c).

NMR δ H (d_6 -DMSO) 7.53-7.51 (1H, d), 7.41-7.40 (1H, d), 7.14-7.11 (1H, dd) 3.77 (2H, s), 2.73-2.68 (1H, m), 2.16-2.10 (1H, m), 1.27-1.14 (2H, m).

5 **e) [3aR-[3a α ,4 α ,6 α (1*R**,2*S**),6a α]-6-[7-[[2-(3,4-Dichlorophenyl)cyclopropyl]amino]-tetrahydro-2,2-dimethyl-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step (a) using the product of step (d).

MS (APCI) 565 (M+H⁺, 100%)

10 NMR δ H (CDCl₃) 7.40-7.33 (2H, m), 7.20-7.01 (1H, m), 5.21-5.15 (2H, m), 4.73-4.70 (1H, m), 3.80-3.75 (2H, m), 3.20-3.00 (3H, m), 2.61-2.34 (4H, m), 2.21-2.09 (1H, m), 2.03-1.93 (1H, m), 1.75-1.61 (1H, m), 1.58 (3H, s), 1.45-1.35 (2H, m), 1.28 (3H, s), 1.05-0.82 (4H, m).

15 **f) [1*R*-[1a,2a,3b(1*R**,2*S**),5b]-3-[7-[[2-(3,4-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

Prepared according to the method of Example 1, step (b) using the product of step (e).

MS (APCI) 526 (M+H⁺, 100%)

20 NMR δ H (d_6 -DMSO) 9.38-9.36 (1H, d), 7.55-7.52 (2H, m), 7.22-7.19 (1H, dd), 5.01-4.70 (2H, m), 4.72-4.70 (2H, m), 4.42-4.40 (1H, m), 3.90-3.85 (1H, m), 3.50-3.40 (2H, m), 3.20-3.16 (1H, m), 3.02-2.70 (2H, m), 2.71-2.43 (1H, m), 2.14-2.09 (1H, m), 2.18-2.03 (1H, m), 1.90-1.81 (1H, m), 1.90-1.41 (4H, m), 0.80 (3H, t).

25 **Example 79**

1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]-3-[(2-Amino)ethoxy]-5-[7-(2-phenylcyclopropyl)amino]-5-propylthio-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol.**

30 To a solution of the product from Example 23 (0.50g) in tetrahydrofuran (20ml) was added diborane (10ml, 1M solution in THF). The reaction was refluxed for 1 hour, cooled and methanol (5ml) added. The solvent was evaporated and the residue dissolved in methanol (25ml)/conc. hydrochloric acid (0.50ml) then heated at reflux for 1 hour. The solvent was evaporated and the residue purified (HPLC, Nova-pak[®] C18 column, 0.1% aqueous trifluoroacetic acid:methanol 50:50) to give the title compound (198mg).

35 MS (APCI) 486 (M+H⁺, 100%)

NMR δ H (d_6 -DMSO) 9.37 (1H, d, $J=4.2$ Hz), 7.83 (3H, s), 7.29 (2H, m), 7.16 (3H, m), 4.96 (1H, q, $J=8.7$ Hz), 4.57-4.53 (1H, m), 4.00 (1H, m), 3.66 (2H, m), 3.21 (1H, m), 3.03 (2H, m), 3.01-3.92 (2H, m), 2.82 (1H, m), 2.10 (1H, m), 2.05 (1H, m), 1.55-1.44 (3H, m), 1.32 (1H, q, $J=7.8$ Hz), 0.80 (3H, t, $J=7.5$ Hz).

5

Example 80

[1*R*-(1 α ,2 α ,3 β (1*R,2*S**),5 β)]-3-[7-[[2-(3,4-Dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

10

a) 3-(3,4-Dimethylphenyl)-prop-2-enoic acid

Prepared according to the method of example 64, step (a), using 3,4-dimethylbenzaldehyde.

MS (APCI) 175 ($M-H^+$, 100%)

15

b) [3*aS*-[1(*E*),3 α ,6 α ,7 $\alpha\beta$]]-1-[3-(3,4-Dimethylphenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide

The subtitle compound was prepared according to the method of Example 19, step (f) using the product from step (a).

MS (APCI) 374 ($M+H^+$, 100%).

20

c) [3*aS*-[1(1*S**,2*S**),3 α ,6 α ,7 $\alpha\beta$]]-1-[[2-(3,4-Dimethylphenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide

The subtitle compound was prepared according to the method of Example 19, step (g) using the product of step (b).

25

MS (APCI) 388 ($M-H^+$, 100%)

d) (1*R-trans*)-2-(3,4-Dimethylphenyl)-cyclopropanecarboxylic acid

The subtitle compound was prepared according to the method of Example 19, step (h) using the product of step (c).

30

MS (APCI) 189 ($M-H^+$, 100%)

e) (1*R-trans*)-2-(3,4-Dimethylphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)

The subtitle compound was prepared according to the method of Example 20, step (b) using the product of step (d).

35

NMR δ H (d_6 -DMSO) 7.03-7.01 (1H, m), 6.88 (1H, s), 6.84-6.81 (1H, m), 3.92 (2H, s), 2.67-2.61 (1H, m), 2.18 (3H, s), 2.16 (3H, s), 2.13-2.06 (1H, m), 1.24-1.17 (1H, m), 1.10-1.03 (1H, m).

- 5 f) **[1*R*-(1 α ,2 α ,3 β (1*R**,2*S**),5 β)]-3-[7-[[2-(3,4-Dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

The title compound was prepared according to the method of Example 1, step (a), using the products of step (e), followed by the method of example 1 step (b).

- 10 MS (APCI) 485 (M+H⁺, 100%)

NMR δ H (d_6 -DMSO) 9.29-9.28 (1H, d), 7.04-7.01 (2H, m), 6.91-6.88 (1H, m), 5.01 (2H, m), 4.73-4.70 (2H, m), 4.43-4.41 (1H, m), 3.88-3.86 (1H, m), 3.51-3.45 (2H, m), 3.13-3.11 (1H, m), 2.98-2.85 (2H, m), 2.26-2.21 (1H, m), 2.20 (3H, s), 2.17 (3H, s), 2.08-2.04 (2H, m), 1.91-1.82 (1H, m), 1.53-1.42 (2H, m), 1.27-1.23 (1H, m), 0.85-0.80 (3H, s).

15

Example 81

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-4-[7-[[2-(3,4-Dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

- 20 a) **[3*aR*-[3 α ,4 α ,6 α (1*R**, 2*S**),6 α]]-6-[7-[2-[(3,4-Dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-ol**

The subtitle compound was prepared according to the method of example 1, step (a) using the product from example 24, step (d) and the product of example 80, step (e).

- 25 MS (APCI) 511 (M+H⁺, 100%)

b) **[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3,4-Dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

- 30 The title compound was prepared according to the method of example 1, step (b) using the product of step (a).

M.p. 175-176°C

MS (APCI) 471 (M+H⁺, 100%)

- 35 NMR δ H (d_6 -DMSO) 9.29 (1H, d), 7.03-6.87 (3H, m), 5.09(1H, d), 5.02 (1H,d), 4.95 (1H, d), 4.90 (1H, d), 4.68 (1H, m), 3.93 (1H, m), 3.77 (1H, m), 3.13 (1H,m) 3.01-2.81 (2H, m), 2.61 (1H, m), 2.19 (3H, s), 2.16 (3H, s), 2.06 (1H, m) 1.90 (1H, m), 1.52-1.42 (2H, m), 1.43 (1H, m), 1.26 (1H, m) 0.81 (3H, t).

Example 82

[1*R*-(1 α ,2 α ,3 β ,5 β)]-3-[7-(Cyclopropylamino)-5-[[4-(trifluoromethyl)phenyl]thio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

a) **[3*aR*-(3 α ,4 α ,6 α ,6 α)]-6-[7-(Cyclopropylamino)-5-(propylsulfonyl)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared by the method of example 4, step (a) using the product of Example 2, step (a).

MS (APCI) 453 ($M+H^+$, 100%)

b) **[3*aR*-(3 α ,4 α ,6 α ,6 α)]-6-[7-(Cyclopropylamino)-5-[[4-(trifluoromethyl)phenyl]thio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared by the method of example 4, step (b) using the product of step (a).

MS (APCI) 523 ($M+H^+$, 100%)

c) **[1*R*-(1 α ,2 α ,3 β ,5 β)]-3-[7-(Cyclopropylamino)-5-[[4-(trifluoromethyl)phenyl]thio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

Prepared by the method of example 1, step (b) using the product of step (b).

MS (APCI) 483 ($M+H^+$, 100%)

NMR δ H (d_6 -DMSO) 9.23 (1H, d), 7.90 (2H, d), 7.70 (2H, d), 4.95-4.90 (2H, m), 4.67-4.60 (2H, m), 4.32-4.30 (1H, m), 3.72-3.70 (1H, m), 3.32 (2H, m), 2.81-2.79 (1H, m), 2.22-2.16 (1H, m), 2.05-2.00 (1H, m), 1.80-1.60 (1H, m), 1.00-0.60 (2H, m).

Example 83

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-4-[7-[[2-(3,5-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

a) **[3*aS*-[1(*E*),3 α ,6 α ,7 α]]-1-[3-(3,5-Dichlorophenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

The subtitle compound was prepared according to the method of example 19, step (f) using 3-(3,5-dichlorophenyl)-2-propenoic acid.

MS (APCI) 414/416/418 ($M+H^+$), 153 (100%)

b) **[3aS-[1(1S*,2S*),3a α ,6 α ,7a β]]-1-[[2-(3,5-Dichlorophenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3H-3a,6-methano-2,1-benzisothiazole-2,2-dioxide**

The subtitle compound was prepared according to the method of example 19, step (g) using the product of step (a).

5 MS (APCI) 428/430/432 (M+H⁺), 364 (100%)

c) **(1R-trans)-2-(3,5-Dichlorophenyl)-cyclopropanecarboxylic acid**

The subtitle compound was prepared according to the method of example 19, step (h) using the product of step (b).

10 NMR δ H (CDCl₃) 1.26-1.42 (1H, m), 1.65-1.72 (1H, m), 1.89-1.95 (1H, m), 2.51-2.58 (1H, m), 6.99 (2H, d, J=1.8 Hz), 7.22 (1H, t, J=1.8 Hz)

d) **(1R-trans)-2-(3,5-Dichlorophenyl)cyclopropanamine, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1)**

15 The subtitle compound was prepared according to the method of example 20, step (b) using the product of step (c).

NMR δ H (d₆-DMSO) 1.19-1.29 (2H, m), 2.13-2.20 (1H, m), 2.71-2.81 (1H, m), 4.00 (2H, s), 7.22 (2H, d, J=1.8 Hz), 7.40 (1H, t, J=1.8 Hz)

20 e) **[1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]]-4-[7-[[2-(3,5-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

The title compound was prepared according to the method of example 24, step (f) using the products of step (d) and example 24, step (d).

MS (APCI) 511/513/515 (M+H⁺), 511 (100%)

25 NMR δ H (d₆-DMSO) 9.39 (1H, d, J=4.2 Hz), 7.40 (1H, t, J=1.8 Hz), 7.30 (2H, d, J=1.8 Hz), 5.11-4.91 (4H, m), 4.68-4.62 (1H, m), 3.93 (1H, br s), 3.78 (1H, br s), 3.20 (1H, br s), 2.99-2.78 (2H, m), 2.64-2.54 (1H, m), 2.17-2.10 (1H, m), 1.95-1.85 (1H, m), 1.62-1.45 (4H, m), 0.81 (3H, t, J=7.2 Hz),

30 **Example 84**

[1R-[1 α (1S*,2R*),2 β ,3 β ,4 α]]-N-[3-[2-[[3-(2,3,4-Trihydroxy-cyclopentyl)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-methanesulfonamide

35 a) **(1R-trans)-N-[2-(3-Nitrophenyl)cyclopropyl]-carbamic acid, 1,1-dimethylethyl ester**

A solution of the acid from example 27 step (a) (1.72g), diphenylphosphoryl azide (2.1ml) and triethylamine (1.4ml) in *tert*-butanol (15ml) and toluene (35ml) was heated at 85°C for 5 hours. Water was added and the mixture was extracted with ether. The organic layers were dried, evaporated and purified (SiO₂, petrol:ether 1:1 as eluent) to give the subtitle compound as a colourless solid (1.91g).

NMR δ H (CDCl₃) 8.03 (1H, d), 7.98-7.95 (1H, m), 7.55-7.50 (1H, m), 7.43 (1H, t), 4.83 (1H, s), 2.78-2.75 (1H, m), 2.21-2.12 (1H, m), 1.46 (9H, s), 1.29-1.23 (2H, m).

b) (1*R*-trans)-N-[2-(3-Aminophenyl)cyclopropyl]-carbamic acid, 1,1-dimethylethyl ester

A suspension of platinum on charcoal (5%, 374mg) and the product from step (a) (1.90g) in ethanol (40ml) was stirred under 1.1 atmospheres pressure of hydrogen for 4 hours. The mixture was filtered and purified (SiO₂, isohexane:ether, 1:3 as eluent) to give the subtitle compound (1.60g).

NMR δ H (CDCl₃) 7.04 (1H, t), 6.53-6.45 (3H, m), 4.81 (1H, s), 3.61 (2H, s), 2.72-2.70 (1H, m), 1.98-1.91 (1H, m), 1.46 (9H, s), 1.19-1.06 (2H, m).

c) (1*R*-trans)-N-[2-[3-[(Methylsulfonyl)amino]-phenyl]cyclopropyl]-carbamic acid, 1,1-dimethylethyl ester

A solution of the product from step (b) (592mg), methanesulfonyl chloride (0.225ml) and pyridine (0.35ml) in dichloromethane (5ml) was stirred for 3 hours. Water was added and the mixture extracted with dichloromethane. The organic layers were dried, evaporated and purified (SiO₂, isohexane:ether, 1:3 as eluent) to give the subtitle compound (724mg). MS (APCI) 325 (M-H⁺, 100%)

d) (1*S*-trans)-N-3-[(2-Aminocyclopropyl)phenyl]-methanesulfonamide, [*R*-(*R,*R**)]-2,3-dihydroxybutanedioate (1:1)**

A solution of the product from step (c) (722mg) in trifluoroacetic acid (3ml) was stirred for 3 hours. The solvent was removed *in vacuo* and the residue basified with sodium bicarbonate solution and extracted with ethyl acetate. The organic layers were dried and evaporated. The resulting amine was dissolved in ethanol (10ml) and a solution of L-tartaric acid (332g) in ethanol (20ml) was added. The solvent was removed *in vacuo* to give the subtitle compound (867mg).

NMR δ H (d₆-DMSO) 7.30-6.81 (4H, m), 4.05 (2H, s), 2.97 (3H, s), 2.74-2.70 (1H, m), 2.23-2.18 (1H, m), 1.34-1.27 (1H, m), 1.17-1.05 (1H, m).

e) **[3aS-[3a α ,4 α (1R*, 2S*),6 α ,6a α]-N-[3-[2-[[3-(2,2-Dimethyl-6-hydroxy-tetrahydro-4H-cyclopenta-1,3-dioxol-4-yl)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-7-yl]amino]cyclopropyl]-phenyl]-methanesulfonamide**

5 The subtitle compound was prepared according to the method of Example 1, step (a) using the products of step (b) and Example 24, step (d).

MS (APCI) 576 (M+H⁺, 100%),

f) **[1R-[1 α (1S*, 2R*),2 β ,3 β ,4 α]]-N-[3-[2-[[3-(2,3,4-Trihydroxy-cyclopentyl)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-methanesulfonamide**

Prepared according to the method of Example 1, step (b) using the product of step (e)
m.p. 170-2°C.

MS (APCI) 536 (M+H⁺, 100%),

15 NMR δ H (d₆-DMSO) 9.67 (1H, s), 9.34 (1H, d), 7.25 (1H, t), 7.06-6.98 (2H, m), 6.92 (1H, d), 5.11 (1H, d), 5.04-4.98 (1H, m), 4.94-4.91 (2H, m), 4.68-4.61 (1H, m), 3.95-3.90 (1H, m), 3.80-3.75 (1H, m), 3.24-3.20 (1H, m), 2.98 (3H, s), 2.97-2.85 (2H, m), 2.62-2.57 (1H, m), 2.18-2.06 (1H, m), 1.97-1.87 (1H, m), 1.54-1.22 (4H, m), 0.82 (3H, t).

20 Example 85

[1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]]-4-[7-[[2-(3,4-Dimethoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

a) **[3aS-[1(E),3a α ,6 α ,7a β]]-1-[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3H-3a,6-methano-2,1-benzisothiazole-2,2-dioxide**

25 The subtitle compound was prepared according to the method of example 19, step (f) using 3-(3,4-dimethoxyphenyl)-2-propenoic acid

MS (APCI) (M+H⁺), 153 (100%)

30 b) **[3aS-[1(1S*,2S*),3a α ,6 α ,7a β]]-1-[[2-(3,4-Dimethoxyphenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3H-3a,6-methano-2,1-benzisothiazole-2,2-dioxide**

The subtitle compound was prepared according to the method of example 19, step (g) using the product of step (a).

MS (APCI) 420 (M+H⁺, 100%)

35

c) **(1R-trans)-2-(3,4-Dimethoxyphenyl)-cyclopropanecarboxylic acid**

The subtitle compound was prepared according to the method of example 19, step (h) using the product of step (b).

NMR δ H (CDCl₃) 1.34-1.41 (1H, m), 1.60-1.66 (1H, m), 1.83-1.88 (1H, m), 2.54-2.61 (1H, m), 3.86 (3H, s), 3.88 (3H, s), 6.65-6.67 (2H, m), 6.79 (1H, d, $J=8.7$ Hz)

5

d) (1*R*-trans)-2-(3,4-Dimethoxyphenyl)cyclopropanamine, [*R*-(*R*^{*},*R*^{*})]-2,3-dihydroxybutanedioate (1:1)

The subtitle compound was prepared according to the method of example 20, step (b) using the product of step (c).

10 NMR δ H (d₆-DMSO) 1.03-1.22 (2H, m), 2.08-2.14 (1H, m), 2.63-2.68 (1H, m), 3.70 (3H, s), 3.74 (3H, s), 3.91 (2H, s), 6.23 (1H, dd, $J=8.1$ Hz, $J'=1.8$ Hz), 6.70 (1H, d, $J=1.8$ Hz), 6.84 (1H, d, $J=8.1$ Hz)

e) [1*S*-[1 α ,2 β ,3 β ,4 α (1*S*^{*},2*R*^{*})]-4-[7-[[2-(3,4-Dimethoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

15 The title compound was prepared according to the method of example 24, step (f) using the products of step (d) and example 24, step (d).

MS (APCI) 503 (M+H⁺, 100%)

20 NMR δ H (d₆-DMSO) 9.28 (1H, d, $J=4.5$ Hz), 6.86 (1H, d, $J=8.4$ Hz), 6.81 (1H, d, $J=2.1$ Hz), 6.70 (1H, dd, $J=8.4$ Hz, $J'=2.1$ Hz), 5.10-4.90 (4H, m), 4.68-4.64 (1H, m), 3.93 (1H, s), 3.76 (3H, s), 3.74 (1H, s), 3.71 (3H, s), 3.13-3.10 (1H, m), 3.05-2.82 (2H, m), 2.65-2.55 (1H, m), 2.10-2.00 (1H, m), 1.95-1.85 (1H, m), 1.56-1.27 (4H, m), 0.82 (3H, t, $J=7.2$ Hz).

Example 86

25 **[1*S*-[1 α ,2 β ,3 β ,4 α (1*S*^{*},2*R*^{*})]-4-[7-[[2-(4-Methoxy-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

30 **a) [3*aR*-[3 α ,4 α ,6 α (1*R*^{*},2*S*^{*}),6 α]]-Tetrahydro-6-[7-[2-[(4-methoxy-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-ol**

The subtitle compound was prepared according to the method of example 1, step (a) using the products from example 24, step (d) and example 77, step (d).

MS (APCI) 527 (M+H⁺, 100%)

b) **[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(4-Methoxy-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

The title compound was prepared according to the method of example 1, step (b) using the product of step (a).

M.p. 135-136°C

MS (APCI) 487 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.28 (1H, d), 7.01-6.80 (3H, m), 5.09(1H, d), 5.01 (1H,d), 4.98 (1H, d), 4.90 (1H, d), 4.66 (1H, m), 3.91 (1H, m), 3.76 (1H, m), 3.73 (3H, s), 3.06 (1H,m) 3.01-2.81 (2H, m), 2.58 (1H, m), 2.12 (3H, s), 2.02 (1H, m) 1.88 (1H, m), 1.56-1.49 (2H, m), 1.42 (1H, m), 1.23 (1H, m) 0.80 (3H, t).

Example 87

[1*R*-[1 α (1*S,2*R**),2 β ,3 β ,4 α]]-*N*-[3-[2-[[3-(2,3,4-Trihydroxy-cyclopentyl)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-acetamide**

a) **(1*R*-*trans*)-*N*-[2-(3-Acetamidophenyl)cyclopropyl]-carbamic acid, 1,1-dimethylethyl ester**

A solution of the product from Example 84, step (b) (582mg), acetic anhydride (0.27ml) and pyridine (0.35ml) in dichloromethane (5ml) was stirred for 18 hours. Water was added and the mixture was extracted with dichloromethane. The organic layers were dried, evaporated and purified (SiO₂, isohexane:acetone, 2:1 as eluent) to give the subtitle compound (703mg).

MS (APCI) 325 (M-H⁺, 100%)

b) **(1*S*-*trans*)-*N*-4-[(2-Aminocyclopropyl)phenyl]-acetamide, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)**

A solution of the product from step (a) (703mg) in trifluoroacetic acid (3ml) was stirred for 3 hours. The solvent was removed *in vacuo* and the residue basified with sodium bicarbonate solution then extracted with ethyl acetate. The organic layers were dried and evaporated. The amine was dissolved in ethanol (10 ml) and a solution of L-tartaric acid (349mg) in ethanol (25 ml) was added. The solvent was removed *in vacuo* to give the subtitle compound (828mg).

NMR δ H (d₆-DMSO) 7.45-7.05 (3H, m), 6.82 (1H, d), 4.19 (2H, s), 2.77-2.71 (1H, m), 2.30-2.23 (1H, m), 2.03 (3H, s), 1.39-1.31 (1H, m), 1.18-1.08 (1H, m).

c) [3aS-[3a α ,4 α (1*R**,2*S**),6 α ,6 α]-*N*-[3-[2-[[3-(2,2-Dimethyl-6-hydroxy-tetrahydro-4*H*-cyclopenta-1,3-dioxol-4-yl)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-acetamide

5 Prepared according to the method of Example 12, step (e) using the product of step (b).

d) [1*R*-[1 α (1*S**,2*R**),2 β ,3 β ,4 α]]-*N*-[3-[2-[[3-(2,3,4-Trihydroxy-cyclopentyl)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-acetamide

10 Prepared according to the method of Example 1, step (b) using the product of step (c).
m.p. 147-8°C.

MS (APCI) 500 (M+H⁺, 100%),

NMR δ H (d₆-DMSO) 9.87 (1H, s), 9.35 (1H, d), 7.41-7.34 (2H, m), 7.18 (1H, t), 6.84 (1H, d), 5.13-4.91 (4H, m), 4.66-4.61 (1H, m), 3.93-3.91 (1H, m), 3.82-3.75 (1H, m), 3.23-2.78
15 (4H, m), 2.62-2.51 (1H, m), 2.17-2.08 (1H, m), 2.02 (3H, s), 1.97-1.85 (1H, m), 1.72-1.61 (1H, m), 1.57-1.09 (3H, m), 0.80 (3H, t).

Example 88

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**))]-4-[7-[[2-(3,4-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

20

a) [3*aR*-[3a α ,4 α ,6 α (1*R**,2*S**),6 α]]-6-[7-[2-[(3,4-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-ol

25 The subtitle compound was prepared according to the method of Example 1, step (a) using the products of Example 24, step (d) and Example 78, step (d).

MS (APCI) 551 (M+H⁺, 100%)

b) 1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**))]-4-[7-[[2-(3,4-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

30

Prepared according to the method of Example 1, step (b) using the product of step (a).
m.p. 140-2°C.

MS (APCI) 511 (M+H⁺, 100%),

NMR δ H (d₆-DMSO) 9.4 (1H, d), 7.54-7.50 (2H, m), 7.18 (1H, dd), 5.13-4.91 (4H, m),
35 4.68-4.60 (1H, m), 3.94-3.90 (1H, m), 3.78-3.75 (1H, m), 3.18-3.02 (1H, m), 2.91-2.76

(2H, m), 2.62-2.51 (1H, m), 2.17-2.06 (1H, m), 1.94-1.84 (1H, m), 1.71-1.37 (3H, m), 0.79 (3H, t).

Example 89

- 5 **[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(4-Chloro-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

a) 3-(4-Chloro-3-methylphenyl)-2-propenoic acid.

- 10 The subtitle compound was prepared according to the method of Example 64, step (a) using (4-chloro-3-methyl)benzaldehyde (prepared according to WO 9603387).
MS (APCI) 191 (M-H⁺, 100%)

- b) **[3*aS*-[1(*E*),3 α ,6 α ,7 α β]]-1-[3-(4-Chloro-3-methylphenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

15 The subtitle compound was prepared according to the method of Example 19, step (f) using the product of step (a).
MS (APCI) 392 (M-H⁺, 100%)

- 20 c) **[3*aS*-[1(1*S**,2*S**),3 α ,6 α ,7 α β]]-1-[[2-(4-Chloro-3-methylphenyl)cyclopropyl]carbonyl]-hexahydro -8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

The subtitle compound was prepared according to the method of Example 19, step (g) using the product of step (b).

- 25 NMR δ H (CDCl₃) 7.22 (1H, d, *J*=8.1 Hz), 7.07 (1H, d, *J*=1.9 Hz), 6.96 (1H, dd, *J*=8.1, *J*=2.1 Hz), 3.92 (1H, dd, *J*=7.5, *J*=5.0 Hz), 3.51 (1H, d, *J*=13.8 Hz), 3.44 (1H, d, *J*=13.8 Hz), 2.33 (3H, s), 2.57-2.47 (2H, m), 2.20-2.02 (2H, m), 1.98-1.82 (3H, m), 1.79-1.73 (1H, m), 1.44-1.29 (3H, m), 1.20 (3H, s), 0.98 (3H, s).

- 30 d) **(1*R*-trans)-2-(4-Chloro-3-methylphenyl)cyclopropanecarboxylic acid**

The subtitle compound was prepared according to the method of Example 19, step (h) using the product of step (c).

- 35 NMR δ H (CDCl₃) 7.24 (1H, d, *J*=8.3 Hz), 6.97 (1H, d, *J*=1.5 Hz), 6.86 (1H, dd, *J*=8.1, *J*=1.9 Hz), 2.54 (1H, ddd, *J*=10.6, *J*=6.7, *J*=4.2 Hz), 2.34 (3H, s), 1.86 (1H, ddd, *J*=9.2,

$J=5.2, J=4.2$ Hz), 1.65 (1H, dt, $J=9.2, J=4.8$ Hz), 1.37 (1H, ddd, $J=11.3, J=6.7, J=4.8$ Hz).

5 e) **(1*R*-trans)-2-(4-Chloro-3-methylphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)**

The subtitle compound was prepared according to the method of Example 20, step (b) using the product of step (d).

MS (APCI) 182/184 ($M+H^+$), 182 (100%)

10 f) **[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**, 2*R**)]]-4-[7-[[2-(4-Chloro-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

15 The title compound was prepared according to the method of Example 24, step (f) using the products of step (e) and Example 24, step (d).

MS (APCI) 491/493 ($M+H^+$), 491 (100%)

NMR δ H (d_6 -DMSO) 9.35 (1H, d, $J=3.9$ Hz), 7.30 (1H, d, $J=8.1$ Hz), 7.22 (1H, d, $J=2.1$ Hz), 7.04 (1H, dd, $J=8.1, J=2.1$ Hz), 5.11 (1H, d, $J=4.2$ Hz), 5.02 (1H, d, $J=6.6$ Hz), 4.95 (1H, q, $J=8.7$ Hz), 4.92 (1H, d, $J=4.2$ Hz), 4.69-4.64 (1H, m), 3.97-3.90 (1H, m), 3.81-3.75 (1H, m), 3.20-2.79 (3H, m), 2.62-2.50 (1H, m), 2.31 (3H, s), 2.26-2.03 (1H, m), 1.97-1.83 (1H, m), 1.75-1.33 (4H, m), 0.80 (3H, t, $J=7.5$ Hz).

Example 90

25 **[1*S*-[1 α ,2 β ,3 β ,4 α (*trans*)]]-4-[7-[[2-(Phenylmethyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

a) **(*trans*)-2-(Phenylmethyl)-cyclopropanecarboxylic acid**

Prepared according to the method of Example 20, step (a) using 2-(phenylmethyl)cyclopropanecarboxylic acid, ethyl ester.

30 MS (APCI) 175 ($M-H^+$, 100%)

b) **(*trans*)-2-(3-Phenylmethyl)cyclopropanamine**

Prepared according to the method of Example 19, step (i) using the product from step (a).

35 NMR δ H ($CDCl_3$) 7.33-7.17 (5H, m), 2.55 (2H, d), 2.53-2.18 (1H, m), 1.03-0.96 (1H, m), 0.60-0.54 (1H, m), 0.45 (1H, m).

c)[1*S*-[1 α ,2 β ,3 β ,4 α (*trans*)]]-4-[7-[[2-(Phenylmethyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

Prepared according to the method of Example 24, step (f) using the product from step (b) and the product from Example 24, step (d).

5 NMR δ H (d_6 -DMSO) 9.10-9.08 (1H, m), 7.35-7.27 (4H, m), 7.21-7.17 (1H, m), 5.11-5.10 (1H, m), 5.03-5.01 (1H, m), 4.97-4.91 (2H, m), 4.69-4.64 (1H, m), 3.94 (1H, s), 3.79 (1H, s), 3.20-3.06 (3H, m), 2.78-2.76 (1H, m), 2.60-2.52 (2H, m), 1.97-1.92 (1H, m), 1.76-1.66 (2H, m), 1.37-1.32 (1H, m), 0.99 (3H, t), 0.78-0.76 (1H, m).

MS (APCI) 457 (M+H⁺, 100%)

10 **Example 91**

[1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(4-Chloro-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

15 a)[3*aR*-[3 α ,4 α ,6 α (1*R**,2*S**),6 α]-6-[7-[[2-(4-Chloro-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol

Prepared according to the method of Example 1, step (a) using the product of example 89, step (e).

20 MS (APCI) 545, 547 (M+H⁺), 545 (100%).

b) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(4-Chloro-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

25 Prepared according to the method of Example 1, step (b) using the product of step (a).

MS (APCI) 505, 507 (M+H⁺), 505 (100%).

NMR δ H (d_6 -DMSO) 9.33 (1H, d), 7.31-7.02 (3H, m), 5.00 (1H, q), 4.42 (1H, q), 3.89-3.86 (1H, m), 3.53-3.42 (2H, m), 3.16-3.12 (1H, m), 2.98-2.82 (2H, m), 2.31 (3H, s), 2.27-2.20 (1H, m), 2.10-2.06 (2H, m), 1.89-1.79 (1H, m), 1.54-1.45 (3H, m), 1.37-1.31 (1H, m), 0.82 (3H, t).

Example 92

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3-Dimethylaminophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol

35

a) **(1*R*-trans)-N-[2-(3-Dimethylaminophenyl)cyclopropyl]-carbamic acid, 1,1-dimethylethyl ester**

A mixture of the product of Example 84, step (b) (520mg), 37% aq. formaldehyde (0.47ml), acetic acid (0.1ml) and sodium triacetoxyborohydride (2.26g) in 1,2-dichloroethane (10ml) was stirred for 3.5 hours. Sodium bicarbonate solution was added and the mixture was extracted with dichloromethane. The organic layers were dried, evaporated and purified (SiO₂, petrol:ether, 1:1 as eluent) to give the subtitle compound (431mg).

NMR δ H (CDCl₃) 7.13 (1H, t), 6.56 (1H, dd), 6.49-6.46 (2H, m), 4.80 (1H, s), 3.92 (6H, s), 2.79-2.76 (1H, m), 2.02-1.96 (1H, m), 1.46 (9H, s), 1.21-1.09 (2H, m).

b) **(1*R*-trans)-2-(3-Dimethylamino)cyclopropanamine**

A solution of the product from step (a) (417mg) in trifluoroacetic acid (3ml) was stirred for 3 hours. The solvent was removed *in vacuo*, the residue basified with sodium bicarbonate solution and extracted with ethyl acetate. The organic layers were dried, evaporated and purified (SiO₂, dichloromethane:ethanol:ammonia, 150:8:1 as eluent) to give the subtitle compound (198mg).

NMR δ H (CDCl₃) 7.12 (1H, t), 6.55 (1H, dd), 6.46-6.44 (1H, m), 6.35 (1H, dd), 2.93 (6H, s), 2.60-2.52 (1H, m), 1.86-1.80 (1H, m), 1.72 (2H, s), 1.04-0.94 (2H, m).

c) **[3*aR*-[3*a* α ,4*a* α ,6*a* α (1*R**,2*S**),6*a* α]]-6-[7-[[2-(3-Dimethylaminophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentan-1,3-dioxol-4-ol**

Prepared according to the method of Example 24, step (f) using the product of step (b).

MS (APCI) 526 (M+H⁺, 100%)

d) **[1*S*-[1*a* α ,2*a* β ,3*a* β ,4*a* α (1*S**,2*R**)]]-4-[7-[[2-(3-Dimethylaminophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

Prepared according to the method of Example 1, step (b) using the product of step (c).
m.p. 187-8°C.

MS (APCI) 486 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.29-9.25 (1H, m), 7.07 (1H, dd), 6.55-6.52 (2H, m), 6.64 (1H, d), 5.10 (1H, d), 5.02-5.00 (1H, m), 4.96-4.92 (1H, m), 4.90 (1H, d), 4.68-4.62 (1H, m), 3.94-

3.91 (1H, m), 3.79-3.75 (1H, m), 3.25-2.92 (2H, m), 2.87 (6H, s), 2.62-2.53 (1H, m), 2.10-2.03 (1H, m), 1.96-1.88 (1H, m), 1.53-1.25 (4H, m), 0.82 (3H, t).

Example 93

5 **[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3-Fluoro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

a) **[3*aR*-[3 α ,4 α ,6 α (1*R**,2*S**),6 α]]-6-[7-[[2-(3-Fluoro-4-methoxyphenyl)-cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopentan-1,3-dioxol-4-ol**

The subtitle compound was prepared according to the method of Example 1, step (a) using the products of Example 24, step (d) and Example 76, step (d).

MS (APCI) 531 (M+H⁺, 100%)

15 b) **[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3-Fluoro-4-methoxyphenyl)-cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

Prepared according to the method of Example 1, step (b) using the product of step (a).

20 m.p. 156-7°C.

MS (APCI) 491 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.32 (1H, d), 7.10-6.94 (3H, m), 5.11 (1H, d), 5.03 (1H, d), 4.93 (1H, d), 4.90 (1H, d), 4.69-4.63 (1H, m), 3.96-3.90 (1H, m), 3.81 (3H, s), 3.79-3.75 (1H, m), 3.14-3.08 (1H, m), 3.01-2.82 (2H, m), 2.63-2.54 (1H, m), 2.10-2.03 (1H, m), 1.96-1.87 (1H, m), 1.57-1.45 (3H, m), 1.34-1.27 (1H, m), 0.83 (3H, t).

Example 94

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-4-[7-[[2-(3,5-Dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

30

a) **3-(3,5-Dimethylphenyl)-prop-2-enoic acid**

Prepared according to the method of Example 64, step (a), using 3,5-dimethylbenzaldehyde.

MS (APCI) 175 (M-H⁺, 100%)

35

b) **[3aS-[1(*E*),3a α ,6 α ,7a β]]-1-[3-(3,5-Dimethylphenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3a,6-methano-2,1-benzisothiazole-2,2-dioxide**

The subtitle compound was prepared according to the method of Example 19, step (f) using the product from step (a).

5 MS (APCI) 374 (M+H⁺ 100%).

c) **[3aS-[1(1*S**,2*S**),3a α ,6 α ,7a β]]-1-[[2-(3,5-Dimethylphenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3*H*-3a,6-methano-2,1-benzisothiazole-2,2-dioxide**

10 The subtitle compound was prepared according to the method of Example 19, step (g) using the product of step (b).

MS (APCI) 388 (M-H⁺, 100%)

d) **(1*R*-trans)-2-(3,5-Dimethylphenyl)-cyclopropanecarboxylic acid**

15 The subtitle compound was prepared according to the method of Example 19, step (h) using the product of step (c).

MS (APCI) 189 (M-H⁺, 100%)

e) **(1*R*-trans)-2-(3,5-Dimethylphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)**

20

The subtitle compound was prepared according to the method of Example 20, step (b) using the product of step (d).

25 NMR δ H (d₆-DMSO) 6.80 (1H, s), 6.70 (2H, s), 3.90 (2H, s), 2.66-2.61 (1H, m), 2.06-1.99 (1H, m), 1.20-1.13 (1H, m), 1.11-1.04 (1H, m).

f) **[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3,5-Dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

30 The title compound was prepared according to the method of Example 24, step (f) using the products of step (e) and Example 24, step (d).

MS (APCI) 471 (M+H⁺, 100%)

35 NMR δ H (d₆-DMSO) 9.31 (1H, d), 6.81 (3H, s), 5.12-5.11 (1H, m), 5.04-5.00 (1H, m), 4.94-4.91 (1H, m), 4.67-4.63 (1H, m), 3.95-3.92 (1H, m), 3.78-3.76 (1H, m), 3.21-3.14 (1H, m), 2.99-2.84 (2H, m), 2.60-2.57 (1H, m), 2.24 (6H, s), 2.05-2.03 (1H, m), 1.92-1.91 (1H, m), 1.56-1.45 (2H, m), 1.32-1.27 (2H, m), 0.83 (3H, t).

Example 95

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-4-[7-[[2-(3-Chloro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

5

a) 3-(3-Chloro-4-methoxyphenyl)-prop-2-enoic acid

Prepared according to the method of Example 64, step (a), using 3-chloro-4-methoxybenzaldehyde.

10 NMR δ H (d₆-DMSO) 7.83 (1H, d), 7.68-7.64 (1H, m), 7.55-7.49 (1H, m), 7.19-7.17 (1H, m), 6.50-6.46 (1H, d), 3.90 (3H, s).

b) [3*aS*-[1(*E*),3 α ,6 α ,7 α β]]-1-[3-(3-Chloro-4-methoxyphenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide

15 The subtitle compound was prepared according to the method of Example 19, step (f) using the product from step (a).

MS (APCI) 408 (M-H⁺ 100%).

c) [3*aS*-[1(1*S,2*S**),3 α ,6 α ,7 α β]]-1-[[2-(3-Chloro-4-methoxyphenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

20

The subtitle compound was prepared according to the method of Example 19, step (g) using the product of step (b).

MS (APCI) 424 (M+H⁺, 100%)

d) (1*R*-trans)-2-(3-Chloro-4-methoxyphenyl)-cyclopropanecarboxylic acid

25

The subtitle compound was prepared according to the method of Example 19, step (h) using the product of step (c).

NMR δ H (CDCl₃) 7.13 (1H, d), 7.02-6.99 (1H, m), 6.85 (1H, d), 3.88 (3H, s).

e) (1*R*-trans)-2-(3-Chloro-4-methoxyphenyl)cyclopropanamine, [*R*-(*R,*R**)]-2,3-dihydroxybutanedioate (1:1)**

30

The subtitle compound was prepared according to the method of Example 20, step (b) using the product of step (d).

35 NMR δ H (d₆-DMSO) 7.20-7.19 (1H, m), 7.09-7.05 (2H, m), 3.91 (2H, s), 2.66-2.61 (1H, m), 2.10-2.04 (1H, m), 1.19-1.05 (2H, m).

f) **[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3-Chloro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

The title compound was prepared according to the method of Example 24, step (f) using the products of step (e) and Example 24, step (d).

MS (APCI) 505 (M-H⁺, 100%)

NMR δ H (d₆-DMSO) 9.33 (1H, d), 7.32-7.31 (1H, m), 7.14-7.12 (1H, m), 7.07-7.05 (1H, m), 5.17-5.15 (1H, m), 5.05-5.04 (1H, m), 4.94-4.93 (2H, m), 4.66-4.64 (1H, m), 3.94-3.93 (1H, m), 3.83 (3H, s), 3.80 (3H, s), 3.29-3.27 (1H, m), 3.12-2.78 (2H, m), 2.63-2.53 (1H, m), 2.09-2.04 (1H, m), 1.95-1.88 (1H, m), 1.56-1.46 (2H, m), 1.36-1.29 (1H, m), 0.84-0.81 (3H, t).

Example 96

[1*R*-[1 α ,2 α ,3 β (1*R,2*S**),5 β]]-3-[7-[[2-(3-Chloro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

a) **[3*aR*-[3 α ,4 α ,6 α (1*R**,2*S**),6 α]-6-[7-[[2-(3-Chloro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared according to the method of Example 1, step (a) using the product of example 95, step (e).

MS (APCI) 561/563 (M+H⁺), 561 (100%).

b) **[1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Chloro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

Prepared according to the method of Example 1, step (b) using the product of step (a).

MS (APCI) 521/523 (M+H⁺), 521 (100%).

NMR δ H (d₆-DMSO) 9.31 (1H, d), 7.33-7.05 (3H, m), 5.00 (1H, q), 4.44-4.41 (1H, m), 3.90-3.86 (1H, m), 3.83 (3H, s), 3.54-3.43 (2H, m), 3.11-3.07 (1H, m), 3.03-2.84 (2H, m), 2.31-2.21 (1H, m), 2.07-2.00 (2H, m), 1.90-1.80 (1H, m), 1.58-1.48 (3H, m), 1.33-1.24 (1H, m), 0.84 (3H, t)

Example 97

[1*R*-[1 α (1*S,2*R**),2 β ,3 β ,4 α]]-*N*-[3-[[2-[3-[2,3-Dihydroxy-4-(hydroxymethyl)cyclopentyl]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-methanesulphonamide**

- 5 a) **[3*aS*-[3 α ,4 α (1*R**,2*S**),6 α ,6 α]-*N*-[3-[2-[3-[Tetrahydro-6-(hydroxymethyl)-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-yl]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-ylamino]cyclopropyl]phenyl]-methanesulphonamide**

The subtitle compound was prepared according to the method of Example 1, step (a) using the product of example 84, step (d).

10 MS (APCI) 590 (M+H⁺, 100%).

b) **[1*R*-[1 α (1*S**,2*R**),2 β ,3 β ,4 α]]-*N*-[3-[[2-[3-[2,3-Dihydroxy-4-(hydroxymethyl)cyclopentyl]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-methanesulphonamide**

- 15 The subtitle compound was prepared according to the method of Example 1, step (b) using the product of step (a).

MS (APCI) 550 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.62 (1H, s), 9.32 (1H, d), 7.25 (1H, t), 7.05-6.91 (3H, m), 5.01-4.95 (2H, m), 4.74-4.70 (2H, m), 4.43-4.40 (1H, m), 3.87 (1H, q), 3.49-3.43 (2H, m), 3.22-3.19 (1H, m), 2.98 (3H, s), 2.95-2.86 (2H, m), 2.27-2.23 (1H, m), 2.13-2.08 (2H, m), 1.90-1.80 (1H, m), 1.55-1.48 (3H, m), 1.29-1.26 (1H, m), 0.83 (3H, t).

20

Example 98

- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,5-Dimethoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**
- 25

Prepared according to the method of Example 1, step (a) using the product of example 64, step (e), followed by the method of Example 1, step (b).

30 MS (APCI) (M+H⁺), 517 (100%)

NMR δ H (d₆-DMSO) 9.31 (1H, d), 6.35-6.30 (3H, s), 4.98-4.96 (2H, m), 4.72-4.70 (2H, m), 4.45-4.40 (1H, m), 3.90-3.87 (1H, m), 3.73 (6H, m), 3.49-3.47 (2H, m), 3.22-3.18 (1H, m), 3.05-2.80 (2H, m), 2.30-2.20 (1H, s), 2.10-2.03 (2H, m), 1.92-1.81 (1H, m), 1.60-1.40 (2H, m), 1.40-1.30 (2H, m), 0.84 (3H, t).

35

Example 99

[1*S*-[1 α ,2 β ,3 β ,4 α (1*S,2*R**)]]-4-[7-[[2-(3-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

a) **[3*aS*-[1(*E*),3 α ,6 α ,7 α β]]-1-[3-(3-Fluorophenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

The subtitle compound was prepared according to the method of example 19, step (f) using 3-(3-fluorophenyl)-2-propenoic acid.

MS (APCI) ($M+H^+$), 364 (100%)

b) **[3*aS*-[1(1*S**,2*S**),3 α ,6 α ,7 α β]]-1-[[2-(3-Fluorophenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3*H*-3*a*,6-methano-2,1-benzisothiazole-2,2-dioxide**

The subtitle compound was prepared according to the method of example 19, step (g) using the product of step (a).

MS (APCI) 378 ($M+H^+$, 100%)

c) **(1*R-trans*)-2-(3-Fluorophenyl)-cyclopropanecarboxylic acid**

The subtitle compound was prepared according to the method of example 19, step (h) using the product of step (b).

NMR δ H (CDCl₃) 1.36-1.43 (1H, m), 1.65-1.71 (1H, m), 1.88-1.94 (1H, m), 2.56-2.63 (1H, m), 6.79 (1H, d, $J=9.9$ Hz), 6.88-6.94 (2H, m), 7.21-7.29 (1H, m).

d) **(1*R-trans*)-2-(3-Fluorophenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)**

The subtitle compound was prepared according to the method of example 20, step (b) using the product of step (c).

NMR δ H (d₆-DMSO) 1.12-1.28 (2H, m), 2.12-2.18 (1H, m), 2.69-2.74 (1H, m), 3.95 (2H, s), 6.92-7.02 (3H, m), 7.27-7.34 (1H, m)

e) **[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

The title compound was prepared according to the method of example 24, step (f) using the products of step (d) and example 24, step (d).

MS (APCI) 461 ($M+H^+$, 100%)

NMR δ H (d₆-DMSO) 9.37 (1H, d, $J=4.2$ Hz), 7.36-7.28 (1H, m), 7.06-6.96 (3H, m), 5.10-4.91 (4H, m), 4.69-4.63 (1H, m), 3.97-3.91 (1H, m), 3.79 (1H, s), 3.25-3.19 (1H, m), 2.99-

2.78 (2H, m), 2.65-2.55 (1H, m), 2.18-2.11 (1H, m), 1.96-1.87 (1H, m), 1.61-1.35 (4H, m), 0.81 (3H, t, $J=7.2$ Hz).

Example 100

5 **[1*R*-[1 α (1*S**,2*R**),2 β ,3 β ,4 α]]-*N*-[[3-[2-[3-(2,3-Dihydroxy-4-hydroxymethylcyclopentyl)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-acetamide**

Prepared according to the method of Example 1, step (a) using the products of example 87, step (b), followed by the method of Example 1, step (b).

MS (APCI) 528 ($M+H^+$, 100%).

NMR δ H (d_6 -DMSO) 9.86 (1H, s), 9.32 (1H, d), 7.41-7.36 (2H, m), 7.22-7.16 (1H, m), 6.87-6.85 (1H, m), 5.01-4.95 (2H, m), 4.71-4.45 (2H, m), 4.43-4.39 (1H, m), 3.88-3.85 (1H, m), 3.51-3.45 (2H, m), 3.21-3.18 (1H, m), 2.97-2.83 (2H, m), 2.27-2.05 (3H, m), 2.05 (3H, t), 1.89-1.79 (1H, m), 1.55-1.50 (3H, m), 1.48-1.26 (1H, m), 0.83 (3H, t).

Example 101

20 **[1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,5-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

a) **[3*aR*-[3 α ,4 α ,6 α (1*R**,2*S**),6 α]-6-[7-[[2-(3,5-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol**

25 Prepared according to the method of Example 1, step (a) using the product of example 83, step (d).

MS (APCI) 565 ($M+H^+$, 100%).

30 **b) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,5-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol**

Prepared according to the method of Example 1, step (b) using the product of step (a).

Purification (HPLC, Symmetry® C18 column, 0.1% aqueous ammonium

acetate:acetonitrile, isocratic elution 50% MeCN over 30 minutes) afforded the title

35 compound (98mg).

NMR δ H (d_6 -DMSO) 9.39 (1H, d), 7.40 (1H, s), 7.31 (2H, d) 7.23 (1H, s), 5.04-4.97 (2H, m), 4.74-4.70 (2H, m), 4.39 (1H, m), 3.89-3.85 (1H, m), 3.51-3.45 (2H, m), 3.19-3.10 (1H, m), 2.93-2.80 (2H, m), 2.30-2.20 (1H, m), 2.10-2.06 (2H, m), 1.89-1.79 (1H, m), 1.67-1.49 (1H, m), 1.58 (1H, m), 0.84 (3H, t).

5

Example 102

Modifications to the 7- position of [1*S*-(1 α ,2 α ,3 β ,5 β)]-3-(2-Hydroxyethyl)-5-[5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

- 10 a) **[3a*R*-(3 α ,4 α ,6 α ,6 α)]-6-[7-Amino-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-carboxylic acid**

A solution of the product of example 6, step (b) (1.40g) and ammonia in 1,4-dioxane (0.5M, 60 ml) was stirred at 50°C for 3 hours. The reaction mixture was evaporated to dryness, the residue triturated with water and the subtitle compound isolated by filtration (1.20g).

15

MS (APCI) 395 (M+H⁺, 100%).

- b) **[3a*R*-(3 α ,4 α ,6 α ,6 α)] -6-[7-Amino-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-acetic acid, methyl ester**

20

Isobutylchloroformate (0.33 ml) was added to an ice-cooled solution of the product of step a) (0.50g) and *N*-methylmorpholine (0.26 ml) in tetrahydrofuran (10 ml). The solution was stirred at room temperature for 60 minutes then added to a solution of diazomethane (1.0g) in ether (100ml). The solution was stirred for 60 minutes then concentrated. The crude diazoketone (0.50 g) was taken into methanol (20 ml) and silver (I) oxide (250 mg) added portionwise at 60°C. The mixture was heated for 3 hours, diluted with chloroform (100 ml) then shaken vigorously with 0.88 aqueous ammonia (50 ml) and water (50 ml) for 20 mins. The mixture was extracted into chloroform and the extracts washed with water then dried and concentrated. Purification (SiO₂, ether:isohexane 2:1 as eluant) afforded the subtitle compound (0.50g).

25

30

MS (APCI) 423 (M+H⁺, 100%).

- c) **[3a*R*-(3 α ,4 α ,6 α ,6 α)]-6-[7-Bromo-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-ethanol**

35

DIBAL-H[®] (1.5 M solution in toluene, 5 ml) was added to an ice-cooled solution of the product of step b) (0.20 g) in toluene (10 ml) and the solution stirred at this temperature for 30 minutes before adding water (2 ml). The product was extracted into ether, the solution filtered through a pad of celite, dried and concentrated (175 mg). The resultant foam (175 mg) was taken into bromoform (5 ml)/ isoamyl nitrite (1 ml) then heated at 85°C for 40 minutes. The solution was concentrated and purified (SiO₂, ether:isohexane 2:1 as eluant) to afford the subtitle compound (0.15g).
MS (APCI) 400 (M+H⁺-57, 100%).

- 10 **d) Modifications to the 7-position of [1*S*-(1 α ,2 α ,3 β ,5 β)]-3-(2-Hydroxyethyl)-5-[5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**
The product of step c) (2.5x10⁻⁶ mol) in 1,4-dioxane (90 μ l) and *N,N*-diisopropylethylamine (1.0x10⁻⁵ mol) in 1,4-dioxane (100 μ l) were added to each of the amine salts listed below (5.0x10⁻⁶ mol). The reaction mixtures were heated at 60°C for 4 hours before adding
15 phthalate buffer (pH4, 400 μ l) and extracting with ethyl acetate (4 x 200 μ l). The extracts were concentrated and the residues taken into 80% acetic acid (150 μ l), then heated at 80°C for 30 minutes, The reaction mixtures were concentrated then azeotroped with ethanol (2 x 200 μ l) to afford the title compounds.

- 20 The following amines were used (Preparations described previously in the experimental):

- (1*S-trans*)-*N*-3-[(2-Aminocyclopropyl)phenyl]-methanesulfonamide, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
(1*R, trans*)-2-(4-phenoxyphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-
25 dihydroxybutanedioate (1:1)
(1*R, trans*)-2-(2-phenoxyphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
(1*R, trans*)-2-(3-phenoxyphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
30 (1*R, trans*)-2-(4-bromophenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
(1*R-trans*)-2-[(1,1'-biphenyl)-2-yl]cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
(1*R-trans*)-2-[(1,1'-biphenyl)-3-yl]cyclopropanamine, [*R*-(*R**,*R**)]-2,3-
35 dihydroxybutanedioate (1:1)

- (1*R*, *trans*)-2-(3,5-dichlorophenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
- (1*R*, *trans*)-2-(3,4-dichlorophenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
- 5 (1*R*, *trans*)-2-(3-chloro-4-methoxyphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
- (1*R*, *trans*)-2-(3,4-dimethoxyphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
- (1*S*-*trans*)-*N*-4-[(2-Aminocyclopropyl)phenyl]-acetamide, [*R*-(*R**,*R**)]-2,3-
- 10 dihydroxybutanedioate (1:1)
- (1*R*, *trans*)-2-(3-chloro-4-methylphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
- (1*R*, *trans*)-2-(4-chloro-3-methylphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
- 15 (1*R*, *trans*)-2-(4-fluoro-3-methylphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
- (1*R*, *trans*)-2-(3-nitrophenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
- (1*R*, *trans*)-2-(4-methoxy-3-methylphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-
- 20 dihydroxybutanedioate (1:1)
- (1*R*, *trans*)-2-(3-methoxy-4-methylphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
- (1*R*, *trans*)-2-(4-*N,N*-dimethylphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
- 25 (1*R*, *trans*)-2-(3,4-difluorophenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
- (1*R*, *trans*)-2-(3,5-difluorophenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
- (1*R*, *trans*)-2-(3-chlorophenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate
- 30 (1:1)
- (1*R*, *trans*)-2-(4-chlorophenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
- (1*R*, *trans*)-2-(4-methoxyphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)
- 35 (1*R*, *trans*)-2-(2-methoxyphenyl)cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1)

(1*R*, *trans*)-2-(3-methoxyphenyl)cyclopropanamine, [*R*-(*R*^{*},*R*^{*})]-2,3-dihydroxybutanedioate (1:1)

(1*R*, *trans*)-2-(3,5-dimethylphenyl)cyclopropanamine, [*R*-(*R*^{*},*R*^{*})]-2,3-dihydroxybutanedioate (1:1)

5 (1*R*, *trans*)-2-(4-fluorophenyl)cyclopropanamine, [*R*-(*R*^{*},*R*^{*})]-2,3-dihydroxybutanedioate (1:1)

(1*R*, *trans*)-2-(3-fluorophenyl)cyclopropanamine, [*R*-(*R*^{*},*R*^{*})]-2,3-dihydroxybutanedioate (1:1)

10 (1*R*, *trans*)-2-(2-methylphenyl)cyclopropanamine, [*R*-(*R*^{*},*R*^{*})]-2,3-dihydroxybutanedioate (1:1)

(1*R*, *trans*)-2-(3-methylphenyl)cyclopropanamine, [*R*-(*R*^{*},*R*^{*})]-2,3-dihydroxybutanedioate (1:1)

(1*R*, *trans*)-2-(4-methylphenyl)cyclopropanamine, [*R*-(*R*^{*},*R*^{*})]-2,3-dihydroxybutanedioate (1:1)

15

The following products were obtained:

a) [1*R*-[1 α (1*S*^{*},2*R*^{*}),2 β ,3 β ,4 α]]-*N*-[3-[2-[[3-[2,3-Dihydroxy-4-(2-hydroxyethyl)-cyclopentyl]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-methanesulfonamide

20 MS (APCI) 564 (M+H⁺, 100%)

b) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S*^{*},2*R*^{*})]-3-(2-Hydroxyethyl)-5-[7-[[2-(4-phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

25 MS (APCI) 563 (M+H⁺, 100%)

c) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S*^{*},2*R*^{*})]-3-(2-Hydroxyethyl)-5-[7-[[2-(3-phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

30 MS (APCI) 563 (M+H⁺, 100%)

d) [1*R*-[1 α ,2 α ,3 β (1*R*^{*},2*S*^{*}),5 β]]-3-[7-[[2-(4-Bromophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol

35 MS (APCI) 551, 549 (M+H⁺, 100%)

e) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-[(1,1'-Biphenyl)-2-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol

MS (APCI) 547 (M+H⁺, 100%)

f) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-[(1,1'-Biphenyl)-3-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol

MS (APCI) 547 (M+H⁺, 100%)

g) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,5-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol

MS (APCI) 539, 541, 543 (M+H⁺, 100%)

h) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,4-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol

MS (APCI) 539, 541, 543 (M+H⁺, 100%)

i) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Chloro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol

MS (APCI) 537, 535 (M+H⁺, 100%)

j) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,4-Dimethoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol

MS (APCI) 531 (M+H⁺, 100%)

k) [1*R*-[1 α (1*S**,2*R**),2 β ,3 β ,4 α]]-*N*-[3-[2-[[3-[2,3-Dihydroxy-4-(2-hydroxyethyl)-cyclopentyl]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-acetamide

MS (APCI) 528 (M+H⁺, 100%)

l) [1R-[1 α ,2 α ,3 β (1*R,2*S**),5 β]]-3-[7-[[2-(3-Chloro-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol**
MS (APCI) 521, 519 (M+H⁺, 100%)

m) [1R-[1 α ,2 α ,3 β (1*R,2*S**),5 β]]-3-[7-[[2-(4-Chloro-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol**
MS (APCI) 521, 519 (M+H⁺, 100%)

n) [1R-[1 α ,2 α ,3 β (1*R,2*S**),5 β]]-3-[7-[[2-(4-Fluoro-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol**
MS (APCI) 519 (M+H⁺, 100%)

o) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(3-nitrophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**
MS (APCI) 516 (M+H⁺, 100%)

p) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(4-methoxy-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**
MS (APCI) 515 (M+H⁺, 100%)

q) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(3-methoxy-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**
MS (APCI) 515 (M+H⁺, 100%)

r) [1R-[1 α ,2 α ,3 β (1*R,2*S**),5 β]]-3-[7-[[2-(4-*N,N*-Dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol**
MS (APCI) 514 (M+H⁺, 100%)

s) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol

MS (APCI) 507 (M+H⁺, 100%)

5

t) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,5-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol

MS (APCI) 507 (M+H⁺, 100%)

10

u) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol

MS (APCI) 507, 505 (M+H⁺, 100%)

15

v)[1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

MS (APCI) 507, 505 (M+H⁺, 100%)

20

w)[1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(2-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

MS (APCI) 501 (M+H⁺, 100%)

25

x)[1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

MS (APCI) 501 (M+H⁺, 100%)

30

y)[1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(3-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

MS (APCI) 501 (M+H⁺, 100%)

35

z) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,5-Dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol

MS (APCI) 499 (M+H⁺, 100%)

5

aa) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol

MS (APCI) 489 (M+H⁺, 100%)

10

bb) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol

MS (APCI) 489 (M+H⁺, 100%)

15

cc)[1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(2-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

MS (APCI) 485 (M+H⁺, 100%)

20

dd)[1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

MS (APCI) 485 (M+H⁺, 100%)

25

ee)[1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

MS (APCI) 485 (M+H⁺, 100%)

30

ff) [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-(cyclopropylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

MS (APCI) 461 (M+H⁺, 100%)

35 **Example 103**

[1S-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxy-2-methylpropoxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

- 5 a) [3*aR*-[3 α ,4 α ,6 α (1*R**,2*S**),6 α]]-2-[6-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methoxy]acetic acid, ethyl ester

A solution of [3*aR*-[3 α ,4 α ,6 α (1*S**,2*R**),6 α]]-6-[7-chloro-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol (0.7g) and rhodium acetate (0.39g) in dichloromethane (20ml) was treated with a solution of ethyl diazoacetate (0.21ml) in dichloromethane (10ml) over 3 hours. The reaction mixture was stirred at room temperature for 60 hours, concentrated and purified (SiO₂, isohexane:ethyl acetate 3:1 as eluant). The resulting intermediate was taken into THF (10ml), (1*R-trans*)-2-phenyl-cyclopropanamine, [*R*-(*R**,*R**)]-2,3-dihydroxybutanedioate (1:1) (0.2g) and *N,N*-diisopropylethylamine (0.2ml) was added and the solution stirred for 18 hours then concentrated. Purification (SiO₂, ether:isohexane 2:1 as eluant) gave the subtitle compound (0.23g).
MS (APCI) 583 (M+H⁺), 545 (100%).

- 20 b) [1S-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxy-2-methylpropoxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

Prepared according to the method of example 10, using the product of step a). Purification (HPLC, Symmetry[®] C18 column, 0.1% aqueous ammonium acetate:acetonitrile, isocratic elution 30% MeCN over 30 minutes) afforded the title compound (115mg).
NMR δ H (d₆-DMSO) 9.32 (1H, d), 7.31-7.15 (5H, m), 5.00-4.98 (2H, m) 4.78 (1H, d), 4.46-4.44 (1H, m), 4.29 (1H, s), 3.89-3.86 (1H, m), 3.51-3.48 (2H, m), 3.18-3.17 (3H, m), 2.96-2.84 (2H, m), 2.27-2.26 (1H, m), 2.21-2.13 (1H, m), 2.13-2.11 (1H, m), 1.88-1.86 (1H, m), 1.50-1.48 (3H, m), 1.32-1.31 (1H, m), 1.09 (6H, s), 0.81 (3H, t).

Example 104

[1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Chloro-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

a) **3-(3-Chloro-4-methylphenyl)-2-propenoic acid.**

The subtitle compound was prepared according to the method of Example 64, step (a) using (3-chloro-4-methyl)benzaldehyde (prepared according to the method of S.O. Nwaukwa et al, Tetrahedron Lett., 1982, 23, 3131).

5 MS (APCI) 191 (M-H⁺, 100%)

b) **[3aS-[1(E),3α,6α,7aβ]]-1-[3-(3-Chloro-4-methylphenyl)-1-oxo-2-propenyl]-hexahydro-8,8-dimethyl-3H-3a,6-methano-2,1-benzisothiazole-2,2-dioxide**

10 The subtitle compound was prepared according to the method of Example 19, step (f) using the product of step (a).

MS (APCI) 394/392 (M-H⁺) 392 (100%)

c) **[3aS-[1(1S*,2S*),3α,6α,7aβ]]-1-[[2-(3-Chloro-4-methylphenyl)cyclopropyl]carbonyl]-hexahydro-8,8-dimethyl-3H-3a,6-methano-2,1-benzisothiazole-2,2-dioxide**

15 The subtitle compound was prepared according to the method of Example 19, step (g) using the product of step (b).

m.p. 154-156°C

20 d) **(1R-trans)-2-(3-Chloro-4-methylphenyl)cyclopropanecarboxylic acid**

The subtitle compound was prepared according to the method of Example 19, step (h) using the product of step (c).

MS (APCI) 209 (M-H⁺, 100%).

25 e) **(1R-trans)-2-(3-Chloro-4-methylphenyl)cyclopropanamine, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1)**

The subtitle compound was prepared according to the method of Example 20, step (b) using the product of step (d).

30 MS (APCI) 182 (M+H⁺, 100%).

f) **[3aR-[3α,4α,6α(1R*,2S*),6α]-6-[7-[[2-(3-Chloro-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-methanol**

35 The subtitle compound was prepared according to the method of example 1, step a), using the product of step (e).

MS (APCI) 547, 545 (M+H⁺), 545 (100%).

g) [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Chloro-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

The title compound was prepared according to the method of example 57, step b), using the product of step (f).

MS (APCI) 507, 505 (M+H⁺), 505 (100%).

NMR δ H (d₆-DMSO) 9.32 (1H, d), 7.29-7.21 (2H, m), 7.08-7.01 (1H, m), 5.04-4.95 (2H, m), 4.74-4.71 (2H, m), 4.46-4.39 (1H, m), 3.90-3.86 (1H, m), 3.55-3.43 (2H, m), 3.17-3.09 (1H, m), 3.00-2.80 (2H, m), 2.29 (3H, s), 2.26-2.20 (1H, m), 2.12-2.05 (2H, m), 1.89-1.79 (1H, m), 1.57-1.45 (3H, m), 1.39-1.32 (1H, m), 0.84 (3H, t).

Example 105

15 [1*R*-[1 α (1*S**,2*R**),2 β ,3 β ,4 α]]-4-[2-[[3-(2,3,4-Trihydroxycyclopentyl)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenylsulfonamide

a) (1*S*-*trans*)-4-(2-Aminocyclopropyl)phenylsulfonamide, hydrochloride

The title compound was prepared from (1*R*-*trans*)-phenylcyclopropanamine according to the method described in US 3,487,154.

m.p. 211-2°C

NMR δ H (d₆-DMSO) 8.71 (3H, s), 7.72 (2H, d), 7.35 (2H, d), 7.33 (2H, s), 2.94-2.82 (1H, m), 2.47-2.42 (1H, m), 1.55-1.47 (1H, m), 1.28 (1H, q).

25 b) [3*aS*-[3 α ,4 α ,6 α (1*R**,2*S**),6 α]]-4-[2-[[3-(2,2-Dimethyl-6-hydroxy-tetrahydro-4*H*-cyclopenta-1,3-dioxol-4-yl)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenylsulfonamide

Prepared according to the method of Example 24, step (f) using the product of step (a) and the product of Example 24, step (d).

MS (APCI) 562 (M+H⁺, 100%)

35 c) [1*R*-[1 α (1*S**,2*R**),2 β ,3 β ,4 α]]-4-[2-[[3-(2,3,4-Trihydroxycyclopentyl)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenylsulfonamide

Prepared according to the method of Example 1, step (b) using the product of step (b).

m.p. 200-1°C.

MS (APCI) 522 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.40 (1H, d), 7.78 (2H, d), 7.52 (2H, d), 5.76 (2H, s), 5.18-4.88 (4H, m), 4.71-4.60 (1H, m), 3.98-3.87 (1H, m), 3.81-3.75 (1H, m), 3.29-3.22 (1H, m), 2.97-2.79 (2H, m), 2.65-2.51 (1H, m), 2.25-2.18 (1H, m), 1.96-1.85 (1H, m), 1.75-1.40 (3H, m), 0.81 (3H, t).

Example 106

[1R-[1 α ,2 α ,3 β (1R*,2S*),5 β]]-3-[5-(Butylthio)-7-[(2-phenylcyclopropyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

a)[1S-[1 α ,2 α ,3 β ,5 β (1S*,2R*)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylsulphonyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2-diol

Prepared according to the method of Example 4, step (a) using the product of Example 1, step (b).

MS (APCI) 489 (M+H⁺, 100%)

b)[1R-[1 α ,2 α ,3 β (1R*,2S*),5 β]]-3-[5-(Butylthio)-7-[(2-phenylcyclopropyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol

Prepared according to the method of Example 4, step (b) using the product of step (a) and butanethiol.

MS (APCI) 471 (M+H⁺, 100%)

NMR δ H (d₆-DMSO) 9.32 (1H, d), 7.33-7.15 (5H, m), 5.01-4.96 (2H, m), 4.73-4.69 (2H, m), 4.45-4.42 (1H, m), 3.87 (1H, q), 3.49-3.44 (2H, m), 3.22-3.19 (1H, m), 3.00-2.85 (2H, m), 2.30-2.20 (1H, m), 2.17-2.08 (2H, m), 1.90-1.80 (1H, m), 1.53-1.44 (3H, m), 1.33-1.20 (3H, m), 0.81 (3H, t).

Example 107

[1S-[1 α ,2 α ,3 β ,5 β (1S*,2R*)]]-3-(Hydroxymethyl)-5-[5-(pentylthio)-7-[(2-phenylcyclopropyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2-diol

Prepared according to the method of Example 4, step (b) using the product of example 107, step (a) and pentanethiol.

MS (APCI) 485 (M+H⁺, 100%)

NMR δ H (d_6 -DMSO) 9.33 (1H, d), 7.31-7.16 (5H, m), 5.03-4.97 (2H, m), 4.72-4.70 (2H, m), 4.45-4.40 (1H, m), 3.88-3.86 (1H, m), 3.49-3.45 (2H, m), 3.21-3.19 (1H, m), 3.00-2.94 (1H, m), 2.89-2.82 (1H, m), 2.33-2.22 (1H, m), 2.14-2.09 (2H, m), 1.87-1.79 (1H, m), 1.53-1.31 (5H, m), 1.21-1.19 (3H, m), 0.81 (3H, t).

5

Example 108

[1S-[1 α ,2 α ,3 β ,5 β (1S*,2R*)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(prop-2-ynylthio)-3H-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol

10 **a)[1S-[1 α ,2 α ,3 β ,5 β (1S*,2R*)]]-3-(Hydroxymethyl)-5-[5-(mercapto)-7-[(2-phenylcyclopropyl)amino]-3H-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

A solution of the product of Example 107, step (a) (0.4g) in DMSO (10ml) was treated with sodium hydrosulphide hydrate (0.4g) and the mixture was stirred at room temperature for 2 hours. The mixture was poured into aqueous brine (150ml) containing acetic acid (2ml) and extracted with ethyl acetate (3 x 100ml). The combined organic extracts were dried and concentrated to afford the subtitle compound (0.3g).

15

MS (APCI) 415 (M+H⁺, 100%)

20 **b)[1S-[1 α ,2 α ,3 β ,5 β (1S*,2R*)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(prop-2-ynylthio)-3H-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

A solution of the product of step (a) (168mg) in DMF (5ml) was treated with *N,N*-diisopropylethylamine (58mg) followed by propargyl bromide (58mg). The mixture was heated at 60°C for 1 hour and then poured into aqueous brine (100ml) and extracted with ethyl acetate (100ml). The organic layer was washed with further aqueous brine (3 x 100ml), dried and concentrated and the residue purified (SiO₂, chloroform:methanol 95:5 as eluant) to afford the title compound (40mg).

25

30 MS (APCI) 453 (M+H⁺, 100%)

NMR δ H (d_6 -DMSO) 9.44 (1H, d), 7.31-7.16 (5H, m), 5.00-4.95 (2H, m), 4.71-4.70 (2H, m), 4.44 (1H, q), 3.94-3.71 (3H, m), 3.54-3.44 (2H, m), 3.23-3.18 (1H, m), 3.05-3.01 (1H, m), 2.30-2.27 (1H, m), 2.20-2.09 (2H, m), 1.93-1.85 (1H, m), 1.52-1.47 (1H, m), 1.37-1.30 (1H, m).

35

Example 109

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(3,5-dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

- 5 a) **[3*aR*-[3 α ,4 α ,6 α (1*R**,2*S**),6 α]-Tetrahydro-2,2-dimethyl-6-[7-[[2-(3,5-dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-4*H*-cyclopenta-1,3-dioxole-4-methanol**

Prepared by the method of Example 1, step (a), using the product of Example 94, step (e).
MS (APCI) 525 (M+H⁺, 100%).

10

- b) **[1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(3,5-dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

Prepared by the method of Example 57, step (b), using the product of step (a).

15

MS (APCI) 485 (M+H⁺, 100%).

NMR δ H (d₆-DMSO) 9.29 (1H, d), 6.85-6.73 (3H, m), 5.06-4.94 (2H, m), 4.75-4.68 (2H, m), 4.48-4.39 (1H, m), 3.91-3.85 (1H, m), 3.56-3.41 (2H, m), 3.19-3.11 (1H, m), 3.05-2.82 (2H, m), 2.32-2.16 (7H, m), 2.13-2.00 (2H, m), 1.92-1.78 (1H, m), 1.61-1.41 (3H, m), 1.37-1.22 (1H, m), 0.90-0.80 (3H, t).

20

Example 110

[1*S*-[1 α ,2 α ,3 β ,5 β (1*S,2*R**)]]-3-(2-Hydroxyethyl)-5-[5-(methylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

25

- a) **[3*aR*-[3 α ,4 α ,6 α (1*R**,2*S**),6 α]-6-[7- [(2-Phenylcyclopropyl)amino]-5-(propylsulfonyl)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-ethanol**

30

DIBAL-H[®] (1.5 M solution in toluene, 20 ml) was added to an ice-cooled solution of the product of Example 11, step a) (2.00 g) in toluene (30 ml) and the solution stirred at this temperature for 30 minutes before adding ethyl acetate (2 ml). The solution was washed with water and concentrated. The residue (1.8 g) was taken into ethanol and cooled to 4°C before adding 3-chloroperoxybenzoic acid (50-55%, 2.5g) and allowing the reaction to stir at room temperature for 18 hours. The solution was washed with aqueous sodium metabisulfite solution (3 x 10ml) then dried and concentrated. Purification (SiO₂, ether:isohexane, 80:20, as eluent) afforded the subtitle compound (1.8g).

35

MS (APCI) 543 (M+H⁺, 100%)

b)[1*S*-(1 α ,2 α ,3 β ,5 β (1*S,2*R**)]-3-(2-Hydroxyethyl)-5-[5-(methylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

Prepared by the method of Example 4, step b), using the product of step a) and commercially available sodium methanethiolate then deprotected using the method of Example 1, step (b). Purification (HPLC, Novapak[®] C18 column, 0.1% aqueous ammonium acetate:acetonitrile, isocratic elution 30% MeCN over 30 minutes) afforded the title compound (110mg).

NMR δ H (d₆-DMSO) 7.31-7.15 (5H, m), 5.01-4.99 (1H, m) 4.40-4.35 (1H, m), 3.76-3.72 (1H, m), 3.47-3.40 (2H, m), 3.18-3.13 (1H, m), 2.37-2.30 (4H, m), 2.16-2.10 (1H, m), 2.05-2.00 (1H, m), 1.75-1.65 (2H, m), 1.56-1.49 (2H, m), 1.35-1.32 (1H, m).

Example 111

[1*R*-[1 α ,2 α ,3 β (1*R,2*S**),5 β]-3-[5-(Butylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol**

Prepared by the method of Example 4, step (b) using the product of Example 110, step a) and butanethiol then deprotected using the method of Example 1, step (b). Purification (HPLC, Novapak[®] C18 column, 0.1% aqueous ammonium acetate:acetonitrile, isocratic elution 45% MeCN over 30 minutes) afforded the title compound (210mg).

NMR δ H (d₆-DMSO) 9.33 (1H, d), 7.31-7.15 (5H, m), 5.01-4.94 (2H, m) 4.77 (1H, d), 4.49-4.39 (1H, m), 3.80-3.75 (1H, m), 3.50-3.48 (2H, m), 3.19-3.10 (1H, m), 3.00-2.85 (2H, m), 2.38-2.29 (1H, m), 2.18-2.13 (1H, m), 2.05-2.00 (1H, m), 1.79-1.64 (2H, m), 1.51-1.38 (4H, m), 1.35-1.21 (3H, t).

Example 112

[1*R*-[1 α ,2 α ,3 β (1*R,2*S**),5 β]-3-[7-[[2-(4-chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-[(2-hydroxy)ethoxy]-cyclopentane-1,2-diol**

a) 2-[[[(1*S*-*cis*)-4-azido-2-cyclopenten-1-yl]oxy]acetic acid, 1,1-dimethylethyl ester
(1*S*-*cis*)-4-Azido-2-cyclopenten-1-ol (3.4g) (prepared as described by D.R.Deardorff et al., J. Org. Chem, 1989, **54**, 2759) in tetrahydrofuran (60ml) was added dropwise to a suspension of sodium hydride (1.1g of a 60% suspension in oil) in tetrahydrofuran (60ml)

at 0°C. On completion of the addition the mixture was allowed to warm to ambient temperature the added dropwise to a solution of *tert*-butyl bromoacetate (10.1ml) in tetrahydrofuran (60ml) at 0°C. Water (200ml) was added and the product extracted into ethyl acetate (200ml) then dried and concentrated. Purification (SiO₂, ethyl

5 acetate:isohexane, 10:90, as eluent) afforded the subtitle compound (3.6g).
NMR δH (d₆-DMSO) 6.21-6.18 (1H, m), 6.02-5.99 (1H, m), 4.49-4.44 (1H, m), 4.33-4.22 (1H, m), 4.03 (2H, s), 2.72-2.64 (1H, m), 1.63-1.55 (1H, m), 1.43 (9H, s).

b) 2-[[[(1*S*-*cis*)-4-[6-Chloro-5-nitro-2-(propylthio)-pyrimidin-4-yl]amino]-2-cyclopenten-1-yl]oxy]-acetic acid, 1,1-dimethylethyl ester

To a solution of the product from step (a) (3.5g) in tetrahydrofuran (250ml) water (25ml) was added triphenyl phosphine (4.3g) and the reaction mixture stirred at ambient temperature for three days. The solvents were evaporated and traces of water removed by evaporation from toluene. A solution of the resulting amine (3.0g) in tetrahydrofuran
15 (100ml) was added dropwise over one hour to a solution of 4,6-dichloro-5-nitro-2-(propylthio)-pyrimidine (prepared as described in WO 9703084) (3.7g). The reaction mixture was stirred for one hour the solvents evaporated and the product redissolved in ethyl acetate (500ml) then washed with water (200ml). The organics were separated, dried and evaporated. Purification (SiO₂, ethyl acetate:isohexane 5:95 as eluant) afforded the
20 subtitle compound (2.5g).

MS (APCI) 445/447 (M+H), 445 (100%).

c) 2-[[[(1*S*-*cis*)-4-[5-amino-6-chloro-2-(propylthio)-pyrimidin-4-yl]amino]-2-cyclopenten-1-yl]oxy]-acetic acid, 1,1-dimethylethyl ester.

25 Prepared according to the method of example 12, step b) using the product of step b).
MS (APCI) 415/417 (M+H), 415 (100%).

d) 2-[(1*S*-*cis*)-4-[7-Chloro-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2-cyclopenten-1-yl]oxy]-acetic acid, 1,1-dimethylethyl ester

30 Prepared according to the method of example 6, step b) using the product of step c).
MS (APCI) 426/428 (M+H), 426 (100%).

e) 2-[(1*S*-*cis*)-4-[7-Amino-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-2-cyclopenten-1-yl]oxy]-acetic acid, 1,1-dimethylethyl ester

35 Prepared according to the method of example 1, step a) using the product of step d) and '880' ammonia solution.

MS (APCI) 407 (M+H⁺, 100%).

f)[3aR-(3α,4α,6α,6α)]-2-[[6-[7-Amino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]acetic acid, 1,1-dimethylethyl ester.

Prepared according to the method of example 15, step c) using the product of step e).

MS (APCI) 481 (M+H⁺, 100%).

g)[3aR-(3α,4α,6α,6α)]-2-[[6-[7-Bromo-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]ethanol.
DIBAL-H[®] (1.5 M solution in toluene, (4 ml) was added to an ice-cooled solution of the product of step f) (0.30 g) in toluene (9 ml). The solution stirred at this temperature for 30 minutes before adding ethyl acetate (2 ml) and water (5ml). The reaction mixture was filtered through a Kieselguhr pad, washed with brine, dried and evaporated. The product was redissolved in bromoform (5ml) and isoamyl nitrite (2ml) added. The reaction mixture was heated at 80°C for thirty minutes, cooled and solvent evaporated. Purification (SiO₂, ethyl acetate:isohexane 3:7 as eluant) to afforded the subtitle compound (0.11 g).

MS (APCI) 474/476 (M+H), 474 (100%).

h)[1R-[1α,2 α,3β(1R*,2S*),5β]]-3-[7-[[2-(4-chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-[(2-hydroxy)ethoxy]-cyclopentane-1,2-diol

The title compound was prepared according to the method of example 1, step b) using the product of step g).

NMR δH (d₆-DMSO) 9.35 (1H, s), 7.33 (1H, d), 7.22 (1H, d), 5.15 (2H, m), 4.95 (1H, q), 4.61 (1H, m), 4.57-4.54 (1H, m), 3.96-3.91 (1H, m), 3.77-3.74 (1H, m), 3.56-3.44 (4H, m), 3.15-3.19 (1H, m), 2.96-2.79 (2H, m), 2.67-2.59 (1H, m), 2.15-2.10 (1H, m), 2.06-1.99 (1H, m), 1.58-1.53 (1H, m), 1.51-1.44 (2H, m), 1.39-1.32 (1H, m), 0.80 (3H, t).

MS (APCI) 521/523 (M+H), 521 (100%).

Example 113

[1S-[1α,2α,3β,5β(1S*,2R*)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-[(3,3,3-trifluoropropyl)thio]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2-diol

a) **[3a*R*-[3aα,4α,6α(1*R**,2*S**),6α]-Tetrahydro-2,2-dimethyl-6-[7-[(2-phenylcyclopropyl)amino]-5-[(3,3,3-trifluoropropyl)thio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-4*H*-cyclopenta-1,3-dioxole-4-methanol**

The subtitle compound was prepared according to the method of Example 6, step (b) using
 5 [3a*R*-[3aα,4α,6α,6α]-6-[[5-amino-6-Chloro-2-[(3,3,3-trifluoropropyl)thio]-4-pyrimidinyl]-amino]-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol (prepared as described in WO 9703084), followed by the method of Example 1, step (a).

10 b) **[1*S*-[1α,2α,3β,5β(1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-[(3,3,3-trifluoropropyl)thio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol**

The title compound was prepared according to the method of Example 1, step (b) using the product of step a).

15 MS (APCI) 511 (M+H⁺, 100%)

NMR δH (d₆-DMSO) 9.43 (1H, d), 7.32-7.27 (2H, m), 7.21-7.16 (3H, m), 5.01-4.95 (2H, m), 4.72-4.70 (2H, m), 4.44-4.41 (1H, m), 3.88-3.84 (1H, m), 3.50-3.44 (2H, m), 3.25-3.11 (3H, m), 2.75-2.70 (1H, m), 2.28-2.19 (2H, m), 2.15-2.05 (1H, m), 1.85-1.78 (1H, m), 1.49-1.46 (1H, m), 1.36-1.10 (2H, m).

20

Example 114

[1*S*-[1α,2β,3β,4α(1*S,2*R**)]]-4-[7-[[2-(3-Chloro-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol**

25 Prepared according to the method of Example 24, step (f), using the products of Example 24, step (d) and Example 104, step (e).

MS (APCI) 493/491 (M+H⁺), 491 (100%)

NMR δH (d₆-DMSO) 9.85 (1H, d), 7.28 (2H, d), 7.26 (1H, d), 7.06 (1H, dd), 5.11 (1H, d), 5.02 (1H, d), 4.96 (1H, q), 4.92 (1H, d), 4.69-4.62 (1H, m), 3.96-3.89 (1H, m), 3.82-3.75 (1H, m), 3.19-2.79 (3H, m), 2.64-2.52 (1H, m), 2.29 (3H, s), 2.25-2.05 (1H, m), 1.95-1.86 (1H, m), 1.73-1.31 (4H, m), 0.80 (3H, t).

30

Pharmacological data

The preparation for the assay of the P_{2T} -receptor agonist/antagonist activity in washed human platelets for the compounds of the invention was carried out as follows.

5 Human venous blood (100 ml) was divided equally between 3 tubes, each containing 3.2% trisodium citrate (4 ml) as anti-coagulant. The tubes were centrifuged for 15 minutes at 240G to obtain a platelet-rich plasma (PRP) to which 300 ng/ml prostacyclin was added to stabilize the platelets during the washing procedure. Red cell free PRP was obtained by
10 centrifugation for 10 minutes at 125G followed by further centrifugation for 15 minutes at 640G. The supernatant was discarded and the platelet pellet resuspended in modified, Calcium Free Tyrode solution (10 ml) (CFT), composition: NaCl 137mM, NaHCO_3 11.9mM, NaH_2PO_4 0.4mM, KCl 2.7 mM, MgCl_2 1.1 mM, dextrose 5.6 mM, gassed with 95% O_2 /5% CO_2 and maintained at 37°C. Following addition of a further 300 ng/ml PGI_2 ,
15 the pooled suspension was centrifuged once more for 15 minutes at 640G. The supernatant was discarded and the platelets resuspended initially in 10 ml CFT with further CFT added to adjust the final platelet count to $2 \times 10^5/\text{ml}$. This final suspension was stored in a 60 ml syringe at 3°C with air excluded. To allow recovery from PGI_2 -inhibition of normal function, platelets were used in aggregation studies no sooner than 2 hours after final
20 resuspension.

In all studies, 3 ml aliquots of platelet suspension were added to tubes containing CaCl_2 solution (60 μl of 50 mM solution with a final concentration of 1mM). Human fibrinogen (Sigma, F 4883) and 8-sulphophenyltheophylline (8-SPT which was used to block any
25 P_1 -agonist activity of compounds) were added to give final concentrations of 0.2 mg/ml (60 μl of 10 mg/ml solution of clottable protein in saline) and 300 nM (10 μl of 15 mM solution in 6% glucose), respectively. Platelets or buffer as appropriate were added in a volume of 150 μl to the individual wells of a 96 well plate. All measurements were made in triplicate in platelets from each donor.

30

The agonist/antagonist potency was assessed as follows.

Aggregation responses in 96 well plates were measured using the change in absorbance given by the plate reader at 660 nm. Either a Bio-Tec Ceres 900C or a Dynatech MRX
35 were used as the plate reader.


The absorbance of each well in the plate was read at 660 nm to establish a baseline figure. Saline or the appropriate solution of test compound was added to each well in a volume of 10 μ l to give a final concentration of 0, 0.01, 0.1, 1, 10 or 100 mM. The plate was then shaken for 5 min on an orbital shaker on setting 10 and the absorbance read at 660 nm.

- 5 Aggregation at this point was indicative of agonist activity of the test compound. Saline or ADP (30 mM; 10 μ l of 450 mM) was then added to each well and the plate shaken for a further 5 min before reading the absorbance again at 660 nm.

Antagonist potency was estimated as a % inhibition of the control ADP response to obtain
10 an IC_{50} . Compounds exemplified have pIC_{50} values of more than 5.0.

Claims

1. A compound of formula (I)



wherein:

R^1 is a C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkenyl, C_{3-8} -cycloalkyl or a phenyl group, each group being optionally substituted by one or more substituents selected from halogen, OR^8 , NR^9R^{10} , SR^{11} or C_{1-6} alkyl (itself optionally substituted by one or more halogen atoms);

R^2 is C_{1-8} alkyl optionally substituted by one or more substituents selected from halogen, OR^8 , NR^9R^{10} , SR^{11} , C_{3-8} -cycloalkyl, aryl (optionally substituted by one or more alkyl groups and/or halogen atoms), or C_{1-6} -alkyl; or R^2 is a C_{3-8} -cycloalkyl group optionally substituted by one or more substituents selected from halogen, OR^8 , NR^9R^{10} , SR^{11} ,

C_{1-6} -alkyl or phenyl, the latter two groups being optionally substituted by one or more substituents selected from halogen, NO_2 , $C(O)R^8$, OR^8 , SR^{11} , $NR^{12}R^{13}$, a fused 5- or 6-membered saturated ring containing one or two oxygen atoms, phenyl or C_{1-6} -alkyl the latter two groups being optionally substituted by OR^8 , NR^9R^{10} or one or more halogen atoms;

one of R^3 and R^4 is hydroxy and the other is hydrogen, hydroxy or NR^9R^{10} ;

R is a group $(CR^5R^6)_mOR^7$ where m is 0 or 1, R^5 and R^6 are independently hydrogen, C_{1-6} alkyl or phenyl the latter two groups being optionally substituted by halogen, and R^7 is hydrogen, C_{1-6} alkyl or $(CR^5R^6)_nR^{14}$ where R^5 and R^6 are as defined above, n is 1 to 3 and R^{14} is $COOH$, OR^{15} , $NR^{16}R^{17}$ or $CONR^{16}R^{17}$;


or R is a C_{1-4} alkyl or C_{2-4} alkenyl group, each of which is substituted by one or more groups selected from $=S$, $=O$, $=NR^{20}$ or OR^{21} and optionally substituted by one or more groups selected from halogen, C_{1-4} alkyl, phenyl, SR^{21} , NO_2 or $NR^{22}R^{23}$ (where R^{21} , R^{22} and R^{23} are independently hydrogen, C_{1-4} alkyl or phenyl; R^{20} is OR^{24} or $NR^{25}R^{26}$, where R^{24} is hydrogen, C_{1-4} alkyl or phenyl, and R^{25} and R^{26} are independently hydrogen, C_{1-4} alkyl, aryl, C_{1-6} acyl, arylsulphonyl or arylcarbonyl);

R^8 is hydrogen, C_{1-6} alkyl optionally substituted by halogen or R^8 is phenyl optionally substituted by one or more substituents selected from halogen, NO_2 , $C(O)R^6$, OR^6 , SR^9 , $NR^{10}R^{11}$;

R^9 , R^{10} and R^{11} are independently hydrogen or C_{1-6} alkyl;

- 5 R^{12} and R^{13} are independently hydrogen, C_{1-6} alkyl, acyl, alkyl sulfonyl optionally substituted by halogen, or phenyl sulfonyl optionally substituted by C_1-C_4 alkyl; and R^{15} , R^{16} and R^{17} are independently hydrogen or C_{1-6} alkyl;
or a pharmaceutically acceptable salt or solvate thereof.

- 10 2. A compound of formula (I) having the following stereochemistry:



- 15 3. A compound according to claim 1 or 2 in which R^1 is C_{1-4} alkyl or phenyl substituted by trifluoromethyl.

4. A compound according to any one of claims 1 to 3 in which R^2 is butyl or cyclopropyl optionally substituted by phenyl, the phenyl group itself being optionally substituted by one or more halogen, C_{3-8} alkyl, phenoxy or phenyl groups.

- 20 5. A compound according to any one of claims 1 to 4 in which R^3 and R^4 are both hydroxy.

- 25 6. A compound according to any one of claims 1 to 5 in which R^5 and R^6 are both hydrogen.

7. A compound according to any one of claims 1 to 6 in which R is OH , CH_2OH , CH_2CH_2OH , OCH_2CH_2OH , $CH_2OCH_2C(CH_3)_2OH$ and $OCH_2C(CH_3)_2OH$.

- 30 8. A compound according to claims 1 which is:

- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
 [1*S*-(1 α ,2 α ,3 β ,5 β)]-5-[7-[(Cyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-3-(hydroxymethyl)-cyclopentane-1,2-diol,
 5 [1*S*-(1 α ,2 α ,3 β ,5 β)]-5-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-3-(hydroxymethyl)-cyclopentane-1,2-diol,
 [1*S*-(1 α ,2 α ,3 β ,5 β)]-5-[7-(Butylamino)-5-[[4-(trifluoromethyl)phenyl]thio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-3-(hydroxymethyl)-cyclopentane-1,2-diol,
 2-[[[1*R*-(1 α ,2 β ,3 β ,4 α)]-4-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,3-dihydroxy-cyclopentyl]methoxy]acetic acid,
 10 1-[[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-2-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,3-dihydroxy-cyclopentyl]-ethanone,
 1-[[1*S*-[1 α ,2 β ,3 β ,4 α]]-4-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,3-dihydroxy-cyclopentyl]-2-hydroxy-ethanone,
 15 1-[[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-2,3-Dihydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]-ethanone,
 1-[[1*S*-[1 α ,2 β ,3 β ,4 α]]-4-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,3-dihydroxy-cyclopentyl]-ethanone,
 [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(1-Hydroxy-1-methylethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-
 20 cyclopentane-1,2-diol,
 [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
 [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[(2-Phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
 25 2-[[[1*S*-[1 α ,3 β ,4 α (1*S**,2*R**)]]-3-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]oxy]acetic acid,
 2-[[[1*S*-[1 α ,2 β ,4 α (1*S**,2*R**)]]-2-Hydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]oxy]acetic acid,
 30 2-[[[1*S*-(1 α ,2 β ,3 β ,4 α)]-4-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,3-dihydroxy-cyclopentyl]oxy]acetic acid,
 2-[[[1*S*-(1 α ,2 β ,3 β ,4 α)]-4-[7-(Butylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-2,3-dihydroxycyclopentyl]oxy]acetamide,
 [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[[5-(Methylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-
 35 1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,

- [1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]]-4-[5-[(Methylethyl)thio]-7-[(2-phenylcyclopropyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1S-[1 α ,2 β ,3 β ,4 α (1S*, 2R*)]]-4-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- 5 [1S-[1 α ,2 β ,3 β ,4 α (1S*, 2R*)]]-4-[7-[[2-(4-Methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]]-4-[7-[[2-(4-Methylphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]]-4-[7-[[2-(4-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- 10 [1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]]-4-[7-[[2-(4-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- 2-[[[1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]]-2,3-Dihydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentyl]oxy]-acetamide,
- [1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]]-4-[7-[[2-(3-Methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- 15 [1S-[1 α ,2 β ,3 β ,4 α (1S*, 2R*)]]-4-[7-[[2-(3-Methylphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1S-[1 α ,2 β ,3 β ,4 α (1S*, 2R*)]]-4-[7-[[2-(3-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1S-[1 α ,2 β ,3 β ,4 α (1S*, 2R*)]]-4-[7-[[2-(3-Nitrophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- 20 [1S-[(1 α ,2 β ,3 β ,4 α (1S*, 2R*)]]-4-[7-[[2-(4-Phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1S-[1 α ,2 β ,3 β ,4 α (1S*, 2R*)]]-4-[7-[[2-(3-Phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- 25 [1S-[1a,2b,3b,4a(1S*, 2R*)]]-4-[7-[[2-(3-Aminophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1S-(1a,2a,3b,5b)]-3-[7-(Butylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(3-hydroxypropoxy)-cyclopentane-1,2-diol,
- [1S-[1a,2a,3b,5b(1S*,2R*)]]-3-(2-Hydroxyethoxy)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- 30 [1S-[1a,2a,3b,5b(1S*,2R*)]]-3-(Hydroxymethyl)-5-[7-[[2-(4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1R-[1a,2a,3b(1S*,2R*),5b]]-5-[7-[[2-(4-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-3-(hydroxymethyl)-cyclopentane-1,2-diol,
- 35 [1R-[1a,2a,3b(1S*,2R*),5b]]-5-[7-[[2-(4-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-3-(hydroxymethyl)-cyclopentane-1,2-diol,

- [1*R*-[1 α ,2 α ,3 β (1*S**,2*R**),5 β]]-3-[7-[[2-(3-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Methoxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[5-(methylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-[(1-methylethyl)thio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(prop-2-enylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[5-(4-methylphenylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(1-Hydroxyethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(1-Hydroxyethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[5-(Ethylthio)-7-[[2-phenylcyclopropyl]amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-[(1,1'-Biphenyl)-4-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1*R*-(1 α ,2 α ,3 β ,5 β)]-3-[7-(Butylamino)-5-(cyclopentylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-[4-(trifluoromethyl)-phenylthio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(4-phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,

- [1*R*-[1 α ,2 α ,3 β (1*S**,2*R**),5 β]]-3-[7-[[2-(2-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**))]-3-(2-Hydroxyethoxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*R*-[1 α ,2 β ,3 β ,4 α (1*R**,2*S**)]]-3-Hydroxy-2-methoxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentanemethanol,
- [1*R*-[1 α ,2 β ,3 β ,4 α (1*R**,2*S**)]]-2-Hydroxy-3-methoxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentanemethanol,
- [1*S*-[1 α ,2 α ,3 β (*E*),5 β (1*S**,2*R**)]]-3-(3-Hydroxy-prop-1-enyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(3-Hydroxypropyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- 1-[[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-2,3-Dihydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]-2-methoxyethanone,
- [1*S*-(1 α ,2 α ,3 β ,5 β)]-3-(Hydroxymethyl)-5-[7-[[(*trans*)-2-(3,4-methylenedioxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(3-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(4-hydroxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(3-phenoyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,

- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(3-nitrophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl] - cyclopentane-1,2-diol,
- [1*R*-[1 α ,2 α ,3 β ,5 β (1*R**,2*S**)]]-3-[7-[[2-(3-Aminophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3,5-Dimethoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-[(2-Hydroxy-2,2-dimethyl)ethoxy]-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-1,2-cyclopentanediol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-[4-(1-methylethoxy)phenyl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(3-Hydroxypropoxy)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-1,2-cyclopentanediol,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**, 2*R**)]]-4-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1*R*-[1 α ,2 α ,3 β (1*S**,2*R**),5 β]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**, 2*R**)]]-4-[7-[[2-(3,5-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**, 2*R**)]]-4-[7-[[2-[[1,1'-Biphenyl]-3-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-[[1,1'-Biphenyl]-3-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- N*-Ethyl-[[[1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-2,3-dihydroxy-4-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentyl]oxy]-acetamide,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**, 2*R**)]]-4-[7-[[2-(3-Methoxy-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(4-*N,N*-Dimethylaminophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-hydroxymethyl-cyclopentane-1,2-diol,

- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Fluoro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(4-methoxy-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,4-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-3-(hydroxymethyl)-cyclopentane-1,2-diol,
- 1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]-3-[(2-Amino)ethoxy]-5-[7-(2-phenylcyclopropyl)amino]-5-propylthio-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*R*-(1 α ,2 α ,3 β (1*R**,2*S**),5 β)]-3-[7-[[2-(3,4-Dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3,4-Dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1*R*-(1 α ,2 α ,3 β ,5 β)]-3-[7-(Cyclopropylamino)-5-[[4-(trifluoromethyl)phenyl]thio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3,5-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1*R*-[1 α (1*S**,2*R**),2 β ,3 β ,4 α]]-*N*-[3-[2-[[3-(2,3,4-Trihydroxy-cyclopentyl)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-methanesulfonamide,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3,4-Dimethoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(4-Methoxy-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1*R*-[1 α (1*S**,2*R**),2 β ,3 β ,4 α]]-*N*-[3-[2-[[3-(2,3,4-Trihydroxy-cyclopentyl)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-acetamide,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3,4-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(4-Chloro-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1*S*-[1 α ,2 β ,3 β ,4 α (*trans*)]]-4-[7-[[2-(Phenylmethyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,

- [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(4-Chloro-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3-Dimethylaminophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3-Fluoro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3,5-Dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3-Chloro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Chloro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1R-[1 α (1*S**,2*R**),2 β ,3 β ,4 α]]-*N*-[3-[[2-[3-[2,3-Dihydroxy-4-(hydroxymethyl)cyclopentyl]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-methanesulphonamide,
- [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,5-Dimethoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
- [1R-[1 α (1*S**,2*R**),2 β ,3 β ,4 α]]-*N*-[[3-[2-[3-(2,3-Dihydroxy-4-hydroxymethylcyclopentyl)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-acetamide,
- [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,5-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1R-[1 α (1*S**,2*R**),2 β ,3 β ,4 α]]-*N*-[3-[2-[[3-[2,3-Dihydroxy-4-(2-hydroxyethyl)-cyclopentyl]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-methanesulfonamide,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(4-phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(3-phenoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,


- [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(4-Bromophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- 5 [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-[(1,1'-Biphenyl)-2-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-[(1,1'-Biphenyl)-3-yl]cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- 10 [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,5-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,4-Dichlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- 15 [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Chloro-4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,4-Dimethoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- 20 [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Chloro-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- [1R-[1 α (1*S**,2*R**),2 β ,3 β ,4 α]]-*N*-[3-[2-[[3-[2,3-Dihydroxy-4-(2-hydroxyethyl)-cyclopentyl]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenyl]-acetamide,
- 25 [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Chloro-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(4-Chloro-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- 30 [1R-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(4-Fluoro-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(3-nitrophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- 35

- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(4-methoxy-3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- 5 [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(3-methoxy-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(4-*N,N*-Dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- 10 [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,5-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- 15 [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- 20 [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(2-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- 25 [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(4-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(3-methoxyphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- 30 [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3,5-Dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- 35 [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(4-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,


- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Fluorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(2-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(3-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-[[2-(4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[7-(cyclopropylamino)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxy-2-methylpropoxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(3-Chloro-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1*R*-[1 α (1*S**,2*R**),2 β ,3 β ,4 α]]-4-[2-[[3-(2,3,4-Trihydroxycyclopentyl)-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopropyl]phenylsulfonamide,
- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[5-(Butylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(hydroxymethyl)-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[5-(pentylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-(prop-2-ynylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[[2-(3,5-dimethylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(2-Hydroxyethyl)-5-[5-(methylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
- [1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[5-(Butylthio)-7-[(2-phenylcyclopropyl)amino]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethyl)-cyclopentane-1,2-diol,

[1*R*-[1 α ,2 α ,3 β (1*R**,2*S**),5 β]]-3-[7-[[2-(4-chlorophenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-[(2-hydroxy)ethoxy]-cyclopentane-1,2-diol,
 [1*S*-[1 α ,2 α ,3 β ,5 β (1*S**,2*R**)]]-3-(Hydroxymethyl)-5-[7-[(2-phenylcyclopropyl)amino]-5-[(3,3,3-trifluoropropyl)thio]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2-diol,
 [1*S*-[1 α ,2 β ,3 β ,4 α (1*S**,2*R**)]]-4-[7-[[2-(3-Chloro-4-methylphenyl)cyclopropyl]amino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-cyclopentane-1,2,3-triol,
 or pharmaceutically acceptable salts or solvates thereof.


9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 in combination with a pharmaceutically acceptable diluent, adjuvant or carrier.
10. A compound according to any one of claims 1 to 8 for use in therapy.
11. A compound according to any one of claims 1 to 8 for use in the treatment or prevention of myocardial infarction, thrombotic stroke, transient ischaemic attacks, peripheral vascular disease and angina.
12. A compound according to any one of claims 1 to 8 for use in the treatment or prevention of angina.
13. A method of treatment a platelet aggregation disorder which comprises administering to a patient suffering from such a disorder a therapeutically effective amount of a according to any one of claims 1 to 8.
14. A process for the preparation of a compound of formula (I) which comprises;
 (a) reacting a compound of formula (II):



where R , R^1 , R^3 and R^4 are as defined in formula (I) or are protected derivatives thereof, and L is a leaving group with a compound of formula (III):




where R^2 is as defined in formula (I) or is a protected derivative thereof, or
(b) reacting a compound of formula (IV):



in which R^1 and R^2 are as defined in formula (I) or are protected derivatives thereof and P^1 and P^2 are protecting groups or hydrogen, with a suitable reagent to introduce a substituent R , or, for compounds where m is 0:

(c) hydroxylation of a compound of formula (V):



where R^1 , R^2 and R^7 are as defined in formula (I) or are protected derivatives thereof, and optionally thereafter (a), (b) or (c) and in any order:

- converting one or more functional groups into a further functional groups
- removing any protecting groups
- forming a pharmaceutically acceptable salt or solvate.

ABSTRACT

The invention provides new triazolo[4,5-*d*]pyrimidine compounds, their use as
5 medicaments, compositions containing them and processes for their preparation.

RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL COMPOUNDS

the specification of which (check applicable box(es)):

- ☐ is attached hereto
- ☐ was filed on _____ as U.S. Application Serial No. _____ (Atty Dkt. No.)
- ☒ was filed as PCT international appl. No. PCT/SE98/01393 on 15 July 1998

and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Prior Foreign Application(s):

Application Number	Country	Day/Month/Year Filed
9702773-4	Sweden	22 July 1997
9702775-9	Sweden	22 July 1997

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

Application Number	Day/Month/Year Filed

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior applications and the national or PCT international filing date of this application:

Prior U.S./PCT Application(s):	Status: patented,	
Application Serial No.	Day/Month/Year Filed	pending, abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And I hereby appoint **NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed)**, and the following attorneys thereof (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Paul J. Henon, 33626; Jeffry H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr., 29366; Thomas E. Byrne, 32205; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Jerry D. Craig, 38026; Alan M. Kagen, 36178; William J. Griffin, 31260.

- 1-00
1. Inventor's Signature: S. Guile Date: 3/9/98
Inventor: Simon Guile British
(first) MI (last) (citizenship)
Residence Address: Loughborough, United Kingdom
Post Office Address: Astra Charnwood, Bakewell Road, Loughborough LE11 5RH, UK GBX
(Zip Code)
- 2-00
2. Inventor's Signature: A. Ingall Date: 3/9/98
Inventor: Anthony Ingall British
(first) MI (last) (citizenship)
Residence Address: Loughborough, United Kingdom
Post Office Address: Astra Charnwood, Bakewell Road, Loughborough LE11 5RH, UK GBX
(Zip Code)
- 3-00
3. Inventor's Signature: B. Springthorpe Date: 3/9/98
Inventor: Brian Springthorpe British
(first) MI (last) (citizenship)
Residence Address: Loughborough, United Kingdom
Post Office Address: Astra Charnwood, Bakewell Road, Loughborough LE11 5RH, UK GBX
(Zip Code)
- 4-00
4. Inventor's Signature: P. Willis Date: 3/9/98
Inventor: Paul Willis British
(first) MI (last) (citizenship)
Residence Address: Nottingham, United Kingdom
Post Office Address: Astra Charnwood, Bakewell Road, Loughborough LE11 5RH, UK GBX
(Zip Code)